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Abstract 
     The pectenotoxins (PTXs) are a family of marine macrolactones produced by Dinophysis dinoflagellates and found in 
coastal areas worldwide. The PTXs have drawn considerable attention not only because of their complex structure and 
toxicity but also because of their potential medical applications. Pectenotoxins have shown selective cytotoxicity against a 
variety cancer cell lines and they are known to interact with the actin cytoskeleton by unique mechanism. These properties 
could be of great clinical importance for the development of new cancer chemotherapy agents. The scarcity of the PTXs 
has hampered further studies into their biological activity, and as such access to synthetic PTXs would be immensely 
helpful. 
     The exquisitely complex structure of the PTXs presents a considerable challenge for a synthetic chemist. One of the 
most challenging structural elements is the AB spiroketal ring fragment that is in the more unstable and less easily 
accessible nonanomeric configuration. Importantly, the PTX congeners that contain this nonanomeric spiroketal ring 
system, has been reported to be the most biologically active. In the literature part, a short discussion of the anomeric effect 
is presented. The previously published syntheses of the AB spiroketal ring fragment of PTXs are discussed. And finally, a 
brief insight into other natural products containing nonanomeric spiroketals and their recent syntheses are presented.  
     In this work the objective was to synthesize the ABCDE ring fragment of PTX2 using a highly convergent strategy. 
Three advanced ring fragments corresponding to the A, C and DE ring systems were synthesized. The A ring lactone was 
also used for the synthesis of the AB spiroketal ring fragment of PTX2. During these studies we developed kinetic 
spiroketalization conditions that delivered for the first time the desired nonanomeric spiroketal isomer of the PTXs as the 
major product. For the C ring fragment an efficient synthesis was developed that delivered the key center peace with the 
right stereochemistry in excellent 46% total yield over nine steps. The connection of the C ring aldehyde with the DE ring 
fragment using Mukaiyama aldol reaction gave access to the CDE ring system in highly stereoselective manner. The CDE 
ring allylic alcohol was connected with the A ring fragment via cross-metathesis. As the final step, the kinetic 
spiroketalization delivered a 3:1 mixture of the nonanomeric and the anomeric spiroketal. Unfortunately, it was discovered 
that the final ABCDE ring product had the wrong stereochemistry at C10. Studies targeting the inversion of this 
stereocenter are under way, which would finally give access to the natural ABCDE ring fragment of PTX2.      
Keywords    pectenotoxin, total synthesis, spiroketal, nonanomeric, anomeric 
ISBN (printed)    978-952-248-075-0 ISSN (printed)        1795-2239 
ISBN (pdf)          978-952-248-076-7 ISSN (pdf)              1795-4584           
Language            English      Number of pages         167 p. 
Publisher      Helsinki University of Technology, Department of Chemistry 
Print distribution      Helsinki University of Technology, Department of Chemistry                                                                     
  The dissertation can be read at http://lib.tkk.fi/Diss/2009/isbn9789522480767/      
 

 
 
 
 
 
 
 
VÄITÖSKIRJAN TIIVISTELMÄ 
TEKNILLINEN KORKEAKOULU 
PL 1000, 02015 TKK 
http://www.tkk.fi 
Tekijä        Jatta Aho 
Väitöskirjan nimi 
     Pektenotoksiini 2:en 10-epi-ABCDE-rengasfragmentin synteesi 
Käsikirjoituksen päivämäärä    29.5.2009 Korjatun käsikirjoituksen päivämäärä     9.9.2009      
Väitöstilaisuuden ajankohta     17.10.2009 
  Monografia   Yhdistelmäväitöskirja (yhteenveto + erillisartikkelit) 
Tiedekunta                    Kemian ja materiaalitieteiden tiedekunta       
Laitos                            Kemian laitos      
Tutkimusala                  Orgaaninen kemia      
Vastaväittäjä(t)             Prof. J. Stephen Clark      
Työn valvoja                 Prof. Ari Koskinen      
Työn ohjaaja                 Prof. Petri Pihko      
Tiivistelmä 
    Pektenotoksiinit (PTX) ovat myrkyllisiä luonnonaineita, joita tuottavat Dinophysis-sukuun kuuluvat panssarisiimalevät. 
Pektenotoksiinit ovat mielenkiintoisia niiden monimutkaisen rakenteen, myrkyllisyytensä ja mahdollisten lääketieteellisten 
sovellusten vuoksi. Pektenotoksiinien tiedetään häiritsevän solun aktiinitukirangan toimintaa ja tällä tavoin selektiivisesti 
ehkäisevän erilaisten syöpäsolujen kasvua. Tämä ominaisuus voi osoittautua erittäin hyödylliseksi uusien kemoterapia-
aineiden kehityksessä. Pektenotoksiineja pystytään eristämään luonnosta vain pieniä määriä ja siksi lääketieteellisten 
tutkimusten edistämiseksi olisikin tärkeää kehittää toimiva menetelmä niiden synteettiseen valmistukseen. 
    Synteettisesti pektenotoksiinit ovat erittäin haastava kohde. Yksi haastavimmista rakenteellisista ominaisuuksista on 
epäanomeerinen AB-spiroketaaliyksikkö joka on termodynaamisesti epästabiilimpi ja vaikeammin syntetisoitavissa kuin 
vastaava anomeerisesti stabiloitu spiroketaali. Epäanomeerisen spiroketaalin omaavien pektenotoksiinien on lisäksi todettu 
olevan kaikkein biologisesti aktiivisimpia. Kirjallisuusosassa esitellään ensin lyhyesti anomeerinen efekti, minkä jälkeen 
esitellään pektenotoksiinien AB-spiroketaalifragmentille aikaisemmin julkaistut synteesit. Lopuksi esitellään lyhyesti muita 
epäanomeerisen spiroketaaliyksikön omaavia luonnonaineita sekä niiden uusimpia synteesimenetelmiä. 
    Tässä työssä oli tavoitteena kehittää synteesi PTX2:en ABCDE-rengasfragmentille. Rengasfragmentit A, C sekä DE 
syntetisoitiin erikseen ja sitten kytkettiin yhteen. A-rengaslaktonia käytettiin myös pektenotoksiinien AB-rengasrakenteen 
syntetisoinnissa. Näissä tutkimuksissa kehitimme kineettiset spiroketalisointiolosuhteet, joilla pystyttiin muodostamaan 
ensimmäistä kertaa haluttua epäanomeerista AB-spiroketaali-isomeeria päätuotteena. C-renkaalle kehitimme tehokkaan 
synteesimenetelmän, jolla saatiin muodostettua yhdeksässä reaktiovaiheessa haluttua avain rakenneyksikköä oikealle 
stereokemialla ja erinomaisella 46 %:n kokonaissaannolla. C-rengasaldehydi kytkettiin erittäin stereoselektiivisesti DE-
rengasfragmentin kanssa käyttäen Mukaiyama aldolireaktiota. CDE-rengasfragmentti kytkettiin edelleen A-
rengasfragmentin kanssa käyttäen ristimetateesia. Viimeisenä reaktiovaiheena kineettinen spiroketalisointi muodosti 3:1 
seoksen epäanomeerista ja anomeerista spiroketaalia. Ikäväksemme havaitsimme, että näin saadussa ABCDE-
rengastuotteessa oli väärä stereokemia hiilessä C10. Tutkimukset tämän stereokeskuksen invertoimiseksi ovat meneillään, 
mikä lopulta mahdollistaisi luonnollisen PTX2:en ABCDE-rengasfragmentin synteesin.      
 
Asiasanat    pektenotoksiini, kokonaissynteesi, spiroketaali, epäanomeerinen, anomeerinen 
ISBN (painettu)     978-952-248-075-0 ISSN (painettu)     1795-2239 
ISBN (pdf)             978-952-248-076-7 ISSN (pdf)             1795-4584           
Kieli                       englanti      Sivumäärä              167 s.      
Julkaisija      Teknillinen korkeakoulu, Kemian laitos 
Painetun väitöskirjan jakelu      Teknillinen korkeakoulu, Kemian laitos 
  Luettavissa verkossa osoitteessa http://lib.tkk.fi/Diss/2009/isbn9789522480767/ 
 
AB

 
 
 
  
ACKNOWLEDGEMENTS 
The research work reported in this thesis was carried out in the Department of Chemistry, 
Helsinki University of Technology, during 2004-2009. A part of the research was done in 
the Department of Chemistry, University of Crete, during September-October 2006, in 
the research group of Professor Georgios Vassilikogiannakis.  
 
I have been fortunate to obtain funding from several sources; Onni Rannikko Fund of the 
Finnish Foundation for Economic and Technology Sciences – KAUTE, Tekniikan 
edistämissäätiö – TES, Alfred Kordelin Foundation, COST D28, Association of Finnish 
Chemical Societies, Orion-Farmos Research Foundation, The National Glycoscience 
Graduate School and Academy of Finland, are all gratefully acknowledged. 
 
I wish to express my utmost gratitude to my supervisor, Professor Petri Pihko, for 
introducing me with the pectenotoxins and giving me the opportunity to do my PhD in his 
group. Petri’s enthusiasm, knowledge and most importantly his trust in me and my 
abilities are the reasons I started studying organic chemistry and kept on going. Thanks 
for being a great “boss”! Credit for my education goes also to Professor Ari Koskinen. 
Thank you for creating a scientific and inspiring atmosphere to study and work. 
 
Professor Georgios Vassilikogiannakis and the whole group, thanks for the great time I 
got to spend in your beautiful island and for turning my period of bad luck in chemistry 
around. I respectfully thank Professor Trond Vidar Hansen and Professor Peter Somfai 
for careful revision of my manuscript. 
 
I would like to thank all the students and post-docs that have shared the ups and downs of 
the pectenotoxin project and been an excellent help in the lab. Inkeri Majander did a good 
job scaling up the A ring lactone. Dr. Syam Krishnan also prepared the valuable A ring 
and did some helpful model studies. Elina Salomäki studied the CDE ring synthesis with 
model compounds, which at the end proved to be of great importance. A wave of German 
energy swept the lab when Dr. Hannes Helmboldt joined our group. I was glad to finally 
share my precious PTX with somebody, and Hannes turned out to be just the right person. 
 
 
 
  
Without Tiia and Jari, I would not know what really happened inside my reaction flasks. 
Tiia has been of immense help as our mass expert, and in many other matters as well. One 
can always count on your help! Jari, the Master of NMR, has maintained our precious 
Bruker  and  also  shared  his  vast  expertise  when  ever  needed.  I  am  also  grateful  to  
Professor Kari Rissanen from the University of Jyväskylä for the X-ray studies and to 
Päivi Joensuu from University of Oulu for the HRMS analyses. 
 
My  warmest  thanks  go  to  all  the  colleagues  and  friends  at  the  lab  for  creating  an  
inspiring, encouraging and most importantly pleasant atmosphere to work in. Kaisa, my 
role model in research, thanks for numerous discussions on all the aspects of research, 
work and life within and outside of the lab. I am indebted to past and current members of 
our beloved “Stern Gruppe”, all of you have contributed to this work in a way or another. 
Antti, who has been there with me the longest to fight the bad chemistry and enjoy the 
good chemistry, deserves special thanks for the bottomless pit of ideas (good and bad!) 
and ever so useful discussions.  
 
I thank all my dear friends outside the world of organic chemistry. Sometimes life spins 
on too quickly and we are too busy with too many things, but I know that you will always 
be there to support and comfort me! Hannes, thanks for being such a good friend ever 
since our undergraduate studies. Most importantly, thanks for dragging me into the 
marathon project. I might have lost my mind during the writing process if it wasn’t for the 
rigorous running schedule. 
 
I am forever grateful to my parents for all the support and encouragement during my 
long-lasting studies. Thank you for believing in me. Johanna, my sister, my true mentor 
in life (and math), and my very best friend. Thank you for being there for me in good 
times and bad, this work is dedicated to you! My dearest Antti, your never-failing love, 
encouragement and optimism have been the utmost important. You have taught me how 
to enjoy life’s little twists. Thank you for being the person you are! 
 
 
– There is no obstacle too difficult to overcome in your life, 
as long as you know what you want. – 
 
 
 
Espoo, September 2009 
Jatta Aho 
 
 
 
  
TABLE OF CONTENTS 
ABSTRACT...........................................................................................................................3 
TIIVISTELMÄ (Abstract in Finnish) ......................................................................................5 
ACKNOWLEDGEMENTS ...................................................................................................5 
TABLE OF CONTENTS .......................................................................................................7 
ABBREVIATIONS AND DEFINITIONS ............................................................................... 12 
AUTHOR’S CONTRIBUTION ............................................................................................ 15 
1 PECTENOTOXINS ................................................................................................... 21 
1.1 Isolation and Structure................................................................................... 21 
1.2 Activity .......................................................................................................... 25 
2 NONANOMERIC SPIROKETALS IN NATURAL PRODUCTS ......................................... 29 
2.1 Anomeric Effect ............................................................................................. 29 
2.2 Nonanomeric [6,5]-Spiroketal Ring of Pectenotoxins...................................... 32 
2.3 Previous Syntheses of AB Spiroketal Ring Fragment of PTXs ........................... 33 
2.3.1 Synthesis by Evans et al. 2002 ................................................................ 34 
2.3.2 Synthesis by Pihko and Aho 2004 ........................................................... 35 
2.3.3 Synthesis by Paquette et al. 2005 ........................................................... 35 
2.3.4 Synthesis by Brimble et al. 2006 ............................................................. 36 
2.3.5 Synthesis by Williams et al. 2007 ............................................................ 37 
2.3.6 Synthesis by Rychnovsky et al. 2007 ....................................................... 40 
2.3.7 Strategies in Comparison........................................................................ 43 
2.4 Other Natural Products with a Nonanomeric [6,5]-Spiroketal ......................... 44 
 
 
 
  
2.4.1 Ciguatoxins ............................................................................................ 46 
2.4.2 Aculeatins and Aculeatols....................................................................... 47 
2.4.3 Unnatural Nonanomeric Spiroketal of Attenol A ..................................... 53 
3 SYNTHESIS OF 10-EPI-ABCDE RING FRAGMENT OF PECTENOTOXIN 2..................... 55 
3.1 Introduction................................................................................................... 55 
3.2 Retrosynthetic Design .................................................................................... 56 
3.3 Synthesis of A Ring Fragment ......................................................................... 57 
3.3.1 Epoxidation Strategy .............................................................................. 57 
3.3.2 Synthesis of AB Spiroketal Ring Fragment ............................................... 59 
3.4 Synthesis of C Ring Fragment ......................................................................... 65 
3.4.1 AE-AD-Metathesis Strategy .................................................................... 65 
3.5 Synthesis of CDE Ring Fragment ..................................................................... 69 
3.5.1 Nucleophilic Addition Strategy ............................................................... 70 
3.5.2 Methylation Strategy ............................................................................. 74 
3.6 Synthesis of ABCDE Ring Fragment................................................................. 79 
4 CONCLUSION AND FUTURE STUDIES ...................................................................... 87 
5 EXPERIMENTAL SECTION ....................................................................................... 89 
5.1 General Experimental .................................................................................... 89 
5.2 Synthesis of A Ring Fragment ......................................................................... 90 
5.2.1 5-Benzyloxypentanol 187 ....................................................................... 90 
5.2.2 5-(Benzyloxy)pentanal 104 ..................................................................... 91 
5.2.3 7-(Benzyloxy)-methyl-2-(Z)-hepteonate 105 ........................................... 91 
5.2.4 7-(Benzyloxy)-methyl-2-(Z)-hepten-1-ol 106 ........................................... 92 
5.2.5 Epoxide 107 ........................................................................................... 93 
5.2.6 (2S, 3S)-7-(Benzyloxy)-2-methyl-heptane-1,3-diol 108 ............................ 94 
5.2.7 Alcohol 109 ............................................................................................ 95 
5.2.8 (5S, 6S)-6-Methyl-7-(tert-butyl-diphenylsilyl)-heptane-1,5-diol 110 ........ 96 
 
 
 
  
5.2.9 Lactone 111 ........................................................................................... 97 
5.3 Synthesis of AB Spiroketal Ring Fragment ...................................................... 98 
5.3.1 Ketoalcohol 114 ..................................................................................... 98 
5.3.2 Ketal 115 ................................................................................................ 99 
5.3.3 Dihydroxyketals 116a and 116b............................................................ 100 
5.3.4 Pivalates 8a and 8b .............................................................................. 101 
5.3.5 Spiroketals 10 and 11 ........................................................................... 102 
5.3.6 Spiroketal 9 .......................................................................................... 104 
5.4 Synthesis of C Ring Fragment ....................................................................... 105 
5.4.1 (E)-Methyl 3-methylhexa-2,5-dienoate 128 .......................................... 105 
5.4.2 (E)-Ethyl 3-methylhexa-2,5-dienoate 130 ............................................. 107 
5.4.3 (E)-3-Methyl-2,5-hexadien-1-ol 126 ...................................................... 108 
5.4.4 3-Methyl-2(S),3(S)-epoxy-5-hexen-1-ol 133 .......................................... 109 
5.4.5 Ester 134 .............................................................................................. 110 
5.4.6 Ester 135 .............................................................................................. 111 
5.4.7 Diol 136................................................................................................ 112 
5.4.8 C Ring Diol 137 ..................................................................................... 113 
5.4.9 C Ring Ester 138 ................................................................................... 114 
5.4.10 C Ring Aldehyde 139 ............................................................................ 115 
5.5 Synthesis of CDE Ring Fragment ................................................................... 116 
5.5.1 Nucleophilic Addition Strategy ............................................................. 116 
5.5.1.1 ?-Hydroxyketone 141 ....................................................................... 116 
5.5.1.2 TES Protected Ketone 190 ................................................................ 117 
5.5.1.3 tert-Butyl(2-methylallyloxy)diphenylsilane 148 ................................. 118 
5.5.1.4 3-((tert-Butyldiphenylsilyloxy)methyl)but-3-en-1-ol  149 .................. 119 
5.5.1.5 tert-Butyl(4-iodo-2-methylenebutoxy)diphenylsilane 150 ................. 119 
5.5.1.6 4-Bromo-2-methylenebutoxy-tert-butyldiphenylsilane 146 .............. 120 
 
 
 
  
5.5.1.7 Ethyl-4-benzyloxy-3-oxobutanoate 152 ............................................ 121 
5.5.1.8 Ethyl 2-(2-(benzyloxymethyl)-1,3-dioxolan-2-yl)acetate 153 ............. 122 
5.5.1.9 2-(2-(Benzyloxymethyl)-1,3-dioxolan-2-yl)ethanol 154 ..................... 123 
5.5.1.10 2-(Benzyloxymethyl)-2-(2-bromoethyl)-1,3-dioxolane 155 ................ 123 
5.5.1.11 Ethyl 2-(2-(hydroxymethyl)-1,3-dioxolan-2-yl)acetate 156 ................ 124 
5.5.1.12 Ester 157 .......................................................................................... 125 
5.5.1.13 Alcohol 158 ...................................................................................... 125 
5.5.1.14 Iodide 160 ........................................................................................ 126 
5.5.1.15 Bromide 159..................................................................................... 127 
5.5.2 Methylation Strategy ........................................................................... 128 
5.5.2.1 3-Benzyloxy-2-chloromethyl-1-propene 192 ..................................... 128 
5.5.2.2 3-Benzyloxy-2-bromomethyl-1-propene 193 .................................... 129 
5.5.2.3 2-Acetyl-4-benzyloxymethyl-pent-4-enoic acid ethyl ester 194 ......... 129 
5.5.2.4 5-Benzyloxymethyl-hex-5-en-2-one 98 ............................................. 130 
5.5.2.5 TMS Enolate 195 .............................................................................. 131 
5.5.2.6 ?-Hydroxyketone 165 ....................................................................... 132 
5.5.2.7 Aldol Reaction Screen ....................................................................... 133 
5.5.2.8 Diol 166 ............................................................................................ 134 
5.5.2.9 CDE Ring Fragment 167 .................................................................... 138 
5.6 Synthesis of ABCDE Ring Fragment............................................................... 140 
5.6.1 CDE Ring Alcohol 170 ........................................................................... 140 
5.6.2 CDE Ring Aldehyde 171 ........................................................................ 141 
5.6.3 CDE Ring Allylic Alcohols 198 and 173 .................................................. 142 
5.6.4 A Ring Triflate 98 .................................................................................. 144 
5.6.5 Ketone 175........................................................................................... 145 
5.6.6 Ketodiol 200 ......................................................................................... 146 
5.6.7 Diene 201 ............................................................................................. 147 
 
 
 
  
5.6.8 Ketodiol 184 ......................................................................................... 148 
5.6.9 Spiroketals 185 and 186 ....................................................................... 149 
5.6.10 Spiroketals 185 and 186 (aqueous conditions) ...................................... 150 
5.6.11 Thermodynamic Equilibration of Spiroketals 185 and 186 .................... 151 
5.6.12 [6,6]-Spiroketal 202 .............................................................................. 152 
6 REFERENCES ........................................................................................................ 155 
 
 
 
  
ABBREVIATIONS AND DEFINITIONS 
Ac acetyl 
AcOH acetic acid 
AD asymmetric dihydroxylation 
AE asymmetric epoxidation 
aq. aqueous 
9-BBN 9-borabicyclo[3.3.1]nonane 
Bn benzyl 
br broad 
Bu butyl 
tBu tert-butyl 
Bz benzoyl 
calcd calculated 
CAN cerium(IV) ammonium nitrate 
cat. catalytic amount 
CB catecholborane 
m-CPBA meta-chloroperbenzoic acid 
CSA camphorsulfonic acid 
CTX ciguatoxin 
D. Dinophysis 
DDQ 2,3-dichloro-5,6-dicyano-p-benzoquinone 
DET diethyl tartrate 
(DHQ)2AQN hydroquinine anthraquinone-1,4-diyl diether 
(DHQ)2PYR dihydroquinine 2,5-diphenyl-4,6-pyrimidinediyl diether 
(DHQD)2PYR dihydroquinidine 2,5-diphenyl-4,6-pyrimidinediyl diether 
DIBAL-H diisobutyl aluminum hydride 
DMAP 4-(N,N-dimethylamino)pyridine 
DMDO dimethyldioxirane 
DMF N,N-dimethylformamide 
DMS dimethyl sulfide 
DMSO dimethyl sulfoxide 
dr diastereomeric ratio 
DSP diarrhetic shellfish poisoning 
 
 
 
  
DTX dinophysistoxin 
ee enantiomeric excess 
EE ethoxyethyl 
equiv equivalent 
Erel relative energy 
Et ethyl 
h hour(s) 
i.p. intraperitoneal injection 
imid. imidazole 
inv inversion 
KHMDS potassium hexamethyldisilazane 
LD50 lethal dose, 50% (is the dose that kills half of the animals tested) 
LDA lithium diisopropylamide 
LiDBB lithium di-tert-butylbiphenylide 
lut. 2,6-lutidine 
m meta 
Me methyl 
min minute(s) 
Ms methanesulfonyl 
MS molecular sieves 
MTBE methyl tert-butyl ether 
NMP N-methyl-2-pyrrolidone 
Nu nucleophile 
OA okadaic acid 
p para 
PCC pyridinium chlorochromate 
Ph phenyl 
PIFA phenyliodonium bis(trifluoroacetate) 
Piv pivaloyl 
PMB para-methoxybenzyl 
PPTS pyridinium para-toluenesulfonate 
iPr iso-propyl 
PTX pectenotoxin 
PTXsa pectenotoxin seco acid 
pyr pyridine 
R arbitrary substituent 
ret retention 
rt room temperature 
sat. saturated 
SM starting material 
 
 
 
  
TASF tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBAF tetrabutylammonium fluoride 
TBDPS tert-butyldiphenylsilyl 
TBHP tert-butyl hydroperoxide 
TBS tert-butyldimethylsilyl 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
TES triethylsilyl 
Tf trifluoromethanesulfonyl 
TFA trifluoroacetic acid 
thexyl 1,1,2-trimethylpropyl 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TMS trimethylsilyl 
TS transition state 
p-TSOH para-toluenesulfonic acid 
YTX yessotoxins 
 
 
 
  
AUTHOR’S CONTRIBUTION 
The author designed and carried out the experiments and analyses and interpreted 
the results that are presented in this work. This work is also written by the author.
21 
 
 
  
O
OO
O OH
O
O
O
R1
O
O
O
O
OH
OH
A
B C
D
FH
O
O
OH
A
B
1 7 11
EG
33
40
20 43
11
7
R2
Pectenotoxins (PTX)
PTX1-7, PTX2b, PTX11, PTX11b, PTX13
PTX2c, PTX8,
PTX9, PTX11c
R3
36
O
OH
36H
OH
36S-PTX12 (C36 -OH)
36R-PTX12 (C36 -OH)
O
O
OH
H
G
33
40
O36
PTX14
17
14
1 PECTENOTOXINS 
1.1 Isolation and Structure 
In 1985, the Yasumoto group reported the isolation and characterization of a 
family of polyether macrolactones, the pectenotoxins (PTXs).1 The pectenotoxin 
family has since grown to comprise over 20 structurally related compounds 
(Figure 1, Figure 2). Originally isolated from scallops (Patinopecten yessoensis),1a 
the actual producers of PTXs are Dinophysis dinoflagellates, found in coastal 
areas worldwide.2  
 
 
 
 
 
 
  
 
 
Figure 1. Structures of pectenotoxins. White: biosynthesis products, grey: produced by 
metabolism of shellfish, red: artificial products formed by acid catalysis. 
The complex structure of the PTXs consist of a closed macrolactone containing a 
spiroketal ring unit, three differently substituted tetrahydrofurans, a bicyclic acetal 
ring  system,  a  cyclic  hemiketal  and  two  sites  of  unsaturation  in  the  form  of  
 R1 R2 R3 C7 
PTX1 CH2OH H H R 
PTX2 CH3 H H R 
PTX2b CH3 H H S 
PTX2c CH3 H H S 
PTX3 CHO H H R 
PTX4 CH2OH H H S 
PTX5 Structures not determined 
PTX6 COOH H H R 
PTX7 COOH H H S 
PTX8 CH2OH H H S 
PTX9 COOH H H S 
PTX10 Structures not determined 
PTX11 CH3 OH H R 
PTX11b CH3 OH H S 
PTX11c CH3 OH H S 
36S-PTX12 CH3 H H R 
36R-PTX12 CH3 H H R 
PTX13 CH3 H OH R 
PTX14 CH3 H - R 
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carbon-carbon double bonds. The PTXs carry a total of 19-20 stereocenters of 
which 7 are quaternary and several prone to epimerization under acidic 
conditions. The main structural differences between the PTXs are the oxidation 
state of C43 and the configuration of the C7 spiroketal center. More recently, 
open-chained  analogues,  PTX  seco  acids  (PTXsa),3 and analogues containing 
variations at the GH ring system have also been isolated and characterized (Figure 
1, Figure 2). A series of fatty acid esters of PTX2sa has been identified, which are 
similar to those reported to exist for example brevetoxins.3b-d 
 
 R4 R5 R6 C7 
PTX2sa and 7-epi-PTX2sa H H H R and S 
37-O-Acyl PTX2sa Fatty acid ester H H R and S 
33-O-Acyl PTX2sa H Fatty acid ester H R and S 
11-O-Acyl PTX2sa H H Fatty acid ester R and S 
PTX11sa CH3 OH H R and S 
36S-PTX12sa CH3 H H R and S 
36R-PTX12sa CH3 H H R and S 
Figure 2. Structures of pectenotoxin seco acids. All of them are produced by metabolism 
of shellfish. 
The most commonly found PTX in algae is PTX2, which is reported to be 
produced by many different dinoflagellate species of the genera Dinophysis and 
found in various parts of the world.4 Initially PTX2 was detected in D. fortii,5 and 
later also in D. acuta,6 D. acuminata,5e,7 D. caudata,8 D. rotundata,6b D. 
norgevica5e, 7b and D. infundibulus.5e Other PTX derivatives,  such as PTX11,6b,  9 
PTX12,7b and PTX1310 have also been identified from samples of Dinophysis. It is 
generally accepted that PTX2 is the parent compound, and a product of a natural 
biosynthesis.11 In addition, PTX11, PTX12 and PTX13 are also considered to be 
biosynthetically derived, where as the remaining PTXs are either produced by 
metabolism in shellfish or are artifacts of the extraction process and have not been 
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isolated from natural sources1b, 12 (see Figure 1 and Figure 2). However, the 
factors controlling the biosynthesis and accumulation of PTXs in shellfish appear 
to be more complicated than suggested thus far. Miles et al. have detected 
presumed C43 oxidized analogues of PTX2 in D. acuta sample from New-
Zealand.10 Also, PTX2b,6a  PTX1410 and PTX2sas8b, 13 together with other PTXs14 
have been identified in algae as minor compounds. These however, are most likely 
just chemically converted from PTX2 and PTX13 during extraction and storage. It 
has been proposed that enzymes released from disturbed cells during the 
extraction process could account for these transformations.6a, 7b PTX1 has been 
identified as the major component in D. acuminata sample harvested in the 
western North Sea.15 Even if quite a strong evidence was presented that PTX1 is 
at least partially, if not entirely, of biosynthetic origin, the writers could not 
entirely rule out the possibility that metabolic activity of heterotrophic organisms 
could effect the transformation of PTX2 to PTX1 in algae. 
 
When digested by shellfish, PTX2 can metabolize to other PTX derivatives. 
Enzymatic hydrolysis to an open-chained derivative PTX2 seco acid occurs in 
most shellfish species (Figure 2).3a-b, 16 Similar transformation takes place also 
with PTX11 and PTX12,5d, 6c however, they appear to be much more resistant to 
hydrolysis and thus these compounds accumulate in shellfish to a greater extent 
than does PTX2.7b, 9a PTX11 is at least two orders of magnitude more resistant to 
hydrolysis than PTX2 by the enzymes of mussels, probably due to steric 
hindrance induced by the C34-OH and hydrogen bonding between C34-OH and 
the carbonyl oxygen.9a   
 
Enzyme-mediated oxidation at C43 methyl group gives C43-hydroxy (PTX1), 
aldehyde (PTX3) and carboxylic acid (PTX6) derivatives (Figure 1).4a, 4c, 12a These 
oxidized PTXs, together with PTX4 and PTX7, have been observed to accumulate 
especially in the Japanese scallops, Patinopecten yessoensis.12, 17 The reason why 
these oxidized derivatives are rarely detected elsewhere might be that in other 
shellfish the conversion of PTX2 to PTX2sa is very rapid.18 This is supported by 
24 
 
 
  
the fact that often PTX2 is the most abundant toxin in Dinophysis, whereas in 
shellfish, PTX2sas predominate with only traces of PTX2.5d, 19 
 
Another important transformation occurring in shellfish is epimerization of the C7 
spiroketal center.6c, 12b Most of the PTXs isolated from natural sources contain a 
nonanomeric [6,5]-spiroketal ring system with R configuration, which easily 
epimerizes into a thermodynamically more stable anomeric spiroketal with S 
configuration (Figure 3). It is still unclear whether this transformation is mediated 
by a shellfish-derived enzyme or random acid catalysis. Miles et al. reported that 
PTX2sa and 7-epi-PTX2sa were found in shellfish in ratios that probably depend 
on the time since exposure of the shellfish to the algae, the shellfish species and 
the procedures used for extraction, treatment and storage of the sample.20 
However, this may not be the case with PTX4 and PTX7 as the formation of C7 
spiroketal epimers appears to occur much more rapidly with seco acids than with 
the corresponding lactones. It has been proposed that the carboxylic acid group in 
the seco acids could intramolecularly catalyze the epimerization of the spiroketal 
center.7b The acid-catalyzed equilibrium between the anomeric and the 
nonanomeric PTX congeners is discussed in more detail in Chapter 2.2. 
 
Figure 3. Crystal structure of PTX1 (CCDC: DIKHEK). The structure is enantiomeric to 
that of natural pectenotoxin. The nonanomeric spiroketal with R configuration is 
highlighted in blue.1a 
Despite increasing research during the past few years, very little is known about 
the dynamics of the toxin production by the dinoflagellate cells. The toxin content 
of a same dinoflagellate species has been reported to vary during the investigation 
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period even within specimens collected in the same locality.7a,b  However,  it  has  
also been reported that the toxin profiles of the same species in the same locality 
stays very stable and the toxin content remains in narrow limits.21 Usually PTXs 
coexist with other toxins, such as okadaic acid (OA) and dinophysistoxins 
(DTXs).4 Blanco et al. reported that no trace of these other toxins was found in D. 
acuminata samples, where the cellular content of PTX2 was exceptionally high.7c 
In other cases, however, D. acuminata specimens appear to contain only very 
small amounts of any of the pectenotoxins.5d Until very recently, there was no 
proof that PTXs are produced by Dinophysis dinoflagellates, because the 
Dinophysis species had not been successfully cultured.22 Recent results by Suzuki 
and Kamiyama strongly suggest that D. acuminata can produce PTXs in 
laboratory cultures.23 However, they did not completely deny the possibility that 
bacteria or prey organisms may be responsible for some roles in the production of 
these toxins. The PTX2 content in the field D. acuminata was 1.5 times higher 
than in the D. acuminata from laboratory culture. This implies that environmental 
conditions are at least one of the reasons for variable cellular toxicities in 
Dinophysis species. 
1.2 Activity 
The consumption of shellfish contaminated with toxins, produced by a number of 
naturally occurring phytoplankton species, can lead to human illness of different 
nature and severity depending on the toxin class. Pectenotoxins were initially 
classified and regulated along with the other diarrhetic shellfish poisoning (DSP) 
group of toxins, including okadaic acid (OA), dinophysistoxins (DTXs) and 
yessotoxins (YTXs), because of their co-occurrence and biological origin.2b 
Recently, it has been agreed that marine biotoxins are classified based on 
chemical structure, as opposed to classification based on clinical symptoms.24  
Due to potential threat to human health from consumption of contaminated 
shellfish and the economic impacts brought by human intoxication incidents, 
many countries have developed monitoring and regulatory systems.2b For 
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example, the European Union requires monitoring of shellfish for these toxins, 
including PTX1 and PTX2.25  
 
The inclusion of PTXs in the DSP group was long under debate, until recent 
studies  with  different  PTXs  failed  to  show  any  signs  of  diarrhetic  activity  even  
with high doses (5 mg/kg).6c, 9a Quite recently, PTX2 seco acids were suggested to 
be responsible for outbreaks of severe diarrhetic illness in Australia.2b However, 
later studies reveled that neither PTX2sa nor 7-epi-PTX2sa cause diarrhea.6c, 26 
Most  likely  the  samples  were  contaminated  with  okadaic  acid  esters,  as  the  
presence of even small amounts of these toxins might be sufficient to account for 
the observed effects.27  
 
Even though PTX2 is of very low toxicity by the oral route, it is highly toxic by 
intraperitoneal injection.2b, 6c, 12a LD50 toxicities have been determined for some of 
the  PTXs,  showing  that  the  most  toxic  congeners  are  PTX1,  PTX2 and PTX11 
(Table 1). PTX2sa and 7-epi-PTX2sa are of low toxicity both orally and 
intraperitoneally.3a, 20 This indicates that the closed macrocyclic structure is 
required for cytotoxicity and thus hydrolytic cleavage of the macrolactone of 
PTX2 to PTX2sa may be protective for detoxification in shellfish.  
 
Also, oxidation of C43 and epimerization of C7 spirocenter appear to be a result 
of a detoxification process. Oxidation of PTX2 to PTX1, then to PTX3 and finally 
to PTX6 is accompanied by a toxicity decrease in a mouse bioassay.12 Not 
surprisingly, the 7S epimer PTX4 was much less toxic than the 7R epimer PTX1 
and the toxicities of the [6,6]-spiroketal containing members, PTX8 and PTX9, 
were further diminished.12 However, oxidation at C34 does not seem to change 
intraperitoneal toxicity, as PTX11 has nearly the same LD50 toxicity as PTX2 and 
has been reported to produce the same symptom of intoxication in mice as 
PTX2.9a 
 
The protective detoxification systems in fish and shellfish have been postulated to 
be effected by a specific enzyme or a toxin-binding protein.28 It has also been 
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suggested that the algae are themselves subject to the toxicity and have their own 
metabolising enzymes to combat and detoxify different toxins.2b 
 
Table 1. Toxicity concentrations for various PTXs in mice. 
Toxin LD50 [?g/kg] (i.p.) Reference 
PTX1 250 12a 
PTX2 216-260 12a, 6c 
PTX3 350 12a 
PTX4 770 12a 
PTX6 500 12a, 29 
PTX7-8 >5000 12b 
PTX11 244 9a 
PTX2sa >5000 3a, 20 
7-epi-PTX2sa >5000 3a, 20 
 
 
Terao et al. were the first to demonstrate that an intraperitoneal injection of PTXs 
into mice produces high hepatotoxicity as the principal symptom.30 This was 
supported by subsequent studies, indicating that liver seems to be the target organ 
of PTXs.31 Also Fladmark et al. observed hepatocyte death in freshly isolated rat 
and salmon hepatocytes, however in this study PTX1 induced apoptosis rather 
than necrosis.32   
 
PTX2 has found to be potently cytotoxic against a variety of lung, colon, and 
breast cancer cell lines.2b, 33 Research in marine natural products has revealed that 
toxic mechanisms and anticancer effects of many compounds involves 
modification of the actin cytoskeleton.34 Actin is one of the most abundant and 
common cytoskeletal proteins for cell growth, motility, signaling, and 
maintenance of cell shape.35 It has been shown that the actin cytoskeleton is also 
the principal molecular target of the PTXs. Spector et al. demonstrated that PTX2 
disrupts the organization of actin in several cell types by G-actin monomer 
sequestration.34 Also, PTX6-induced disruption of F-actin cytoskeleton was 
observer, although at higher doses than those reported for PTX2. 36, 37 More recent 
data showed that also PTX11 triggered a remarkable depolymerizing effect on 
actin cytoskeleton and modifications in the shape of cells.38 In contrast, PTX2sa 
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did not evidence the same effects on F-actin and the depolymerizing activity of 
PTX1 was  about  half  that  of  PTX2.38 These results indicate that the diminished 
ability to disrupt F-actin is again related to structural changes in C43 oxidation 
state  and  that  the  macrolactone  ring  is  essential  for  the  action  of  PTXs on  actin  
cytoskeletal  dynamics.  Again,  it  seems that  oxidation  at  C34 does  not  affect  the  
potency of PTXs.  
 
Most recent studies on the mechanism of action at a molecular level have shown 
that PTX2 does not induce severing of F-actin but that it very efficiently inhibits 
actin polymerization by capping the fast-growing barber-end.39 However, based 
on the previous studies, G-actin sequestering effect cannot be ruled out as another 
possible mode of action. Kim et al. have investigated PTX2-induced anticancer 
mechanism in human leukemia cells and found that PTX2 inhibited the growth of 
leukemia cells and caused a marked increase in apoptosis.40 Chae et al.41 and 
Botane et al.42 independently discovered a higher sensitivity of cancerous cells to 
PTXs compared to normal cells, which could be of great clinical importance for 
the development of new cancer chemotherapy agents. 
 
However, further studies are still needed, because much of the toxicological 
effects,  the  mechanism  of  action  and  also  the  potential  impacts  the  PTXs  may  
have on public health in the long term are not yet fully understood. This is where 
the total synthesis comes into play, aiming to provide access to higher quantities 
of material than would ever be available from the marine sources. Further, in 
order  to  obtain  reliable  results,  the  purity  of  PTXs  isolated  from  the  natural  
sources may at times not be sufficient enough, especially due to potential 
contamination with the DSP toxins.  
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2 NONANOMERIC SPIROKETALS IN NATURAL PRODUCTS 
The majority of the naturally occurring spiroketal systems appear to be in the 
thermodynamically most stable anomeric configuration. There are, however, a 
number of naturally occurring spiroketal systems that contain the more unstable 
and less easily accessible nonanomeric configuration. These nonanomeric 
spiroketal systems have been found in natural products from a wide variety of 
sources: insect pheromones, different kinds of polyketide antibiotics and in 
marine toxins. Due to their fragile nature, nonanomeric spiroketals have often 
been the stumbling blocks of natural product syntheses, requiring a lot of work 
and determination before a successful synthesis has been achieved.43 
 
The fact that PTXs contain this challenging and intriguing nonanomeric spiroketal 
system is one of the major reasons why we became interested in the PTXs. We 
have recently published a thorough review covering nonanomeric spiroketals in 
natural products and the synthetic strategies used to access these structures.43 In 
this chapter, a short discussion of the anomeric effect is first presented. In the 
following section, the previously published syntheses of the AB spiroketal ring 
system of the PTXs are discussed. Finally, the most recent results with the 
syntheses of [6,5]-nonanomeric spiroketals in other natural products are 
presented.44 
2.1 Anomeric Effect 
The term anomeric effect45 describes the tendency of an electronegative 
substituent at the anomeric center C1 of a pyranose ring to prefer axial rather than 
equatorial orientation despite unfavorable steric interactions. The anomeric effect 
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is believed to arise from a stabilizing interaction between one of the lone pairs on 
the endocyclic oxygen and the antibonding ?*-orbital of the exocyclic C-O bond. 
For the overlap to be efficient, the lone pair on the oxygen has to be antiperiplanar 
to the C-O bond (Scheme 1).46 The contribution of anomeric stabilization to the 
total energy has been estimated to be in the range of 1.4-2.4 kcal/mol per 
interaction.47 The lone pair of the exocyclic oxygen can also exert similar effects 
to the antibonding orbital of the bond between the anomeric carbon (C1) and the 
ring oxygen. This is called the exo-anomeric effect, where also the conformation 
of the substituent must be such that a lone pair orbital is antiperiplanar to the 
antibonding orbital in the pyranose ring (Scheme 1).48 The exo-anomeric effect 
can also be stabilizing with equatorial substituents, and is also stronger with 
equatorial than with axial substituents.49 
 
Scheme 1. Molecular orbital model for the anomeric effect. 
The anomeric-nonanomeric configurational dichotomy becomes meaningful only 
if there is a clear difference between the anomeric and the nonanomeric 
substituent. The clearest case is the six-membered ring, where the difference 
between axial and equatorial substituents is clear-cut. Given the rapid 
pseudorotation in five-membered ring systems,50 nonanomeric relationships 
cannot be stabilized in five-membered rings. It is, however, reasonable to assume 
31 
 
 
  
that suitably substituted seven-membered rings or larger ring systems might 
display the anomeric-nonanomeric dichotomy. In addition, conformational 
locking by ring fusion or suitable placed equatorial substituent on the six-
membered ring is required to prevent access to the anomeric configuration by 
simple ring flipping. Not surprisingly, nearly all nonanomeric spiroketals, 
including the PTXs, bear an alkyl substituent in the 6-position of the 
tetrahydropyran ring, which prevents ring flipping due to unfavorable 1,3-diaxial 
interactions (Scheme 2). 
O
O
R
O
R O
severe 1,3-diax ial interact ions
 
Scheme 2. Unfavorable 1,3-diaxial interactions. 
In addition to the anomeric effect, steric interactions, intramolecular hydrogen 
bonding and other effects influence the conformation of a spiroketal.51 In natural 
products, the nonanomeric configuration may be stabilized by these additional 
factors, which override the thermodynamic preference for the anomeric 
configuration. In addition, the constraints imposed by the macrocyclic structures 
may favor the nonanomeric configuration. As such, for the anomeric stabilization 
to  effect  the  conformation  at  all,  it  must  be  more  stabilizing  than  the  sum of  all  
these other factors.  
 
In many syntheses of nonanomeric spiroketal ring systems, acid-catalyzed 
spiroketalization, typically accompanied with the release of acid-labile protecting 
groups has been used.43 The downside of this approach is that a thermodynamic 
mixture of the spiroketal isomers is formed, favoring in most situations the 
thermodynamically more stable anomeric configuration. The key thermodynamic 
question is how to stabilize the nonanomeric structure and thus favor it in the 
equilibrium?  Quite a few synthetic approaches have built upon the utilization of 
solvent effects, intramolecular hydrogen bonding or related chelation effects using 
different metal salts. However, most of these examples are case specific and the 
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selectivities are only moderate in many instances.43 Better selectivities can be 
obtained if the spiroketalization can be carried out under kinetic control, an 
approach that we have used successfully.52 The acid-catalyzed kinetic 
spiroketalization is a relatively mild method, giving it an advantage in complex 
settings with many functionalities. Also, the generation of nonanomeric 
spiroketals under mild acid catalysis may be sufficient to explain the formation of 
nonanomeric spiroketals in nature. It has been reported that the biogenesis 
pathway of certain spiroketals involves hemiketal-type precursors.53 In  an  
alternative approach, the acid-catalyzed spiroketalization can be avoided 
altogether.43 Recently, Rychnovsky has disclosed a general and practical method 
for a kinetic formation of nonanomeric spiroketals using reductive cyclization.54 
2.2 Nonanomeric [6,5]-Spiroketal Ring of Pectenotoxins 
The spiroketal unit of the PTXs has been observed to undergo isomerization under 
acid catalysis.12b Upon treatment with trifluoroacetic acid, the nonanomeric PTX6 
isomerized into an equilibrium mixture of the anomeric isomer PTX7, PTX6, and 
a third isomer PTX9. In PTX9, the [6,5]-spiroketal unit is expanded into a [6,6]-
spiroketal system, having the thermodynamically most stable doubly anomeric 
configuration  (Figure 4). The proportions of different isomers after equilibration 
were 40:16:44 (PTX6:PTX7:PTX9). A slightly different equilibrium mixture was 
obtained with PTX1, giving a mixture of PTX1, PTX4 and PTX8 in a ratio of 
29:14:57.12b More recently, Suzuki et al. reported very similar equilibration ratios 
with PTX1 (PTX1:PTX4:PTX8, 26:16:58) and PTX6 (PTX6:PTX7:PTX9, 
48:14:38).6b Also PTX2 was observed to undergo isomerization giving a 29:15:59 
equilibration mixture of PTX2, PTX2b and PTX2c, comparable to that for PTX1, 
PTX4 and PTX8.6b Interestingly, the Evans group reported that they had obtained 
an equilibration ratio of 11:10:79 with PTX1:PTX4:PTX8, starting from synthetic 
PTX4. Apparently, the macrocyclic structure helps in stabilizing the nonanomeric 
structure enough that it is still detectable after equilibration. However, both 
Yasumoto and Evans report that they only isolated PTX8 from the equilibrium 
mixture of PTX1:PTX4:PTX8.12b, 55b  
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Figure 4. Acid-catalyzed equilibration. 
2.3 Previous Syntheses of AB Spiroketal Ring Fragment of PTXs 
The exquisitely complex structure of the PTXs presents a considerable challenge 
for a synthetic chemist. By virtue of the structural complexity, natural scarcity and 
biological activity, many groups have chosen PTXs as their synthetic target. 
Despite the growing amount of research during the past decade, the first total 
synthesis by Evans and co-workers in 2002 still remains the only one.55 However, 
the next total syntheses are most likely just around the corner, as several groups, 
including Brimble,56 Paquette,57 and  Murai  and  Fujiwara58 have already most of 
the carbon backbone completed, lacking connection and the final finishing touch. 
 
The  AB  spiroketal  ring  system  is  one  of  the  most  studied  targets  of  the  PTXs.  
Especially during the past few years the spiroketal fragment has attracted more 
and more attention, resulting new fresh ideas and excellent syntheses. However, 
even though the nonanomeric PTX congeners appear to be the most cytotoxic and 
most biologically active, not to mention the extreme synthetic challenge provided 
by the thermodynamically less stable nonanomeric spiroketal, they have not 
attracted the attention they would deserve. Instead, most of the synthetic 
approaches have targeted PTXs with anomeric spiroketals. However, many 
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groups have envisaged that the corresponding PTXs with nonanomeric spiroketal 
configuration could be formed under equilibrium conditions in later stages of the 
synthesis, taking advantage of the constraints imposed by the macrocyclic ring. 
 
The synthetic studies towards pectenotoxins have been recently reviewed by 
Brimble and Halim.59  In the following discussion, the most recent advances in the 
AB spiroketal ring synthesis are presented and discussed in detail. Also, all of the 
earlier syntheses are shortly introduced to enable comparison.  
2.3.1 Synthesis by Evans et al. 2002 
In 2002, Evans group published the first synthesis for the AB spiroketal ring 
fragment of PTX4, together with the total synthesis.55 The  key  steps  are  boron-
mediated oxazolidinone aldol reaction to form the C2-C3 syn stereochemistry and 
tin-catalyzed aldol reaction to form the C10 stereocenter (Scheme 3). Wittig 
reaction was applied to connect aldehyde 6 and the A ring phosphonium salt 3. 
For the removal of the TES protection, camphor sulfonic acid was used which 
also effected cyclization of the ketal precursor to give the anomeric spiroketal 
product 7. This synthesis is quite an amazing achievement in the sense that 
incomparable 54% total yield was achieved over the 9 synthetic steps. 
 
Scheme 3. Synthesis of the AB spiroketal fragment of PTX4 by Evans et al.55a 
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2.3.2 Synthesis by Pihko and Aho 2004 
In our synthesis for the AB spiroketal ring fragment of PTX2 kinetic 
spiroketalization conditions were developed (Scheme 4).52 After screening 
different acids to effect the spiroketalization of a PMB ketal precursor 8, 
chloroacetic acid was found to be the best, delivering the desired nonanomeric 
spiroketal isomer 9 as  the  major  product  in  49% yield.  Our  synthesis  of  the  AB 
spiroketal ring fragment is fully presented in Chapter 3.3. 
 
Scheme 4. Synthesis of the AB spiroketal fragment of PTX2 by Pihko and Aho.52  
2.3.3 Synthesis by Paquette et al. 2005 
Paquette group also used a boron-mediated oxazolidinone aldol to form the 
desired C2-C3 syn product in stereoselective manner (Scheme 5).57c The B ring 
side of the carbon chain was synthesized starting from L-glutamic acid 12 in five 
steps. Connection of an organolithium species of 17 and Weinreb amine 14, 
furnished ketone 18,  which  under  the  conditions  used  for  removal  of  the  PMB  
protection groups (DDQ, pH7 buffer) cyclized to give the anomeric spiroketal 19 
in 92% yield. 
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Scheme 5. Synthesis of the AB spiroketal fragment of PTX2b by Paquette et al.57c 
2.3.4 Synthesis by Brimble et al. 2006 
In a similar manner, Brimble group applied oxazolidinone aldol for the 
construction of the C2-C3 syn stereochemistry (Scheme 6).56b, c This time the C8-
C7 connection was constructed using Julia olefination between the anion of 
sulfone 23 and aldehyde 21. After oxidation and reductive elimination of the 
sulfone, p-toluenesulfonic acid induced the removal of the TBS protections and 
ring closure to give the anomeric spiroketal product 19 in 85% yield.  
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Scheme 6. Synthesis of the AB spiroketal fragment of PTX7 by Brimble et al.56b, c 
2.3.5 Synthesis by Williams et al. 2007 
In comparison to the previous syntheses, Williams group developed quite a 
different  approach  to  synthesize  the  AB  spiroketal  ring  fragment  of  PTX4.60 In 
their synthesis, also the C12 quaternary center is selectively formed by using an 
intramolecular spirodiepoxide cyclization as the key step (Scheme 7). The C2-C3 
syn stereochemistry of the A ring building block was once again formed by 
utilizing the ever so popular oxazolidinone aldol reaction. The other building 
block was synthesized from a Weinreb amide 29 and a TBDPS protected alkyne 
diol 31 to give propargyl alcohol 32 after enantioselective reduction. Conversion 
to the corresponding mesylate and then to allene 33 proceeded in excellent 96% 
yield. Alkylation of aldehyde 27 with the organolithium species derived from 34, 
followed by oxidation furnished ketone 35. Finally, an optimized single flask 
procedure effected the removal of the PMB protection group, oxidation to form a 
spirodiepoxide and acid-catalyzed spirodiepoxide opening together with 
spiroketal ring closure to give the anomeric spiroketal product 36 in 89% yield 
and 7:1 diastereoselectivity.  
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Scheme 7. Synthesis of the AB spiroketal fragment of PTX4 by Williams et al.60 
The key allene oxidation was first studied with a model compound 37 to show that 
a mixture of two diastereomeric spirodiepoxides could be formed in >5:1 
diastereoselectivity (Scheme 8). The writers propose that the first oxidation takes 
place on the more highly substituted double bond, giving high diastereoselectivity 
(20:1) due to unfavourable steric interaction. These syn-pentane interactions 
together  with  the  bulky  substituents  in  C14  were  also  considered  to  control  the  
facial selectivity of the second oxidation by enforcing a preference for a top face 
approach. The increased reactivity of the allene oxide 39 compared to that of an 
allene 37 was proposed to be the reason for the lower selectivity obtained for the 
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second oxidation. Fortunately, a slight improvement in the selectivity was 
obtained with the actual substrate. 
 
Scheme 8. Stereoselectivity of the allene oxidation. 
For the spiroketal formation the writers proposed two alternative pathways 
(Scheme 9). Either A) the ketone attacks the spirodiepoxide, followed by trapping 
of the formed oxocarbenium ion with the C2 hydroxyl to give spiroketal 44, or B) 
a six-membered lactol 45 is formed before the spirodiepoxide, and the lactol 
hydroxyl then attacks the spirodiepoxide to form spiroketal 44. 
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Scheme 9. Two possible pathways for the formation of spiroketals via intramolecular 
spirodiepoxide cyclization. 
2.3.6 Synthesis by Rychnovsky et al. 2007 
Rychnovsky and co-workers have developed a method that constitutes a 
significant breakthrough in the synthesis of nonanomeric spiroketals. By reversing 
the usual roles of the nucleophile and the electrophile in spiroketal synthesis, the 
normal preference for the anomeric isomer is effectively suppressed.54 A sequence 
of stereoselective reductive lithiation followed by cyclization, gives different 
kinds of nonanomeric spiroketal structures, including [6,5]-spiroketals, as single 
diastereomers (Scheme 10). Upon treatment of the ortho ester-derived axial nitrile 
48 with lithium di-tert-butylbiphenylide (LiDBB), the resulting lithium species 49 
retains its axial configuration. The lithiated acetal can now act as a nucleophile, 
displacing the primary chloride and generating the nonanomeric spiroketal 50. 
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Scheme 10. Synthesis of nonanomeric spiroketals by stereoselective reductive lithiation 
and cyclization.  
Taking advantages of this methodology, a successful synthesis of the AB 
spiroketal ring fragment of PTX2 was achieved (Scheme 11).61 Again, the 
synthesis began with the well-tried and reliable boron-mediated oxazolidinone 
aldol reaction. The requisite ortho ester was formed from thio-phenyl 
dihydropyran 52 and diol 54, itself derived from a commercially available alcohol 
53.  Cleavage  of  the  orthoester  with  TMSCN  and  BF3·OEt2 produced two 
regioisomers, with the preferred isomer 56 formed in 50% yield. In previous cases 
this cleavage had been very regioselective for the primary group.54 The  lack  of  
selectivity in this case was attributed to the fact that 55 was  less  sterically  
hindered than the previously studied intermediates. After TBS protection, the 
reductive cyclization using freshly prepared LiDBB furnished the nonanomeric 
spiroketal 59 as a single diastereomer in 76% yield. 
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Scheme 11. Synthesis of the nonanomeric AB spiroketal fragment of PTX2 by 
Rychnovsky et al.61 
Based on recent studies with the synthesis of related spiroketals, Rychnovsky and 
co-workers proposed a detailed mechanism for the cyclization and provided two 
different explanations for the origin of the anomeric spiroketals that have 
occasionally been identified as minor products (Scheme 12).62 The radical 
intermediate, generated by single electron transfer and the subsequent C-CN bond 
fission from 60, can still undergo inversion of stereochemistry. The preference for 
the radical to occupy an axial position (61) has been calculated to be ~1.9 
kcal/mol, apparently as a result of anomeric effect.63, 62 When the second electron 
is added in the reduction, the corresponding alkyllithiums 63 and 64 are formed in 
precisely the same ratio. In an alternative rationalization, the radical can undergo 
inversion to equatorial configuration 62 giving  access  to  larger  amounts  of  the  
anomeric isomer 66 (path A).62, 64 In addition, the anomeric isomer could arise 
from a cyclization with partial inversion of configuration (path B). However, the 
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configurational stability of ?-oxygenated alkyllithiums is well documented,65 and 
thus the inversion pathway B would presumably be far less facile. 
 
Scheme 12. Mechanism of the reductive cyclization. The preferred route to the 
nonanomeric spiroketal in red. 
2.3.7 Strategies in Comparison 
The different methods that have been used to construct the stereocenters in the AB 
spiroketal ring fragment of PTXs are summarized in Scheme 13. From the six 
syntheses developed for this fragment, five of them utilize oxazolidinone aldol 
chemistry to form the C2-C3 syn stereochemistry. With new modern methods for 
asymmetric catalysis breaking ground, the use of chiral auxiliaries is often 
considered to be old-fashioned and rather inefficient. However, chiral auxiliary-
based aldol reactions are still one of the best and most reliable ways to synthesize 
syn-?-methyl-?-hydroxy structures in highly stereoselective fashion. 
 
As expected, an acid-catalyzed cyclization to form the C7 spiroketal center was 
by far the most popular method of choice. The thermodynamic conditions 
delivered the anomeric spiroketals in good yields. With the kinetic 
spiroketalization, the nonanomeric spiroketal could be formed as the major 
product, although substantial amounts of the anomeric isomer was still formed. 
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Further research is needed, as the factors controlling the kinetic selectivity 
towards the nonanomeric isomers are still poorly understood. In terms of 
selectivity towards the nonanomeric isomer, the reductive cyclization method 
developed by Rychnovsky et al. stands out from all other protocols. However, in 
order to avoid epimerization of the extremely fragile nonanomeric spiroketal, it 
should be formed as one of latest steps of the total synthesis. The acid-catalyzed 
kinetic spiroketalization is a relatively mild method giving it an advantage with 
complex substrates, whereas the applicability of the reductive cyclization protocol 
in such demanding conditions still remains to be seen. 
 
Scheme 13. Comparing different methods used to construct the stereocenters. 
2.4 Other Natural Products with a Nonanomeric [6,5]-Spiroketal  
The nonanomeric [6,5]-spiroketal is a quite rare structure in natural products 
compared to the nonanomeric [6,6]-spiroketals. Two of the largest groups 
containing nonanomeric [6,5]-spiroketals are insect pheromones and ionophore 
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antibiotics (Figure 5).43, 66  An extensive selection of naturally occurring 
spiroketals have been isolated as pheromones from several insect species and the 
nonanomeric [6,5]-spiroketal systems have been identified as the minor 
components. However, there are only few synthetic studies addressing these 
structures67 whereas the corresponding nonanomeric [6,6]-spiroketals of insect 
pheromones have attracted more attention and there are multiple synthesis 
examples.43  
  
Figure 5. Insect pheromones with [6,5]-spiroketals, endusamycin (CP-63.517) and 
crystal structure of endusamycin rubidium salt (CCDC: SAWGIG). 
A total of 13 members of the dianemycin/endusamycin class of antibiotics have 
been identified, all having a nonanomeric configuration in the CD spiroketal ring 
system (Figure 5).68 However, neither total synthesis of these natural products, nor 
synthesis for the nonanomeric CD spiroketal ring system has been reported.  
 
Two other natural products bearing a nonanomeric [6,5]-spiroketal have attracted 
more attention from the synthetic community, namely the ciguatoxins and the 
aculeatins. 
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2.4.1 Ciguatoxins  
The spiroketal ring system is relatively common structural feature in marine 
natural products. However, in addition to pectenotoxins, only ciguatoxins (CTXs) 
have been identified to contain a nonanomeric [6,5]-spiroketal ring unit. Over 20 
members of the CTXs have been identified, and four of the CTX congeners have 
been assigned to contain a nonanomeric LM spiroketal ring system (Figure 6).  
 
Figure 6. 52-epi-Ciguatoxin (CTX4A). 
Several research groups have studied the synthesis of different CTXs,69 but once 
again the nonanomeric congeners have not been set as the primary targets. 
Recently Fujiwara et al. obtained the nonanomeric isomers as unwanted side 
products in their synthetic studies towards CTX3C.70, 71 Hemiacetal 67 was used 
as a substrate in the model studies, which upon treatment with CSA underwent 
deprotection of the ethoxyethyl and TES protection groups and subsequent 
spiroketalization to form a 3:1 mixture of the spiroketal products 68 and 69, in 
favour of the anomeric isomer 68 (Scheme 14). 
 
Scheme 14. Synthesis of a model compound of the LM spiroketal of CTX3C. 
47 
 
 
  
In the actual synthesis of the IJKLM ring fragment of CTX3C, a photochemical 
hypoiodite oxidation72 was  used  to  give  a  1:1  mixture  of  the  anomeric  (72) and 
nonanomeric (71) spiroketal (Scheme 15).70b This mixture was equilibrated with 
CSA in MeOH to give the desired IJKLM fragment with an anomeric spiroketal 
in 73% yield.  
 
Scheme 15. The synthesis of the IJKLM fragment of CTX3C. 
2.4.2 Aculeatins and Aculeatols 
One of the most recently identified group of natural products possessing a 
nonanomeric [6,5]-spiroketal are the aculeatins.73 Aculeatins A-D were isolated 
from the herbaceous plant Amonum aculeatum distributed in Malaysia, Indonesia 
and Papua New Guinea, where it is used as a folk medicine against fever and 
malaria. Initial studies have shown the aculeatin compounds to display 
antiprotozoal and antibacterial activity. Not surprisingly, one of the nonanomeric 
spiroketal containing aculeatins, aculeatin D, is found to be the most biologically 
active.73 Even more recently, four new aculeatin derivates, aculeatols A-D were 
isolated and characterized.74 The structures of the nonanomeric aculeatin 
congeners are presented in Figure 7. The aculeatins have been the target of several 
synthetic studies in the recent years. However, the creativity has been quite low, 
as all of the syntheses have applied similar kinds of protected ketophenols as 
substrates for the key oxidative spiroketalization with hypervalent iodine 
reagent.75 
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Figure 7. The nonanomeric aculeatin congeners: aculeatin B, aculeatin D and aculeatol 
D.  
Marco et al. achieved the first enantioselective synthesis of aculeatins A, B and 
D.76, 77 Treating acetonide 76 with phenyliodonium bis(trifluoroacetate) (PIFA) 
triggered phenolic oxidation together with acetonide hydrolysis and 
spiroketalization to form a 5.5:1 mixture of the anomeric aculeatin A (77) and 
nonanomeric aculeatin B (73) (Scheme 16). In a similar manner, a 2.7:1 mixture 
of the anomeric 6-epi-aculeatin D (79) and the nonanomeric aculeatin D (74) was 
formed starting from a TBS protected ketone 78. (Scheme 16).  
 
Scheme 16. The synthesis of aculeatins A, B, D and 6-epi-aculeatin D by Marco et al.76  
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Chandrasekhar et al. synthesized aculeatins A and B using a ketophenol 80 as 
substrate.78 After catalytic hydrogenolysis of the benzylidene, benzyloxy and 
acetylene groups, treatment of the crude product with PIFA furnished a 2.5:1 
mixture of aculeatin A and aculeatin B (Scheme 17).  
 
Scheme 17. Synthesis of aculeatins A and B by Chandrasekhar et al.78 
Wong et al. screened two different kinds of substrates for the synthesis of 
aculeatin D (Table 2).79  Oxidative cyclization with PIFA gave a 2:3 mixture of 
the nonanomeric and anomeric isomers when lactol 81 was used as a substrate 
(entries 1-3), whereas with methoxy ketal 82, a 1:1 mixture was formed (entries 4-
6). TFA and zinc chloride had neither influence on the selectivity nor the yield of 
the reaction. It was proposed that the oxygen of the methoxy group in ketal 82 
might be less nucleophilic than the free hydroxyl group in 81,  allowing  a  
competitive intermolecular addition of water leading to the nonanomeric isomer 
74 via path 2. In an alternate pathway (path 1) intramolecular attack by the free 
hydroxyl group of lactol (83) on the phenoxonium cation leads to prefential 
formation of the anomeric isomer 79 (Table 2).  
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Table 2. Synthesis of aculeatin D and 6-epi-aculeatin D by Wong et al. 
Entry Substrate Additive Ratio 74:76 Total yield [%] 
1 81  41:59 64 
2 81 TFA (0.4 equiv) 44:56 71 
3 81 ZnCl2 (1.2 equiv) 42:58 69 
4 82  51:49 69 
5 crude 82  52:48 65 (over 2 steps) 
6 crude 82 ZnCl2 (1.2 equiv) 49:51 51 (over 2 steps) 
 
 
Similar spiroketalization conditions were screened for the formation of aculeatins 
A and B (Table 3). When an open-chained ketodiol precursor 87 was  used  as  a  
substrate, a 2:3 ratio in favor of the anomeric isomer, aculeatin A, was obtained 
(entries 2-4). With methoxy ketal 86, a ~1:1 product ratio was again obtained 
(entry 1). The reaction with the open-chained ketodiol 87 was proposed to 
proceed via oxonium ion intermediate 88 (Table 3). 
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Table 3. Synthesis of aculeatins A and B by Wong et al. 
Entry Reactant Additive Ratio 73:77 Total yield [%] 
1 86  47:53 68 
2 87 TFA (0.4 equiv) 42:58 82 
3 87 ZnCl2 (1.2 equiv) 43:57 57 
4 87  38:62 71 
 
 
The three most recent syntheses developed for different aculeatin congeners are 
presented in Scheme 18. Ramana et al.80 and Wu et al.81 also obtained a 1:1 
mixture of 6-epi-aculeatin D and aculeatin D. With the thioketal protected 
substrate 90, pH6 buffer was needed to obtain the nonanomeric product, when 
without any buffer the anomeric isomer was obtained as a single product in 74% 
yield. Venkateswarlu et al.82 used a similar acetonide protected ketone 91 as 
Falomir et al. in their previous studies (Scheme 16). By adding TFA and reducing 
the reaction time to 4 hours, a slight increase in the selectivity in favor of the 
nonanomeric isomer was obtained (5.5:1 vs. 5:2) 
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Scheme 18. Aculeatin syntheses by Ramana,80 Wu81 and Venkateswarlu82. 
For a comparison, under most circumstances the anomeric isomer is formed as the 
major product. At best, a 1:1 mixture of the spiroketal isomers has been obtained. 
Surprisingly little work has been done in screening different conditions for these 
reactions. In order to gain more information about the selectivity issues with these 
systems, at least a thorough study covering different reaction temperatures and 
different solvent systems should be implemented.  
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2.4.3 Unnatural Nonanomeric Spiroketal of Attenol A 
Rychnovsky et al. have applied their reductive cyclization protocol also for the 
synthesis of other nonanomeric spiroketals. The most recent example, in which 
excellent yield and selectivity for the nonanomeric spiroketal isomer was 
obtained, is the synthesis of Attenol A (Scheme 19).62 Attenol A was isolated 
from Chinese bivalve Pinna attenuate in 1999, and have shown moderate 
cytotoxicity against various tumor cell lines.83 The  spiroketal  in  Attenol  A  is  
really in an anomeric configuration, but it was envisaged that the corresponding 
compound with a nonanomeric spiroketal could be used as a pro-drug for its 
natural isomer. It was proposed that the acidic media of solid tumors (pH ca. 6.8) 
could trigger the isomerization of the nonanomeric isomer, and this property could 
be used to selectively target tumor cells.62 
 
Spiro orthoester 92 was opened as usual, now with good regioselectivity to give 
the desired cyanoacetal in 71% yield (Scheme 19). In this synthesis the 
electrophile had to be installed after the cyanoacetal and a phosphate ester was 
chosen to serve the purpose, because it could be installed under reaction 
conditions mild enough to preserve the cyanoacetal and the TBS protection. 
Reductive cyclization of the intermediate phosphate 93 produced the nonanomeric 
spiroketal 94 as the major product in remarkable 94% yield! This intermediate 
was further equilibrated to the more stable anomeric spiroketal 95 (PPTS, MeOH) 
and then carried on the final three steps to Attenol A. As such, the reductive 
cyclization method is a powerful strategy for the construction of spiroketal 
containing natural products, as it opens access selectively to form either of the 
spiroketal isomers. 
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Scheme 19. Synthesis of the unnatural nonanomeric spiroketal ring of Attenol A. 
To  investigate  the  possible  use  of  the  nonanomeric  isomer  as  a  pro-drug,  
epimerization of the spiroketal 94 in aqueous buffer solutions (NaOAc/AcOH) 
were evaluated (Scheme 19). This spiroketal precursor, however, turned out to be 
impractical for the use as a pro-drug, because under normal physiological 
conditions the nonanomeric spiroketal would be stable indefinitely. Only partial 
epimerization occurred in a pH 4.0 buffer, leading to 10:1 ratio of the 
nonanomeric and anomeric isomers.  
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3 SYNTHESIS OF 10-EPI-ABCDE RING FRAGMENT OF PECTENOTOXIN 2 
3.1 Introduction 
The pectenotoxins came to my life already during my undergraduate studies, as I 
came to choose the A ring lactone structure for my synthesis design assignment. 
At that point, however, I was not aware that my long lasting journey with the 
PTXs had begun. Later, I had the opportunity to try out my design in a lab course 
and since then my work in the lab has been all for the PTXs. During these years I 
have learned that natural product synthesis is probably one of the most 
challenging areas of organic chemistry. An understanding of a wide range of 
chemical principles in combination with experimental skills and most importantly 
imagination is required to achieve the synthetic goals.  
 
Natural products have found many uses in medicinal chemistry and the 
exceptional structural and chemical diversity of these compounds promises new 
discoveries also in the future.84 For this very reason, natural product synthesis is 
often rationalized through the biological activity of these compounds. In my 
opinion however, the reaction chemistry, both at strategic and operational levels, 
that provides new information and solutions, and in some cases new methods for 
organic synthesis, is more than a sufficient rationale.  
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3.2 Retrosynthetic Design 
Our retrosynthetic analysis for the ABCDE ring fragment of PTX2 is presented in 
Figure  8.  This  fragment  contains  the  bicyclic  acetal,  the  cis-fused THF ring and 
the nonanomeric spiroketal as challenging and interesting structural motifs that 
may need special attention from a synthetic point of view due to their 
stereochemical features and fragile nature. In order to allow easy scale-up and 
provide an efficient route to the desired target, our strategy was to use a highly 
convergent synthesis using three advanced fragments 96-98 (Figure 8). The 
carbon framework was envisioned to be assembled via aldol addition and Suzuki-
Miyaura coupling. The key feature of the strategy was the need to form the 
delicate nonanomeric AB spiroketal ring structure in the late stages of the 
synthesis. In the following chapters the syntheses of fragments 96-98 and their 
assembly to form the ABCDE ring system of PTX2 are presented and discussed. 
 
Figure 8. Retrosynthetic analysis for the ABCDE ring fragment of PTX2. 
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3.3 Synthesis of A Ring Fragment 
3.3.1 Epoxidation Strategy 
Among  several  possible  routes  for  the  construction  of  the  A  ring  fragment,  we  
selected a strategy wherein the lactone ring structure 99 would arise from allylic 
alcohol 102 through a sequence of Katsuki-Sharpless asymmetric epoxidation85 
and regioselective epoxide ring opening (Scheme 20). 
 
 
Scheme 20. Retrosynthetic analysis for the A ring fragment. 
Commercially available 1,5-pentanediol 103 was monobenzylated using a 
procedure by Kiddle et al.,86 followed by Swern oxidation using the standard 
conditions87 to afford a known aldehyde 104.88 (Scheme 21) Horner-Wadsworth-
Emmons olefination89 by using the Ando phosphonate90 and a combination of 
NaH/NaI as the base, an improved protocol developed previously in our group,91 
gave the desired (Z)-enoate 105 in excellent 97:3 Z:E selectivity. The remaining E 
isomer was easily removed by column chromatography and the subsequent 
DIBAL-H reduction furnished pure Z allylic alcohol 106 in 94% yield.  
58 
 
 
  
 
Scheme 21. Synthesis of allylic alcohol 106. 
The construction of the C2-C3 syn stereochemistry commenced with a Katsuki-
Sharpless asymmetric epoxidation to deliver the desired cis epoxide 107 in 60-
72% yield and 75-83% ee. (Scheme 22) Epoxide ring opening with a higher order 
mixed cuprate92 and subsequent cleavage of the 1,2-diol side product with NaIO4 
furnished a crystalline diol 108 in 65% overall yield after recrystallization. The 
enantiomeric purity, which could be determined only after conversion to diol 110, 
had improved to 95% ee upon recrystallization. Monosilylation of the diol 108 
and subsequent reductive debenzylation cleanly afforded diol 110. Finally, 
oxidation with PCC afforded the A ring lactone 111 in 58% yield.  Recently, 
TEMPO oxidation was discovered to be a much better in effecting the oxidation 
of 110, giving 89% yield of the lactone 111.93 Overall, 9 steps were required to 
synthesize the A ring fragment in 14% overall yield (22% if TEMPO oxidation is 
used). 
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Scheme 22. The synthesis of the A ring lactone 111. 
3.3.2 Synthesis of AB Spiroketal Ring Fragment 
Before going forward with the strategic plan presented in Figure 8, the A ring 
lactone was used to synthesize the AB spiroketal  ring fragment of PTX2. In the 
initial studies, the main objective was to develop suitable kinetic conditions for 
the spiroketalization to deliver the desired nonanomeric isomer as the major 
product. Also, we were expecting to obtain indispensable information regarding 
the sensitivity of the spiroketal ring structure that would be useful in later stages 
of the synthesis. 
 
Deslongchamps and co-workers were first to study the formation of nonanomeric 
spiroketal isomers under kinetic control in the [6,6]-spiroketal series.51b They 
suggest that the formation of the nonanomeric spiroketal isomers can be explained 
by assuming an early transition state (TS) for the spiroketalization. In the early TS 
the formation of the C-O bond would not be sufficiently advanced to generate 
significant energy differences between the pseudoequatorial and pseudoaxial 
attacks (Scheme 23). On the contrary, a late transition state would become more 
and  more  boat-like  and  thus  would  be  expected  to  suffer  from  severe  
stereoelectronic strain. As we started our studies with the pectenotoxin 
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spiroketals, kinetically controlled spiroketalization to give nonanomeric isomers 
as the major product in the [6,5]-series had not been reported. 
 
Scheme 23. Pseudoequatorial and pseudoaxial attacks. 
The AB spiroketal ring fragment 112 was  envisioned  to  arise  from  the  A  ring  
lactone 99 by Grignard addition and asymmetric dihydroxylation94 (Scheme 24). 
 
Scheme 24. Retrosynthetic analysis for the AB spiroketal ring fragment of PTXs. 
To this end, lactone 111 was treated with 4-butenylmagnesium bromide to afford 
ketoalcohol 114 in  total  yield  of  60% after  two recycles  of  the  starting  material  
(Scheme 25). Acid-catalyzed methanolysis (MeOH, PPTS) failed to give the 
desired methoxy ketal as it readily decomposed to give a mixture of elimination 
products. However, benzyl and especially p-methoxybenzyl (PMB) ketals were 
stable enough and PMB ketal 115 could be obtained in 83% yield after 
purification by column. 
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Dihydroxylation using the Sharpless ligand (DHQ)2PYR94b, 95 cleanly afforded the 
diol product in 70:30 diastereoselectivity (Scheme 25). (DHQ)2AQN was also 
tested for this dihydroxylation, but this ligand gave no improvement to the 
selectivity.96 Protection of the crude diol furnished a mixture of the monopivalates 
8a and 8b in 62% yield over two steps. The protection was crucial in order to 
prevent the formation of the thermodynamically more stable but undesired [6,6]-
spiroketals.6b, 12b 
 
Scheme 25. Synthesis of the spiroketalization substrate. 
Now that we had the spiroketalization substrate at hand, all that remained was to 
close  the  ring.  For  this  key  reaction,  different  acid  promoters  were  screened  
(Table 4). The use of a strong acid (p-TsOH) led to a rapid formation of a mixture 
of four spiroketal isomers (entries 2-3). The two anomerically stabilized 
spiroketals 10 and 11 (C10 epimer of 10) were identified as the major products. 
The more polar nonanomeric isomers 9 and 117 (C10 epimer of 9) were only 
observed in the initial stages of the reaction. Further equilibration afforded the 
anomeric spiroketals 10 and 11 almost exclusively, demonstrating that the desired 
nonanomeric spiroketal 9 appears to be a kinetic product.  
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With weaker acids such as acetic acid, formic acid and chloroacetic acid (entries 
4-7), progressively larger amounts of the desired nonanomeric spiroketal isomer 9 
was afforded. Surprisingly, PPTS gave similar results with those of p-TsOH, thus 
appearing to be effectively stronger acid than any of the carboxylic acids in the 
reaction medium. This indicates that in this case, pKa values in DMSO are more 
reliable guides to reactivity than those measured in H2O, presumably because the 
spiroketalizations were performed in an aprotic solvent (CH2Cl2). Chloroacetic 
acid was found to be the optimal acid catalyst for the kinetic spiroketalization 
(entry 4), affording the nonanomeric spiroketal 9 as the major product in 49% 
yield. Interestingly, under these conditions, less than 5% of the minor C10 epimer 
117 was formed.  
Table 4. Spiroketalizations with different acid promoters. 
 
Entry Acid promoter pKa H2O (DMSO) 
Reaction 
time 10 11 9 (+117) 
1 PPTS (20 mol-%) 5.21 (3.4) 10 min 53 18 29b 
2 p-TsOH (20 mol-%) -1.3 10 min 50 20 30 
3 p-TsOH (20 mol-%)  -1.3 90 min 69 29 <2 
4 ClCH2CO2H (80 mol-%) 2.86 4 h 29 22 49
c 
5 HCOOH (40 mol-%) 3.77 4 h 29 28 43 
6 AcOH  (200 mol-%)d 4.76 (12.3) 6 h 35 25 40 
7 AcOH   (3300 mol-%) 4.76 (12.3) 21 h 64 34 <2 
a For entries 2-3 and 5-6, product ratios were determined by HPTLC after the reaction had 
reached >90% conversion. Spiroketals 9-11 and 117 were the only products identified, isolated 
yields were not determined. For entries 1, 4 and 7, the ratios represent isolated yields [%] of the 
products. b Including  10%  of  117. c Including  5%  of   117. d With  20  or  40  mol-%  of  AcOH,  the  
reaction failed to go to completion within 24 h. 
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The configurations of the different spiroketal isomers were assigned by NOESY 
experiments. Several diagnostic NOESY cross-peaks clearly identified spiroketal 
9 as the nonanomeric isomer (Figure 9).  Also, 13C  NMR  chemical  shift  of  the  
spiro carbon (C7) in 9 was shifted downfield relative to 10 and 11 (109.4 ppm in 9 
vs. 107.2 in 10 and 107.3 in 11), a trend that is also seen in the pectenotoxins12b 
and in the [6,6]-spiroketal series51b. In addition, 1H NMR coupling constant data 
clearly indicates a chair conformation for the A ring (Figure 9). 
 
Figure 9. The NOESY cross-peaks and the coupling constants. 
More recently, additional studies were conducted in our group by Daniele 
Castagnolo to further examine the kinetic formation of nonanomeric [6,5]-
spiroketals.97 By using different mixed ketal-alcohol precursors for the 
spiroketalization the anomeric isomers were formed as the major products (Table 
5). However, also nonanomeric spiroketal isomers were observed when the 
reaction was performed under kinetic conditions using an appropriately tuned 
acid. Surprisingly, water had a dramatic accelerating effect when THF was used 
as a solvent, and the highest yields of the nonanomeric products were obtained in 
aqueous THF (Table 5, entries 4-5).98 In addition, the product ratio was strongly 
affected by the substituents and the stereochemistry of the starting alcohol. 
Similar to our results with the AB spiroketal ring system, the C10 epimer that 
corresponds to the natural PTX gave rise to both nonanomeric (122) and anomeric 
(120) spiroketals, whereas the unnatural C10 epimer afforded the anomeric 
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spiroketal 121 as the major product with only trace amounts of the nonanomeric 
isomer 123.  
Table 5. Spiroketalization with simple ketal-alcohol precursors. 
 
Entry R Acid (60 mol-%) pKa Solvent Time [h] 120
a 121a 122a 
1 Me ClCH2COOH
b 2.86 CH2Cl2 4 40
c 24c 26c 
2 Me Cl3CCOOH 0.65 THF 28 23 19 25
d 
3 Me ClCH2COOH 2.86 THF/H2O 4:1 16    
4 Me Cl3CCOOH 0.65 THF/H2O 4:1 5.5 23
c 23c 49c 
5 PMB Cl3CCOOH 0.65 THF/H2O 4:1 5 24
 21 44 
6 Me ClCH2COOH 2.86 CH3CN/H2O 4:1 1 44 29 26 
7 Me ClCH2COOH 2.86 CH3CN/H2O 4:1
e 5 29 26 43 
8 Me Cl3CCOOH 0.65 CH3CN/H2O 4:1 0.25 55
 33 16 
a For  entries  2-3  and  5-8,  product  ratios  were  determined  by  HPTLC.  Isolated  yields  were  not  
determined. b 80  mol-%  of  catalyst  was  used.  c The ratios represent isolated yields [%] of the 
products. d Recovered starting material 32%. e The reaction was done at 0 °C. 
 
According to the late transition state model presented by Deslongchamps (Scheme 
23), the anomeric isomers should always predominate over the nonanomeric 
isomers. However, our group’s results with the pectenotoxin spiroketal system 
and with the above mentioned simplified spiroketal units, clearly indicate that the 
model is applicable only when there are no sterically hindering substituents. As 
such, it is tempting to speculate that the formation of nonanomeric spiroketals in 
nature could be simply explained by kinetic preference rather than some sort of 
sophisticated directed spirocyclization. Or, is the nature still one step ahead? 
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3.4 Synthesis of C Ring Fragment 
The synthesis of the C ring fragment, a structural unit common to all PTXs, 
proved to be the most challenging part of the whole project. Many different 
synthetic strategies were elaborated and tested (Scheme 26) before arriving at the 
final efficient and reliable synthesis. The C ring is the central subunit of the 
ABCDE ring system: it incorporates a handle towards the A ring, from which the 
spiroketal unit is constructed, and a functional group at C16 that can be used in 
the synthesis of the DE bicyclic acetal. These handles must be built in during the 
synthesis. Above all, the objective was to develop an efficient synthesis that could 
be easily conducted on a large scale, thus providing quantities of material to 
continue the synthesis in both directions of the PTX skeleton.  
 
Scheme 26. Different synthetic strategies that failed to give the C ring fragment. 
3.4.1 AE-AD-Metathesis Strategy 
Transformations that had proven to be efficient and reliable in previous studies 
were combined in the successful synthesis of the C ring fragment. Namely, cross-
metathesis99 combined with Sharpless asymmetric epoxidation and 
dihydroxylation, were used as the key steps to reach the final target (Scheme 27). 
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Scheme 27. Retrosynthetic analysis of the AE-AD-metathesis strategy. 
The synthesis started with an addition of an allylcopper reagent to a commercially 
available tetrolate 129, a reaction that had already been screened and optimized 
previously (Table 6-7). When allylmagnesium bromide was used as a starting 
material to form the allylcopper reagent100 no desired product 128 was formed. 
Mostly unreacted starting material 127 was  recovered  (Table  6,  entries  1-3).  
When the reaction was repeated using allyltributyltin and butyllithium to form the 
cuprate101 the desired product 128 could be obtained (Table 7, entry 1), but 
especially in large scale substantial amounts of an undesired side product 131 was 
formed (entry 2). Replacing butyllithium with methyllithium and addition of 
lithium chloride100,102 slightly improved the reaction outcome by suppressing the 
formation of the side product (entry 3). Further improvement was achieved by 
using a larger excess of the allylcopper reagent (entry 4). Finally, a considerable 
improvement in yield was obtained by using ethyl-2-butynoate 129 as a starting 
material and 3 equivalents of the allylcopper reagent to provide the desired 
conjugated ester 130 in excellent 92% yield (entry 5). 
Table 6. Allylcopper addition screens using allylMgBr to form the cuprate. 
 
Entry AllylMgBr equiv Cu salt Scale [mmol] Yield [%] 
1 2 CuI 0.5 SM recovered 
2 1.25 CuBr·Me2S 0.8 SM recovered 
3 2 CuBr 0.5 SM recovered 
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Table 7. Allylcopper addition screens using allylBu3Sn to form the cuprate. 
O
RO
O
RO
O
RO
127: R = Me
129: R = Et
AllylBu3Sn, CuI, RLi
additives
128: R = Me
130: R = Et
131: R = Me
132: R = Et
THF
 
Entry R AllylBu3Sn equiv RLi Additivies Scale [mmol] Yield [%] (128:131) 
1 Me 1.6 nBuLi  0.6 60 (9:1) 
2 Me 1.6 nBuLi  2.0 65 (1:1) 
3 Me 1.6 MeLi LiCl 0.5 23 (1:0) 
4 Me 3.0 MeLi LiCl 1.0 67 (no 132) 
5 Et 3.0 MeLi LiCl 1.0 92 (no 132) 
6 Et 3.0 MeLi LiCl 50.0 85 (no 132) 
 
 
Reduction of ester 130 was efficiently achieved by DIBAL-H to give allylic 
alcohol 126, which under Katsuki-Sharpless asymmetric epoxidation conditions 
furnished epoxide 133 in 90% yield and excellent 93% ee (Scheme 28). The 
terminal olefin was reacted with methyl acrylate in the presence of Hoveyda-
Grubbs 2nd generation catalyst103 followed by TBS protection to afford ester 135 
in 83% yield over 2 steps.  
 
Scheme 28. Synthesis of ester 135. 
Asymmetric dihydroxylation was used to introduce the remaining two 
stereocenters at C14 and C15. (Scheme 29) After screening different ligands and 
conditions, the Sharpless’ ligand (DHQD)2PYR proved to be the best, giving the 
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desired diol 136 in excellent 95% yield and 9:1 diastereoselectivity. However, ten 
mol-% of the ligand and eleven mol-% of the oxidant were required for the 
reaction to proceed in a reasonable time. Exposure of the diol mixture to catalytic 
PPTS resulted in cyclization to give the desired tetrahydrofuran ring system. At 
this stage the diastereomers could be easily separated by column chromatography 
to give crystalline 137 in 90% yield as a single diastereomer. X-ray 
crystallographic analysis confirmed the stereochemistry of 137 (Figure 10). 
Finally, TBS protection of the secondary hydroxyl groups, followed by DIBAL-H 
reduction furnished aldehyde 139 in 46% overall yield for 9 steps. The entire 
synthetic sequence was successfully scaled up to nearly 20 gram scale. 
 
Scheme 29. The final steps of the C ring fragment synthesis. 
 
Figure 10. Crystal structure of the C10-C16 tetrahydrofuran ring system 137. 
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3.5 Synthesis of CDE Ring Fragment 
With quantities of the C ring fragment in hand, it was time to move forward. From 
the very beginning we had two optional strategies planned for the CDE ring 
synthesis (Scheme 30). In the methylation strategy, the carbon chain incorporating 
the DE ring system was to be introduced using an aldol addition followed by 
methylation to form the C18 quaternary center. In the nucleophilic addition 
strategy, an enol equivalent of acetone was to be added in the aldol step followed 
by C-alkylation using an organometallic reagent 142 incorporating rest of the DE 
ring carbon chain. A key feature of both strategies is that after a mild ozonolytic 
cleavage  of  the  C21 masking  olefin,  the  ketalization  to  form the  DE ring  would  
take place under very mild conditions, without a need to unmask any protecting 
groups. In regard of selectivity the formation of the C18 quaternary center was our 
major concern as only few literature precedents for hydroxyl-directed alkylations 
of ?-hydroxyketones were found.104 
 
 
 
Scheme 30. Retrosynthetic analysis for the synthesis of the CDE ring fragment. 
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3.5.1 Nucleophilic Addition Strategy 
A BF3·OEt2 mediated Mukaiyama aldol reaction105 between the C ring aldehyde 
139 and commercially available (isopropenyloxy)trimethylsilane 145 furnished 
the desired ?-hydroxyketone 141 in quantitative yield as the only observed 
diastereomer (Scheme 31). The rationale behind this selectivity is discussed in 
more detail in Chapter 3.5.2. 
.  
Scheme 31. The nucleophilic addition strategy in action. 
Many different kinds of functionalized organometallic compounds have been 
successfully used in total synthesis with a variety of complex substrates.106 
Encouraged by these literature precedents, a group of alkylation reagents were 
synthesized and screened. 
 
Bromide 146 was synthesized starting from a commercially available ?-methallyl 
alcohol 147 (Scheme 32). After TBDPS protection, regiospecific formaldehyde-
ene reaction furnished homoallylic alcohol 149, which under standard 
bromination conditions (CBr4, Ph3P) furnished bromide 146. The corresponding 
iodide 150 was synthesized in a similar manner from the intermediate alcohol 149 
using standard iodination conditions (I2, Ph3P, imidazole). 
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Scheme 32. Synthesis of alkylation reagents 146 and 150. 
The synthesis of bromide 155 commenced with alkylation of a commercially 
available ethyl 4-chloroacetoacetate 151 to give ester 152 in 90% yield (Scheme 
33). Acetal protection furnished 153 in very low yields giving rise to significant 
amounts of side products. Reduction was initiated with LiAlH4 to afford alcohol 
154, which under standard bromination conditions furnished bromide 155.  
 
Scheme 33. Synthesis of alkylation reagent 155. 
The corresponding reagents 159 and 160 with TBDPS protection were 
synthesized starting from ester 153. Two additional protection group 
manipulations outlined in Scheme 34 were needed. After LiAlH4 reduction, both 
the bromide 159 and the iodide 160 were accessed using the standard conditions 
as above. 
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Scheme 34. Synthesis of the alkylation reagents 159 and 160. 
The different alkylation reagents were tested both as lithium and Grignard 
organometallic species to effect the C-alkylation of two different ketones 141 and 
161 (Table 8). Also, different methods for the lithium-halogen exchange107, 
different solvent systems (Et2O, THF, 2:3 Et2O/pentane108) and different reaction 
temperatures, times and addition times were investigated (Table 8). To our 
disappointment, however, nucleophilic addition to ?-hydroxyketones 141 and 161 
could not be effected. All the reactions failed to deliver any detectable amount of 
the desired products. In some cases the starting ketone was recovered, also 
significant decomposition occurred especially when lithium metal was used. With 
tBuLi the reduction of the alkylation reagent was the major reaction observed 
(Scheme 35).107c 
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Table 8. Unsuccessful alkylation screens. 
 
Entry Substrate Reagent Li/Grignard forming reagent Solvent 
1 141 160 tBuLi 2:3 Et2O:pentane 
2 141 159 tBuLi 2:3 Et2O:pentane 
3 141 159 Mg THF 
4 141 146 Mg THF 
5 161 155 tBuLi THF 
6 161 155 tBuLi Et2O 
7 161 155 tBuLi 2:3 Et2O:pentane 
8 161 160 tBuLi 2:3 Et2O:pentane 
9 161 159 tBuLi 2:3 Et2O:pentane 
10 161 150 tBuLi Et2O 
11 161 150 tBuLi Et2O TMEDA 
12 161 146 tBuLi Et2O 
13a 161 150 Li Et2O 
14a 161 146 Li Et2O 
a) The reaction was also tested using microwave. 
 
Besides reduction, also other known side reactions such as ?-elimination and self-
coupling together with the reversible nature of the lithium-halogen exchange 
might have made the generation of the organolithium reagents impossible.107d,  109 
On the other hand, the problem may well be in the electrophile, which could 
simply be too unreactive or readily enolizable. 
 
Scheme 35. The unwanted reduction of the alkylation reagents. 
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After significant amount of the intermediate ketones 141 and 161 were lost to 
baseline during the alkylation screens, our attention was directed to the alternative 
construction of the CDE ring fragment by means of the methylation strategy. 
3.5.2 Methylation Strategy  
To this end, the aldol partner 98 was synthesized according to previously 
published procedure.110, 111 Aldol addition between aldehyde 139 and lithium 
enolate of ketone 98 proceeded nicely to give a single anti product 165 in 82% 
yield (Scheme 36). The anti selectivity is in agreement with the modified 
Cornforth112 transition state model, although the polar Felkin-Anh113 model also 
predicts  the  same  outcome  (Scheme  36).  Furthermore,  the  high  level  of  
diastereoselection observed suggests that the ???-syn relationship of the oxygen 
substituents in 139 represents a stereochemically matched case. Similar 
selectivities, albeit reduced yields (61%), were obtained by using a related 
enolsilane (TMS/BF3·OEt2). 
 
Scheme 36. Cornforth selective aldol addition between aldehyde 139 and ketone 98. 
Based on the precedent by Fujisawa,104a titanium reagents were considered as 
prime candidates for the hydroxyl-directed methylation to obtain the desired anti 
product. There are two possible modes to achieve 1,3-induction in hydroxyl-
directed additions: either the nucleophile is delivered externally (from an external 
reagent) or internally (directed addition) (Figure 11).114  
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Figure 11. Reetz model for chelation controlled 1,3-induction and Evans model for 
internal and external addition (in hydride reduction of ?-hydroxyketones).  
To our delight, initial experiment in 0.25 mmol scale with MeTi(OiPr)3 gave the 
desired anti-diol product 166 in 8:1 diastereoselectivity (Table 9). However, 
considerable difficulties were encountered in reproducing this result. With 
determination to resolve this complication, experiments to screen different 
conditions for this key transformation were conducted (Table 9).  
 
In comparison with methyltitanium reagents, Mg and Zn reagents gave inferior 
selectivity (entries 2-3). Surprisingly, predistilled MeTi(OiPr)3115 turned out to be 
very unreactive,  even with 15 equiv of the reagent (entry 4).  More Lewis acidic 
reagents, MeTiCl3 or MeTi(OiPr)2Cl (entries 5-6) gave no progress under 
comparable conditions, neither did the use of more reactive Me2Ti(OiPr)2 or less 
hindered MeTi(OMe)3 (entries 7-9). An excess of Ti(OiPr)4 has been suggested to 
facilitate the removal of the product from the metal center thus promoting the 
formation of an active complex.116 In our hands, using excess Ti(OiPr)4 did not 
afford any improvement in selectivity or reproducibility (entry 10). Eventually, 
the best reproducible selectivities (9:1) and yields (91%) were obtained using an 
excess of the in situ prepared MeTi(OiPr)3 at –78 °C followed by quick warming 
to 0 °C (entry 11). The two diastereomers could be separated by a careful column 
chromatography after cyclization of the DE ring system. Further details, including 
screens with different solvents and additives in the methylation step are presented 
in the experimental section under Chapter 5.5.2.8. 
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Table 9. Anti selective addition of methyl nucleophiles with different reagents. 
 
Entry 
Methylation 
reagenta 
Equiv Solvent T [°C] 
Time [min 
at –78/0°C ] 
drb 
Conversion 
[%]b 
1 MeTi(OiPr)3 5 Et2O –78 to 0 10/10 8:1 – 2:3 100 
2 MeLi/ZnBr2  4 CH2Cl2 –78 240 3:2 100 
3 MeMgBr 1 Et2O –78 15 2:1 100 
4 MeTi(OiPr)3
c 15 Et2O –78 to 0 10/10 4:1 80 
5 MeTiCl3 15 Et2O –78 to 0 10/10 1:1 20 
6 MeTi(OiPr)2Cl 15 Et2O –78 to 0 10/10 3:1 100 
7 Me2Ti(OiPr)2  15 Et2O –78 to 0 10/10 6:1 100 
8 Me2Ti(OMe)2 15 Et2O –78 to 0 10/10 2:1 100 
9 MeTi(OMe)3 15 Et2O –78 to 0 10/10 4:1 100 
10 MeTi(OiPr)3
d 15 Et2O –78 to 0 10/10 4:1 100 
11 MeTi(OiPr)3 15 Et2O –78 to 0 10/10 9:1 100 
 
a Reagents were prepered in situ. b Determined by 1H NMR from the crude reaction mixture. c MeTi(OiPr)3 was distilled 
prior to use. d Excess Ti(OiPr)4 (15 equiv) was used.  
 
 
Having found a solution to the methylation problem, all that remained was 
ozonolysis of the double bond followed by ketalization to furnish the CDE ring 
system. Fortunately, using the mild reductive work-up for the ozonolysis (Me2S at 
–78 ºC to rt, for 3h), trickered also the ketalization to afford the desired CDE ring 
fragment 167 in 91% yield (Scheme 37). 
 
Scheme 37. The synthesis of the CDE ring fragment 167. 
NOESY  cross-peaks  confirmed  both  the  selectivity  of  the  aldol  step  and  the  
methylation step (Figure 12). Furthermore, analysis of the relevant coupling 
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constants clearly indicated a chair conformation for the D ring and close to an 
antiperiplanar orientation between H15 and axial H16 (Figure 12). 
O
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Figure 12. Selected NOESY cross-peaks and coupling constants. 
The final step of the CDE ring synthesis was also used in the CDEF ring synthesis 
by my co-worker Hannes Helmboldt.117 In his study the ozonolysis – ketal 
cyclization sequence was tested using a mixture of diol 168 and a small amount of 
the nonanomeric AB spiroketal 9 (Scheme 38). To our surprise, even these 
conditions were not mild enough to preserve the nonanomeric AB spiroketal, 
which underwent fast and complete isomerization into the more stable anomeric 
isomer 10 during the Me2S work-up. This result further confirmed our assumption 
that a key strategic issue in this total synthesis venture is the stability of the ever-
enthralling nonanomeric AB spiroketal ring system.  
 
Scheme 38. Testing the stability of the nonanomeric AB spiroketal during the CDEF ring 
synthesis. 
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Selective  deprotection  of  the  primary  TBS  group  in  167 turned out to be 
problematic. Eventually, HF·pyridine served this purpose best, giving alcohol 170 
in moderate 58% yield after two recycles of the starting material (Scheme 39). In 
addition, the over-deprotected products could be separated and further recycled. 
Other methods (PPTS, p-TsOH, TASF, CAN on silica118) either afforded 
recovered starting material, or gave similar yields with HF·pyridine accompanied 
with decomposition of the starting material. While the yields obtained with 
HF·pyridine were not excellent, being so close to the end, the decision was made 
to proceed rather than attempt to optimize the reaction any further.  
 
Having secured the targeted CDE ring fragment, it was time to add two carbons 
required to form the B ring of the PTX2 structure. Grignard addition into an 
aldehyde was chosen to deliver the desired anti relationship between C10 and C11 
hydroxyl groups (Scheme 39). Sequential oxidation of alcohol 170 using  the  
Swern protocol, followed by addition of vinyl Grignard delivered a 5:1 mixture of 
isomeric allylic alcohols in nearly quantitative yield (Scheme 39). The two 
isomers were readily separated with column chromatography to furnish the major 
isomer 172 in 67% yield. When vinyllithium was used for this reaction, slightly 
better selectivities (6:1) were obtained albeit much lower yields (~45%) due to 
considerable formation of a side product (see Experimental Section 5.6.3). 
 
Although the stereochemistry of the addition step was not determined at this 
stage, we were confident that the stereochemistry could be confirmed after the 
formation  of  the  ABCDE  ring  system.  We  predicted  however,  that  the  addition  
would follow the modified Cornforth model for anti-?,?-alkoxy aldehydes, and 
thus would deliver the desired anti product 173 (Scheme 39).112b As such we were 
confident enough that we had the right isomer to move ahead with the synthesis.  
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Scheme 39. Synthesis of allylic alcohol 172. 
3.6 Synthesis of ABCDE Ring Fragment 
With efficient syntheses for the A ring lactone and the CDE ring fragment 
accomplished, we now turned our attention to the construction of the ABCDE ring 
system as defined by the retrosynthetic analysis in Figure 8. To set the stage for 
the planned Suzuki-Miayura coupling119,  all  that  was  needed  was  conversion  of  
the A ring lactone into the corresponding enol triflate and hydroboration120 of the 
CDE ring allylic alcohol.  
 
Trapping the enolate of the A ring lactone 111 using Comins` reagent121 cleanly 
afforded the desired enol triflate 98 (Scheme 40). However, hydroboration failed 
completely to give the desired coupling partner 174. Extensive screening of 
different reagents (9-BBN,122 CB,123 thexylborane,124 BH3·SMe2125)120b turned out 
unsuccessful, giving either recovered starting material together with 
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decomposition or a large number of products, none of which resembled the 
desired borates.  
 
Scheme 40. Suzuki coupling in action. 
Despite the double bond was found entirely unreactive towards hydroboration, we 
decided to give it another change and once again turned our attention to 
metathesis. As a bit of a surprise, cross-metathesis between an open-chained 
ketone 176 and the CDE ring allylic alcohol 172 initiated by Hoveyda-Grubbs 2nd 
generation catalyst furnished the desired product 177 in moderate 50% yield 
(Table 10, entry 1). We were quite pleased with this result as the two olefins are 
not exactly a perfect match to achieve a selective cross-metathesis.126 
Unfortunately, however, reproducibility problems were once again encountered. 
Repeating the reaction under precisely similar conditions, as were used for the 
initial successful reaction, only furnished an undesired product 178 (entry 2). 
Nonetheless,  encouraged  by  the  first  positive  result  we  set  of  to  explore  this  
protocol further. As matters turned out, the metathesis product exhibits a 
considerable tendency to undergo ring closure followed by elimination of water to 
give diene 178 under the reaction condition. This diene is extremely unstable and 
significant decomposition occurs within few hours at 8 ºC. Also, when subjected 
to a variety of hydrogenation conditions it totally decomposes.  
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The mild Lewis-acidic nature of Hoveyda-Grubbs 2nd generation catalyst127 was 
considered as the potential source of these complications. This hypothesis was 
tested by buffering the reaction mixture with pyridine. Under these conditions, the 
desired product 177 could again be isolated in 48% yield with no trace of diene 
178 (entry 3). Further experimentation revealed that Grubbs 2nd generation 
catalyst128 is ideal for this coupling, affording the desired metathesis product 177 
in reproducible yields (48-55%, plus 36-45% recovered 172), without a need for a 
basic  buffer  (entry  4).  As  such,  metathesis  once  again  proved  to  be  a  reliable  
construction tool in a total synthesis venture with complex and highly 
functionalized substrates.129  
Table 10. Cross-metathesis. 
 
Entry Catalyst Product (yield [%]) 
1 Hoveyda-Grubbs 2nd gen. catalyst 177 (50) 
2 Hoveyda-Grubbs 2nd gen. catalyst 178 (52) 
3 Hoveyda-Grubbs 2nd gen. cat. + pyridine 177 (48) 
4 Grubbs 2nd gen. catalyst 177 (48-55) 
 
 
The metathesis product 177 included all the carbon atoms required for the targeted 
ABCDE  ring  fragment,  and  we  were  only  two  steps  away  from  the  final  
destination. It was time to confront the hydrogenation challenge. To avoid an 
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uncontrolled closure of the spiroketal ring system under the hydrogenation 
conditions, two sets of experiments were needed (Table 11). The Wilkinson 
catalyst was selected as the first candidate, mainly because it was easily accessible 
and operationally simple to test. However, when ketone 177 was hydrogenated in 
the presence of Wilkinson catalyst, after a few hours a substantially less polar 
product mixture was formed, that was characterized as a 1:1 mixture of the 
anomeric and the nonanomeric spiroketals (entry 1). The Wilkinson catalyst was 
also tested using 2,6-lutidine as a buffer, but under these conditions only starting 
material was recovered (entry 2). 
 
The  classical  reduction  using  catalytic  palladium on  charcoal  was  chosen  as  the  
second candidate also for its reliability and simplicity. As was the case with the 
Wilkinson catalyst, Pd/C cleanly hydrogenated the double bond, but also effected 
ring closure to give a 1:1 mixture of the spiroketal isomers 180 and 181 (entry 3). 
Ultimately, it was found that Pd/C poisoned with pyridine130 gave the desired 
product 179 in almost quantitative yields (entry 4). 
Table 11. Hydrogenation screens. 
 
Entry Catalyst Additive Product (conversion [%]) 
1 Wilkinson - 180 and 181 (100) 
2 Wilkinson 2,6-lutidine No reaction 
3 Pd/C - 180 and 181 (100) 
4 Pd/C pyridine 179 (100) 
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Finally, it was time to test the kinetic spiroketalization, and above all reach for the 
final target, the ABCDE ring fragment of PTX2. The optimal conditions 
developed in the AB spiroketal ring synthesis (ClCH2COOH, CH2Cl2) gave a 
clean conversion into a 1:3 mixture of the anomeric 180 and the nonanomeric 181 
spiroketal isomers (Table 12, entry 1). Even though this result was all that we 
could ever have expected, we still needed to dig further. It is known that the 
anomeric effect decreases with increasing dielectric constant of the medium.47a, 98 
This  effect  was  also  demonstrated  by  my  co-workers  with  the  simple  
spiroketalization substrates.97 Surprisingly,  the  aqueous  conditions  (Cl3CCOOH, 
4:1 THF:H2O)  that  gave  the  best  results  with  the  simpler  systems,  furnished  an  
unsatisfying 1:1 mixture of the spiroketal isomers (entry 2). In addition, when 
chloroacetic acid was used in THF:H2O a significant decrease in the reaction rate 
was observed compared to CH2Cl2 as the medium (entry 3). 
Table 12. Kinetic spiroketalizations to form the ABCDE ring fragment. 
 
Entry Acid Solvent Time [h] 180:181 (conversion [%]) 
1 ClCH2COOH CH2Cl2 0.5 1:3 (100) 
2 Cl3CCOOH 4:1 THF:H2O 4 1:1 (100) 
3 ClCH2COOH 4:1 THF:H2O 20 1:1 (20) 
 
In contrast to our previous experience, the nonanomeric isomer was less polar 
than the anomeric isomer and the difference in the polarities was very small. For 
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this reason, significant difficulties were encountered in purification. The pure 
nonanomeric isomer 181 could be isolated in 29% yield after careful column 
chromatography. After equilibrating a mixture of the spiroketal isomers with 
PPTS a 3:1 mixture of the anomeric and the nonanomeric isomer was formed, 
giving after purification the pure anomeric isomer 180 in 67% yield. 
 
The configurations of the spiroketal isomers were confirmed by NOESY 
experiments. Based on a NOE between H3 and H8, spiroketal 182 was clearly 
identified as the nonanomeric isomer (Figure 13, the ABCDE ring fragments are 
presented as the desired C10-(S)  isomers).  Further  confirmation  was  again  
obtained from the 13C  NMR,  where  the  chemical  shift  of  the  spiro  carbon  (C7)  
was shifted downfield for the nonanomeric isomer relative to the anomeric isomer 
(108.0 ppm in 182 vs. 105.8 in 183).12b, 51b The  2D-NOESY  spectra  of  the  
anomeric spiroketal 183 showed a surprising and slightly alarming correlation 
between H11 and C41 methyl group, which could indicate that we have the wrong 
stereochemistry at C10 (Figure 13).   
 
Figure 13. The most important NOESY cross-peaks. 
In order to confirm this suspicion, the anomeric spiroketal isomer 180 was treated 
with TBAF which cleanly removed the TBS and TBDPS protection groups. Acid-
catalyzed equilibration of the crude product with p-TsOH in CH2Cl2 then 
delivered the corresponding [6,6]-spiroketal product in 86% yield (Scheme 41). 
We were expecting to see a large coupling constant characteristic to diaxial 
hydrogens, however to our great disappointment a very small coupling constant of 
1.1 Hz was observed, indicating that we had the wrong C10 isomer! (Scheme 41).  
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Scheme 41. Checking the C10 stereochemistry. 
In all of our previous studies, the unnatural C10-(R) isomer only gave very small 
amounts,  if  any,  of  the  nonanomeric  product.  For  this  reason  we  were  very  
surprised to discover the wrong stereochemistry at C10. As such, a model to 
explain the formation of the nonanomeric spiroketal 185 as the major product was 
developed (Scheme 42). Under acidic conditions the five-membered ring is 
expected to close first. Also, the reaction is assumed to proceed via oxonium ion 
intermediate, from which follows that the five-membered ring becomes almost 
flat in the transition state. The incoming nucleophile should prefer the less 
hindered top face (TS1), giving the nonanomeric isomer 185. Whereas, TS2 
should have higher activation energy, and thus smaller amounts of the anomeric 
isomer 186 should be formed under kinetic conditions. 
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Scheme 42. Proposed transition states for the formation of the anomeric and nonanomeric 
10-epi-ABCDE ring fragments. 
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4 CONCLUSION AND FUTURE STUDIES 
The objective of this work was to synthesize the ABCDE ring fragment of PTX2. 
Towards this objective, three advanced fragments corresponding to the A, C and 
DE rings were synthesized and connected in highly convergent manner. As a key 
feature, the delicate nonanomeric AB spiroketal ring structure was formed as the 
last synthetic step. 
 
The A ring lactone was synthesized in 9 steps with 14% overall yield, using 
Sharpless asymmetric epoxidation and regioselective epoxide ring opening as the 
key steps. The A ring lactone was also used for the synthesis of the AB spiroketal 
ring  fragment  of  the  PTXs.  Importantly,  as  a  result  of  kinetic  control  in  the  
spiroketalization reaction, the nonanomeric isomer could be formed as the major 
product.  
 
For the synthesis of the C ring fragment, Sharpless asymmetric epoxidation and 
dihydroxylation were used as the key steps, to give the important central unit with 
high stereocontrol in 9 steps and 46% overall yield. An aldol union of the C ring 
aldehyde with the DE ring fragment furnished the desired ?-hydroxyketone 
intermediate with excellent stereoselectivity. After extensive screening and 
optimization, methylation of this ketone to form the C18 quaternary center was 
achieved with reproducible 9:1 selectivity, giving access to the CDE ring 
fragment of PTX2 with the correct stereochemistry. 
 
For the extension of the carbon chain towards the A ring, an addition of a vinyl 
organometallic reagent to the CDE ring aldehyde was used, affording a mixture of 
two diastereomeric allylic alcohols in 5:1 selectivity. The major isomer was 
connected with the A ring building block by cross-metathesis. Finally, the kinetic 
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spiroketalization conditions afforded the ABCDE ring product as a 3:1 mixture of 
the nonanomeric and anomeric isomers. Unfortunately, it was observed that the 
vinyl organometallic addition step had favored the undesired C10 diastereomer. 
Thus, instead of the natural ABCDE ring system, we had synthesized the 10-epi-
ABCDE ring fragment of PTX2.  
 
Needless to say, I was of course very disappointed with this result, but not totally 
discouraged. A long the way, I have come to realize, that as the substrates become 
more and more complex and highly functionalized, there is little room for 
predictions. Most of the models that apply with the simple substrates might give 
an  entirely  the  opposite  result  when  more  complex  substrates  are  used.  Overall,  
every total synthesis project is a high-risk endeavor. Negative results are 
expected, they are a fundamental part of the process and also critical to success. 
When we discover a reaction that doesn’t work, we gain knowledge that 
eventually will help us learn and discover new reactions and methods that do 
work. 
 
The correction of the C10 stereocenter will be studied in the near future. As 
primary solutions, Mitsunobu inversion and a sequence of oxidation and 
stereoselective reduction will be tested. These methods would provide a quick 
access to the spiroketalization substrate, allowing further research on the key 
kinetic spiroketalization step. However, also the possibility of altering the 
selectivity of the vinyl organometallic addition step will be evaluated in due 
course. In any case, we are confident that the stereochemistry of the C10 can be 
inverted, finally giving access to the natural ABCDE ring fragment of PTX2.  
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5 EXPERIMENTAL SECTION 
5.1 General Experimental 
All reactions were carried out under an argon atmosphere in flame-dried 
glassware, unless otherwise noted. Nonaqueous reagents were transferred under 
argon via syringe or cannula and dried prior to use. Et3N and i-Pr2NH were 
distilled  from Na.  THF and  Et2O were distilled from Na/benzophenone. CH2Cl2 
was distilled from CaH2 and DMF was distilled from molecular sieves (4 Å). A 
stock  sample  of  dry  TBHP  was  dried  by  the  procedure  of  Sharpless  and  co-
workers.85c All batches of TBHP were also dried on 4 Å molecular sieves 
immediately prior to use. Other solvents and reagents were used as obtained from 
supplier, unless otherwise noted. Analytical TLC was performed using Merck 
silica gel F254 (230-400 mesh) plates and analyzed by UV light or by staining 
upon heating with vanillin solution (6 g vanillin, 5 mL conc. H2SO4, 3 mL glacial 
acetic acid, 250 mL EtOH) or KMnO4 solution (1 g KMnO4, 6.7 g K2CO3, 1.7 mL 
1M  NaOH,  100  mL  H2O).  For  silica  gel  chromatography,  the  flash  
chromatography technique was used, with Merck silica gel 60 (230-400 mesh) 
and p.a. grade solvents unless otherwise noted. 
 
The 1H NMR and 13C  NMR  spectra  were  recorded  in  either  CDCl3, CD3CN or 
C6D6 on a Bruker Avance 400 (1H 399.98 MHz; 13C 100.59 MHz) spectrometer. 
The chemical shifts  are reported in ppm relative to CHCl3 (? 7.26),  CHD2CN (? 
1.94) or C6D5H (7.16) for 1H NMR. For the 13C NMR spectra, the residual CDCl3 
?? 77.0), CD3CN (? 118.26) or C6D6 (128.06) were used as the internal standards. 
The enantiomeric excess (ee) of the products were determined by HPLC in 
comparison to the corresponding racemic samples using Waters 501 pump and 
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Waters 486 detector. Melting points (mp) were determined in open capillaries 
using Gallenkamp melting point apparatus. IR spectra were recorded on a Perkin-
Elmer Spectrum One FT-IR spectrometer. Optical rotations were obtained with a 
Perkin-Elmer 343 polarimeter. High resolution mass spectrometric data were 
measured using MicroMass LCT Premier Spectrometer. Some of the high 
resolution mass spectrometric data was obtained by the University of Oulu on 
Micromass LCT spectrometer. Elemental analyses were recorded on a Perkin-
Elmer 2400 CHN by the Elemental Analytical Services of the Department of 
Chemistry. 
 
The racemic samples corresponding to compound 107 were prepared using m-
CPBA (120 mol-% in CH2Cl2) as the oxidant for 106. All racemic samples were 
purified and all subsequent reactions were performed in a manner identical to their 
enantioenriched counterparts. 
5.2 Synthesis of A Ring Fragment 
5.2.1 5-Benzyloxypentanol 18786 
 
To neat 1,5-pentanediol 103 (47.3 mL, 46.9 g, 450 mmol, 349 mol-%) at rt was 
added both benzyl bromide (15.3 mL, 22.1 g, 129 mmol, 100 mol-%) and 
powdered KOH (30.4 g, 542 mmol, 420 mol-%) in four equal portions over 1 h. 
After the last addition the solution was stirred for an additional 4 h. H2O (75 mL) 
was then added. The layers were separated and the aqueous phase was extracted 
with EtOAc (4 x 30 mL). The combined organic extracts were dried over MgSO4 
and concentrated. Purification of the residue by flash chromatography (initially 
30% EtOAc/hexanes, finally 70% EtOAc/hexanes) afforded 5-benzyloxypentanol 
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187 (20.1 g, 80%) as pale yellow oil. IR- and 1H NMR-data match those reported 
in literature.88 
5.2.2 5-(Benzyloxy)pentanal 104 
 
A solution of oxalyl chloride (1.9 mL, 2.74 g, 21.6 mmol, 110 mol-%) in CH2Cl2 
(20 mL) was cooled to –55 ºC and DMSO (3.1 mL, 3.37 mg, 43.1 mmol, 220 
mol-%) was added. After 5 min, a solution of 5-benzyloxypentanol 187 (3.81 g, 
19.6 mmol, 100 mol-%) in CH2Cl2 (45 mL) was added. The resulting mixture was 
stirred for 15 min. Triethylamine (13.1 mL, 9.52 g, 94.1 mmol, 480 mol-%) was 
then added dropwise. Stirring was continued at –55 ºC for an additional 10 min 
and then the mixture was allowed to warm to rt. H2O (100 mL) was added and the 
layers were separated. The aqueous phase was extracted with CH2Cl2 (2 x 60 mL). 
The combined organic extracts were washed with brine (2 x 60 mL), dried over 
MgSO4 and concentrated. Purification of the residue by flash chromatography 
(30% EtOAc/hexanes) afforded 5-(benzyloxy)pentanal 104 (3.5 g, 93%) as pale 
yellow oil. IR- and 1H NMR-data match those reported in the literature.88  
5.2.3 7-(Benzyloxy)-methyl-2-(Z)-hepteonate 105 
 
To a solution of bis(o-cresyl) phosphonoacetate90a (7.4 mL, 9.03 g, 27.0 mmol, 
130 mol-%) in THF (150 mL) at 0 ºC was added NaI (3.12 g, 20.8 mmol, 100 
mol-%). After 5 min, NaH (60% dispersion in mineal oil, 0.65 g, 27 mmol, 130 
mol-%) was slowly added and the resulting mixture was cooled to –78 ºC. A 
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solution of 5-(benzyloxy)pentanal 104 (4.0 g, 20.8 mmol, 100 mol-%) in THF (15 
mL) was added dropwise via cannula. The resulting solution was stirred at –78 ºC 
for an additional 8 h, after which time half-saturated NH4Cl (120 mL) was added. 
H2O (50 mL) was added to obtain a clear solution and the mixture was allowed to 
warm to rt. The layers were separated and the aqueous phase was extracted with 
Et2O  (3  x  80  mL).  The  combined  organic  extracts  were  dried  over  Na2SO4 and 
concentrated. Purification of the residue by flash chromatography (5% 
EtOAc/hexanes) afforded 7-(benzyloxy)-methyl-2-(Z)-heptenoate 105 (4.39 g, 
85%, Z/E 97/3) as pale yellow oil. 
 
Rf (50 % EtOAc/hexanes) = 0.63; IR (film, cm–1): 2944, 2859, 1723, 1645, 1438, 
1199, 1170, 1103, 736, 698; 1H NMR (400 MHz,  CDCl3): ? 7.37-7.25 (m, 5H), 
6.22 (dt, 1H, J = 11.5, 7.5 Hz), 5.78 (dt, 1H, J = 11.5, 1.7 Hz), 4.50 (s, 2H), 3.70 
(s, 3H), 3.49 (t, 2H, J = 6.4 Hz), 2.68 (dq, 2H, J = 7.5, 1.7 Hz), 1.70-1.63 (m, 2H), 
1.60-1.50 (m, 2H); 13C  NMR  (100  MHz,  CDCl3): ? 166.8, 150.4, 138.6, 128.3, 
127.6, 127.5, 119.4, 72.9, 70.0, 51.0, 29.3, 28.7, 25.6; HRMS (ESI+): m/z calcd 
for [C15H20O3Na] 271.1310, found 271.1307, ? = 1.1 ppm. 
5.2.4 7-(Benzyloxy)-methyl-2-(Z)-hepten-1-ol 106 
 
A solution of enoate 105 (2.86 g, 11.5 mmol, 100 mol-%) in THF (150 mL) was 
cooled to –78 ºC and DIBAL-H (28.8 mL of 1M solution in toluene, 28.8 mmol, 
250 mol-%) was added dropwise over a period of 10 min. The resulting solution 
was  stirred  at  –78  ºC  for  an  additional  45  min  and  then  warmed  to  0  ºC.  After   
1.5 h, the reaction was quenched with sat. aq. Rochelle’s salt (100 mL). The 
mixture  was  warmed  to  rt  and  stirred  for  an  additional  1.5  h.  The  layers  were  
separated and the aqueous phase was extracted with EtOAc (3 x 60 mL). The 
combined organic extracts were washed with H2O, sat. aq. NaHCO3 and brine  
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(60 mL each), dried over MgSO4 and concentrated. Purification of the residue by 
flash chromatography (40% MTBE/hexanes) afforded 7-(benzyloxy)-methyl-2-
(Z)-hepten-1-ol 106 (2.39 g, 94%) as pale yellow oil.  
 
Rf (50 % EtOAc/hexanes) = 0.33; IR (film, cm–1): 3369, 2935, 2859, 1454, 1102, 
1027, 735, 697; 1H NMR (400 MHz, CDCl3): ? 7.37-7.28 (m, 5H), 5.65-5.50 (m, 
2H), 4.50 (s, 2H), 4.18 (d, 2H, J = 6.6 Hz), 3.47 (t, 2H, J = 6.4 Hz), 2.10 (q, 2H, J 
= 7.3 Hz), 1.66-1.59 (m, 2H), 1.50-1.43 (m, 3H); 13C NMR (100 MHz, CDCl3): ? 
138.6, 132.8, 128.7, 128.3, 127.6, 127.5, 72.9, 70.2, 58.5, 29.2, 27.2, 26.2; HRMS 
(ESI+): m/z calcd for [C14H20O2Na] 243.1361, found 243.1360, ? = 0.4 ppm. 
5.2.5 Epoxide 10785c 
 
To a stirred 0 ºC solution of crushed 4Å molecular sieves (0.6 g) in CH2Cl2  
(20 mL) were added D-(-)-diethyltartrate (0.23 mL, 0.28 g, 1.36 mmol, 30 mol-%) 
and Ti(OiPr)4 (0.27 mL, 0.26 g, 0.91 mmol, 5 mol-%). This mixture was cooled to 
–20 ºC and tert-butyl hydroperoxide (1.8 mL of a ~5.0 M solution in isooctane, 
~9.08 mmol, 200 mol-%) was added. The resulting mixture was stirred for 20 min 
before a solution of allylic alcohol 106 (1.0 g, 4.54 mmol, 100 mol-%) in CH2Cl2 
(5 mL) was added dropwise via cannula. The allylic alcohol was first 
azeotropically dried with toluene and then dissolved in CH2Cl2 and dried over 4Å 
molecular  sieves.  The  resulting  mixture  was  stirred  at  –20  ºC  for  an  additional   
70 h and then warmed to 0 ºC. H2O (4 mL) was added and stirring was continued 
at 0 ºC for an additional 1 h. The mixture was allowed to warm to rt. A solution of 
30% NaOH in saturated aqueous NaCl (1 mL) was added and the resulting 
mixture  was  stirred  for  45  min.  The  solution  was  diluted  with  H2O  (4  mL)  and  
filtered to get a better separation of the two layers. The layers were separated and 
the aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The combined organic 
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extracts were dried over Na2SO4 and concentrated. Purification of the residue by 
flash chromatography (40% EtOAc/hexanes) afforded epoxide 107 (0.67 g, 62%, 
83% ee) as colorless oil. 
 
Rf (70 % EtOAc/hexanes) = 0.27; [?]D = +2.5 (c 0.59, CH2Cl2); IR (film, cm–1): 
3436, 2932, 2861, 1727, 1454, 1101, 1044, 737, 698; 1H NMR (400 MHz, 
CDCl3): ? 7.37-7.27 (m, 5H), 4.50 (s, 2H), 3.82 (ddd, 1H, J = 12.0, 7.4, 4.5 Hz), 
3.68 (ddd, 1H, J = 12.0, 6.8, 5.1 Hz), 3.49 (t, 2H, J = 6.2 Hz), 3.14 (dt, 1H, J = 
6.8, 4.3 Hz), 3.03 (m, 1H), 1.71-1.51 (m, 6H); 13C NMR (100 MHz,  CDCl3): ? 
138.5, 128.4, 127.7, 127.6, 73.0, 70.0, 60.8, 57.2, 56.6, 29.4, 27.7, 23.5. These 
data match those reported in literature.131 HRMS  (ESI+): m/z calcd for 
[C15H20O3Na] 259.1310, found 259.1336, ? = 10 ppm. The enantiomeric purity 
was determined by HPLC (Daicel Chiralcel AD column, 15 % iPrOH/hexanes, 
flow rate 0.5 mL/min): ?major = 14.94 min; ?minor = 16.85 min. 
5.2.6 (2S, 3S)-7-(Benzyloxy)-2-methyl-heptane-1,3-diol 108132 
 
A mixture of CuCN (1.25 g, 14.0 mmol, 600 mol-%) in Et2O (35 mL) was cooled 
to –78 ºC and methyllithium (17.0 mL of a 1.48 M solution in Et2O, 25.1 mmol, 
1080 mol-%) was added dropwise. The resulting mixture was warmed to –20 ºC 
and stirred vigorously for 1 h. The color of the solution turned pale green (some 
CuCN remained undissolved). A solution of epoxide 107 (0.55 g, 2.33 mmol, 100 
mol-%) in Et2O (15 mL) was added via cannula and the stirring was continued at 
–15 ºC for 2.5 h. Et2O  (15  mL)  and  sat.  aq.  NH4Cl (20 mL) were added. The 
resulting mixture was warmed to rt and filtered. The layers were separated. The 
organic phase was washed with sat. aq. NH4Cl, H2O and brine (2 x 25 mL each). 
The combined aqueous phases were back-extracted with Et2O  (25  mL)  and  the  
combined  organic  phases  were  dried  over  Na2SO4 and concentrated to yield the 
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crude 108. To this crude material were added THF (15 mL), H2O  (15  mL)  and  
NaIO4 (0.16 g, 0.77 mmol) at rt. The resulting solution was stirred for 1.5 h and 
then diluted with Et2O  (20  mL).  The  layers  were  separated.  The  organic  phase  
was washed with sat. aq. NaHCO3 (25 mL) and brine (25 mL). The combined 
aqueous phases were back-extracted with Et2O (25 mL) and the combined organic 
phases were dried over Na2SO4 and concentrated. Purification of the residue by 
flash chromatography (50% MTBE/hexanes), followed by recrystallization of the 
product from EtOAc/hexanes (1:10) afforded diol 108 (0.38 g, 65%) as white 
crystalline solid. 
 
Rf (70 % EtOAc/hexanes) = 0.23; mp 50-52 ºC; [?]D = –5.7 (c 0.42, CH2Cl2, 95 % 
ee); IR (film, cm–1): 3370, 2937, 2864, 1455, 1101, 1028, 736, 698; 1H NMR (400 
MHz, CDCl3): ? 7.37-7.26 (m, 5H), 4.50 (s, 2H), 3.82 (m, 1H), 3.69 (m, 2H), 3.49 
(dt, 2H, J = 12.7, 0.9 Hz), 2.22 (s, 2H), 1.82-1.36 (m, 7H), 0.90 (d, 3H, J = 7.1 
Hz); 13C NMR (100 MHz, CDCl3): ? 138.5, 128.4, 127.7, 127.5, 74.5, 72.9, 70.3, 
67.2, 39.1, 33.8, 29.6, 22.9, 10.1. These data match those reported in literature.133 
HRMS (ESI+): m/z calcd for [C15H24O3Na] 275.1623, found 275.1628, ? = 1.8 
ppm; Anal. calcd for [C15H24O3] C: 71.39, H: 9.59, found C: 71.62, H: 9.64. 
5.2.7 Alcohol 109 
 
To a stirred 0 ºC solution of diol 108 (0.38 g, 1.51 mmol, 100 mol-%) in CH2Cl2 
(6 mL) were added triethylamine (0.48 mL, 1.35 g, 3.46 mmol, 229 mol-%) and 
TBDPSCl (0.47 mL, 0.5 g, 1.81 mmol, 120 mol-%). The reaction mixture was 
allowed  to  warm  to  rt  and  stirring  was  continued  for  14  h.  The  mixture  was  
diluted  with  Et2O (5 mL). The layers were separated and the organic phase was 
washed  with  H2O (5 mL). The aqueous phase was back-extracted with Et2O (5 
mL) and the combined organic extracts were dried over MgSO4 and concentrated. 
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Purification of the residue by flash chromatography (30% EtOAc/hexanes) 
afforded alcohol 109 (0.73 g, 98%) as pale yellow viscous oil. 
 
Rf (70 % EtOAc/hexanes) = 0.69; [?]D = –3.4 (c 0.44, CH2Cl2);  IR (film, cm–1): 
3460, 2932, 2858, 1472, 1428, 1112, 740, 702; 1H NMR (400 MHz, CDCl3): ? 
7.68-7.65 (m, 4H), 7.46-7.27 (m, 11H), 4.51 (s, 2H), 3.86 (m, 1H), 3.75 (dd, 1H, J 
= 10.1, 4.2 Hz), 3.66 (dd, 1H, J = 10.1, 6.0 Hz), 3.49 (dt, 2H, J = 6.5, 1.0 Hz), 
2.77 (d, 1H, J = 2.9 Hz), 1.79-1.36 (m, 7H), 1.06 (s, 9H), 0.90 (d, 3H, J = 7.2 Hz); 
13C NMR (100 MHz, CDCl3): ? 138.7, 135.7, 135.6, 133.1, 133.0, 129.83, 129.79, 
128.3, 127.8, 127.6, 127.5, 74.1, 72.9, 70.4, 68.7, 39.1, 34.0, 29.8, 26.9, 22.9, 
19.2, 10.2; HRMS (ESI+): m/z calcd for [C31H42O3NaSi] 513.2801, found 
513.2823, ? = 4.3 ppm. 
5.2.8 (5S, 6S)-6-Methyl-7-(tert-butyl-diphenylsilyl)-heptane-1,5-diol 110 
 
To  a  stirred  solution  of  alcohol  109 (0.66 g, 1.34 mmol, 100 mol-%) in EtOAc  
(20 mL) was added Pd(OH)2 on charcoal (0.10 g of 20% Pd catalyst, 0.15 mmol, 
11 mol-%) under argon flow. The reaction flask was repeatedly evacuated and 
flushed with H2. The suspension was vigorously stirred under H2 atmosphere for 
13 h and then filtered through Celite. The filter pad was washed with EtOAc (3 x 
20 mL) and the combined filtrates were concentrated. Purification of the residue 
by flash chromatography (40% EtOAc/hexanes) afforded 6-methyl-7-(tert-butyl-
diphenylsilyl)-heptane-1,5-diol 110 (0.46 g, 89%) as colorless viscous oil. 
 
Rf (70 % EtOAc/hexanes) = 0.33; [?]D = –3.4 (c 0.61, CH2Cl2, 95% ee); IR (film, 
cm–1): 3339, 2931, 2585, 1428, 1112, 740, 701; 1H NMR (400 MHz, CDCl3): ? 
7.68-7.65 (m, 4H), 7.46-7.38 (m, 6H), 3.87 (m, 1H), 3.76 (dd, 1H, J = 10.1, 4.2 
Hz), 3.69-3.65 (m, 3H), 2.02 (br s, 2H), 1.80-1.71 (m, 1H), 1.66-1.35 (m, 6H), 
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1.06 (s, 9H), 0.92 (d, 3H, J = 7.1 Hz); 13C  NMR  (100  MHz,  CDCl3): ? 135.7, 
135.6, 133.1, 132.9, 129.9, 129.8, 127.8, 74.2, 68.7, 62.9, 39.2, 33.8, 32.7, 26.9, 
22.5, 19.2, 10.3; HRMS (ESI+): m/z calcd  for  [C24H36O3NaSi] 423.2331, found 
423.2345, ? = 3.3 ppm. The enantiomeric purity was determined by HPLC 
(Daicel Chiralcel OD column, 1:9 iPrOH/hexanes, flow rate 0.5 ml/min): ?major = 
11.15 min; ?minor = 14.82 min, 95% ee. 
5.2.9 Lactone 111 
OTBDPSO
O
111
HO
OH
OTBDPS
110
PCC, 4Å MS
CH2Cl2, rt
58%
 
To a stirred solution of diol 110 (0.70 g, 1.75 mmol, 100 mol-%) in CH2Cl2  
(20 mL) were added crushed 4 Å molecular sieves (0.75 g) and pyridinium 
chlorochromate (PCC, 0.66 g, 3.06 mmol, 175 mol-%) at rt. After 3 h, second 
portions of molecular sieves (0.25 g) and PCC (0.66 g, 3.06 mmol, 175 mol-%) 
were added. Stirring was continued for an additional 13 h and a third portion 
molecular sieves (0.2 g) and PCC (0.57 g, 2.63 mmol, 150 mol-%) were added. 
After 3 h, a fourth portion of PCC (0.18 g, 1.88 mmol, 106 mol-%) was added. 
This mixture was stirred for an additional 3 h before the mixture was filtered 
through silica  gel  with  EtOAc and  then  concentrated.  Purification  of  the  residue  
by flash chromatography (10% EtOAc/hexanes) afforded lactone 111 (0.40 g, 
58%) as colorless oil. 
 
Rf (70 % EtOAc/hexanes) = 0.56; [?]D = +26.3 (c 1.15, CH2Cl2); IR (film, cm–1): 
2958, 2931, 2883, 2857, 1736, 1428, 1239, 1112, 702; 1H  NMR  (400  MHz,  
CDCl3): ? 7.67-7.63 (m, 4H), 7.45-7.37 (m, 6H), 4.49 (ddd, 1H, J = 11.5, 4.1, 3.0 
Hz), 3.73 (dd, 1H, J = 10.2, 7.0 Hz), 3.61 (dd, 1H, J = 10.2, 5.3 Hz), 2.58 (m, 1H), 
2.41 (dt, 1H, J = 8.8, 7.2 Hz), 1.96-1.77 (m, 4H), 1.70-1.59 (m, 1H), 0.98 (s, 9H), 
0.97 (d, 3H, J =  6.9  Hz);  13C  NMR  (100  MHz,  CDCl3): ? 172.0, 135.6, 135.5, 
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133.7, 133.5, 129.7, 127.7, 80.4, 65.1, 40.4, 29.5, 26.9, 25.5, 19.3, 18.7, 11.1; 
HRMS (ESI+): m/z calcd for [C24H32O3NaSi] 419.2018, found 419.2011, ? = 1.6 
ppm. 
5.3 Synthesis of AB Spiroketal Ring Fragment 
5.3.1 Ketoalcohol 114 
 
To a stirred mixture of Mg powder (36 mg, 1.46 mmol, 290 mol-%) in THF  
(3 mL) was added 4-bromo-1-butene (0.15 mL, 1.19 g, 1.46 mmol, 290 mol-%). 
Heat was evolved and the formation of the Grignard reagent was evident from the 
darkening of the reaction mixture. After 50 min, 1.55 mL of this Grignard reagent 
solution was added dropwise to a –78 ºC solution of lactone 111 (0.2 g,  
0.50 mmol, 100 mol-%) in THF (3 mL). The resulting solution was stirred at  
–78 ºC for an additional 40 min and then sat. aq. NH4Cl  (1.5  mL)  and  H2O  
(1.5 mL) were added. The mixture was warmed to rt and the layers were 
separated. The aqueous phase was extracted with MTBE (3 x 10 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. Purification 
of the residue twice by flash chromatography (initially 20% EtOAc/hexanes, 
finally 15% EtOAc/hexanes) afforded ketoalcohol 114 (60.7 mg, 27%) as pale 
yellow oil and lactone 111 (132.8 mg, 66%). This process was repeated twice to 
obtain 114 in 60% overall yield. 
 
Rf (40 % EtOAc/hexanes) = 0.44; [?]D = +0.5 (c 0.42, CH2Cl2); IR (film, cm–1): 
3469, 2930, 2857, 1713, 1428, 1275, 1261, 1112, 912, 824, 750, 702; 1H NMR 
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(400 MHz, CDCl3): For 114: ? 7.69-7.66 (m, 4H), 7.48-7.39 (m, 6H), 5.82 (ddt, 
1H, J = 17.1, 10.3, 6.6 Hz), 5.01 (dq, 1H, J = 17.1, 1.8 Hz), 4.94 (dtd, 1H, J = 
10.3, 2.0, 1.3 Hz), 3.72-3.68 (m, 1H), 3.67 (dd, 1H, J = 10.0, 6.7 Hz), 3.57 (dd, 
1H, J = 9.8, 5.7 Hz), 2.62 (d, 1H, J = 5.5 Hz), 2.49 (t, 2H, J = 7.3 Hz), 2.41 (t, 2H, 
J = 7.3 Hz), 2.28-2.22 (m, 2H), 1.78-1.27 (m, 5H), 1.03 (s, 9H), 0.84 (d, 3H, J = 
7.0 Hz); For 188: ? 5.86 (m), 4.99 (dq, J = 17.2, 5.5 Hz), 4.90 (m), 3.56 (dd), 0.95 
(d, 3H, J =  6.8  Hz);  13C  NMR  (100  MHz,  CDCl3): For 114: ? 211.0, 136.44, 
136.40, 134.7, 134.6, 130.8, 128.75, 115.3, 71.9, 67.9, 43.0, 42.2, 41.4, 34.8, 28.8, 
27.2, 21.2, 19.8, 10.9; For 188: ? 140.3, 138.7, 130.7, 128.70, 114.5, 96.9, 71.0, 
67.0, 43.1, 41.7, 34.0, 28.8, 28.4, 20.0, 12.7; HRMS (ESI+): m/z calcd for 
[C28H40O3NaSi] 475.2644, found 475.2667, ? = 4.8 ppm. 
5.3.2 Ketal 115 
 
To a stirred solution of ketoalcohol 114 (50 mg, 0.11 mmol, 100 mol-%) in 
CH2Cl2 (4 mL) at rt was added p-methoxybenzyl alcohol (0.1 mL, 0.11 g,  
0.77 mmol, 700 mol-%) and pyridinium p-toluenesulfonate (5.5 mg, 0.022 mmol, 
20 mol-%). The resulting solution was stirred for 3 h and then sat. aq. NaHCO3  
(2 mL) and H2O (4 mL) were added. The layers were separated and the aqueous 
phase was extracted with EtOAc (4 x 10 mL). The combined organic extracts 
were  dried  over  Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (3% MTBE/hexanes, using silica gel containing ca. 0.1% Ca 
(Fluka)) afforded ketal 115 (53 mg, 83%) as pale yellow oil. 
 
Rf (60 % EtOAc/hexanes) = 0.56; [?]D = +7.4 (c 1.04, CH2Cl2); IR (film, cm–1): 
3070, 2958, 2931, 2857, 1726, 1472, 1428, 1239, 1112, 1027, 931, 824, 741, 702; 
1H NMR (400 MHz, CDCl3): ? 7.65-7.63 (m, 4H), 7.46-7.36 (m, 6H), 7.23-7.20 
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(m, 2H), 6.82-6.78 (m, 2H), 5.86 (ddt, 1H, J = 17.1, 10.3, 6.6 Hz), 5.02 (dq, 1H, J 
= 17.1, 1.7 Hz), 4.93 (dtd, 1H, J = 10.3, 1.6, 1.2 Hz), 4.36 (ddAB, 2H,?JAB?= 11.1 
Hz, ?v = 31.9 Hz), 3.78- 3.76 (m, 1H), 3.74 (s, 3H), 3.72 (dd, 1H, J = 10.0, 5.1 
Hz), 3.61 (dd, 1H, J = 10.0, 6.0 Hz), 2.11-2.02 (m, 2H), 1.85-1.16 (m, 9H), 1.01 
(obscured d, 3H), 1.00 (s, 9H); 13C NMR (100 MHz, CDCl3): ? 159.9, 139.9 
136.4, 134.84, 134.82, 132.2, 130.71, 130.69, 130.0, 128.7, 114.7, 114.5, 100.4, 
71.8, 67.0, 61.9, 55.8, 41.8, 37.3, 33.4, 28.8, 28.7, 27.3, 19.9, 19.8, 12.8; HRMS 
(ESI+): m/z calcd for [C36H48O4NaSi] 595.3220, found 595.3209, ? = 1.8 ppm. 
5.3.3 Dihydroxyketals 116a and 116b94b 
 
(DHQ)2PYR (5.6 mg, 0.006 mmol, 6.7 mol-%), K3Fe(CN)6 (89 mg, 0.27 mmol, 
300 mol-%), K2CO3 (37 mg, 0.27 mmol, 300 mol-%), CH3SO2NH2 (8.6 mg,  
0.09 mmol, 100 mol-%) and K2OsO4·2H2O (0.3 mg, 0.0009 mmol, 1 mol-%) 
were dissolved in 1:1 tert-butanol/H2O (1.5 mL each) at rt. The resulting mixture 
was vigorously stirred for 20 min and then cooled to 0 ºC. A solution of ketal 115 
(52 mg, 0.09 mmol, 100 mol-%) in tert-butanol (0.5 mL) was added via cannula. 
Stirring was continued at 0 ºC for an additional 17.5 h before Na2SO3 (0.14 g) was 
added. The resulting mixture was vigorously stirred and allowed to warm to rt. 
The mixture was diluted with EtOAc (10 mL). The layers were separated and the 
aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic 
extracts were washed with H2O (10 mL), dried over Na2SO4 and concentrated. 
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The crude product was immediately used in the next reaction without further 
purification. 
 
Rf (60 % EtOAc/hexanes) = 0.16; 1H NMR (400 MHz, CDCl3): ? 7.65-7.63 (m, 
4H), 7.47- 7.37 (m, 6H), 7.23-7.20 (m, 2H), 6.81-6.79 (m, 2H), 4.36-4.26 (m, 2H), 
3.77-3.76 (m, 1H), 3.74 (s, 3H), 3.72 (dd, 1H, J = 9.9, 5.0 Hz), 3.61 (dd, 1H, J = 
9.9, 5.8 Hz), 3.49 (m, 1H), 3.41 (m, 1H), 3.30 (m, 1H), 2.82 (m, 1H), 2.69 (m, 
1H), 1.81-1.23 (m, 11H), 1.01 (obscured d, 3H), 1.00 (s, 9H); 13C NMR (100 
MHz, CDCl3): ? 159.8, 136.4, 134.82, 134.80, 132.3, 130.69, 130.68, 130.0, 
128.7, 114.5, 100.5, 72.8, 71.8, 67.1, 67.0, 61.8, 55.8, 41.8, 34.1, 33.4, 28.8, 28.2, 
27.3, 19.9, 19.8, 12.8; For 116b, the following signals were also observed in 13C 
NMR: ? 72.8, 67.1, 61.9, 34.2, 28.9, 28.1. 
5.3.4 Pivalates 8a and 8b 
 
To a stirred 0 ºC solution of dihydroxyketal 116 (0.05 g, 0.082 mmol, 100 mol-%) 
in pyridine (0.5 mL) was added pivaloyl chloride (12 µl, 12 mg, 0.1 mmol,  
122  mol-%).  The  resulting  solution  was  stirred  at  0  ºC  for  an  additional  2  h  15  
min. Sat. aq. NaHCO3 (1  mL)  and  H2O (5  mL)  were  added  and  the  layers  were  
separated. The aqueous phase was extracted with EtOAc (3 x 5 mL) and the 
combined organic extracts were washed with H2O (5 mL), dried over Na2SO4 and 
concentrated. Purification of the residue by flash chromatography (15% 
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EtOAc/hexanes) afforded a mixture of pivalates 8a and 8b (40.1 mg, 62% over 2 
steps) as pale yellow viscous oil. 
 
Rf (40 % EtOAc/hexanes) = 0.47; [?]D = +12.4 (c 0.27, CH2Cl2); IR (film, cm–1): 
3469, 2930, 2957, 1713, 1428, 1275, 1261, 1112, 912, 824, 750, 701; 1H NMR 
(400 MHz, CDCl3): For 8a: ? 7.65-7.62 (m, 4H), 7.46-7.36 (m, 6H), 7.22-7.20 (m, 
2H), 6.80-6.78 (m, 2H), 4.35 (dd, 1H, J = 11.1, 3.0 Hz), 4.28 (dd, 1H, J = 11.1, 
4.6 Hz), 3.96-3.91 (m, 2H), 3.77-3.76 (m, 1H), 3.74 (s, 3H), 3.72 (dd, 1H, J = 
10.0, 4.9 Hz), 3.61 (dd, 1H, J = 10.0, 5.9 Hz), 2.97 (d, 1H, J = 5.5 Hz), 1.80-1.21 
(m, 11H), 1.17 (s, 9H), 1.01 (obscured d, 3H), 1.00 (s, 9H); For 8b, the following 
additional resonances could be observed: ? 2.97 (d, J = 5.3 Hz), 1.17 (s); 13C 
NMR (100 MHz, CDCl3): For 8a: ? 178.93, 159.8, 136.4, 134.83, 134.81, 132.3, 
130.70, 130.69, 130.0, 129.9, 128.7, 114.5, 100.4, 71.8, 70.1, 68.9, 67.0, 61.85, 
55.8, 41.9, 39.4, 34.0, 33.4, 28.8, 28.4, 27.4, 27.2, 19.9, 19.8, 12.8; For 8b, the 
following additional resonances could be observed: ? 178.91, 100.5, 70.0, 68.8, 
61.89, 28.5; HRMS (ESI+): m/z calcd  for  [C41H58O7NaSi] 713.3850, found 
713.3872, ? = 3.0 ppm. 
5.3.5 Spiroketals 10 and 11 
 
To a solution of pivalate 8 (3.5 mg, 0.005 mmol, 100 mol-%) in CDCl3 (1 mL) 
was added AcOH (1 drop, ca 10 µL, 3300 mol-%) at rt. After 21 h, the reaction 
was quenched by the addition of sat. aq. NaHCO3 (0.5  mL)  and  H2O (0.5 mL). 
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The layers were separated and the aqueous phase was extracted with EtOAc (3 x 3 
mL). The combined organic extracts were dried over Na2SO4 and concentrated. 
Purification of the residue by flash chromatography (3% EtOAc/hexanes) 
afforded fraction A: spiroketal 10 (1.5 mg, 54%), fraction B: a mixture of 
spiroketals 10 and 11 (0.5 mg, 17%), fraction C: spiroketal 11 (0.8 mg, 29%). 
 
10: Rf (10 % EtOAc/hexanes) = 0.33; [?]D =  +2.6  (c 0.53, CH2Cl2); IR (film,  
cm–1): 2930, 2857, 1732, 1460, 1367, 1282, 1153, 1113, 1075, 1023, 824, 742, 
702; 1H NMR (400 MHz, CDCl3): ? 7.67-7.64 (m, 4H), 7.48-7.38 (m, 6H), 4.19-
4.12 (m, 1H), 4.03 (dd, 1H, J = 11.4, 3.9 Hz), 3.97 (dd, 1H, J = 11.4, 5.0 Hz), 3.83 
(ddd, 1H, J = 11.7, 2.1, 5.3 Hz), 3.66 (dd, 1H, J = 9.9, 6.0 Hz), 3.52 (dd, 1H, J = 
9.9, 6.0 Hz), 2.05-1.98 (m, 1H), 1.79-1.57 (m, 7H), 1.49-1.44 (m, 1H), 1.36-1.22 
(m, 2H), 1.15 (s, 9H), 1.04 (s, 9H), 0,90 (d, 3H, J = 7.0 Hz); 13C NMR (100 MHz, 
CDCl3): ? 178.8, 136.41, 136.39, 134.89, 134.84, 130.7, 128.7, 107.2, 76.3, 71.4, 
67.0, 66.7, 41.4, 39.4, 38.1, 33.5, 28.7, 27.4, 27.3, 26.6, 21.4, 19.8, 12.4; HRMS 
(ESI+): m/z calcd for [C33H48O5NaSi] 575.3169, found 575.3176, ? = 1.2 ppm. 
 
11: Rf (10 % EtOAc in hexanes) = 0.30; [?]D = +1.4 (c 0.14, CH2Cl2); 1H NMR 
(400 MHz, CDCl3): ? 7.67-7.64 (m, 4H), 7.47-7.38 (m, 6H), 4.21- 4.13 (m, 1H), 
3.99 (dd, 1H, J = 11.0, 7.3 Hz), 3.94 (dd, 1H, J = 11.0, 5.3 Hz), 3.73 (ddd, 1H, J = 
7.8, 5.7, 2.1 Hz), 3.70 (dd, 1H, J = 9.9, 4.6 Hz), 3.54 (dd, 1H, J = 9.9,  6.9 Hz),  
2.11-2.10 (m, 1H), 1.86-1.47 (m, 10H), 1.15 (s, 9H), 1.03 (s, 9H), 0,97 (d, 3H, J = 
6.8 Hz); 13C  NMR  (100  MHz,  CDCl3): ? 178.7, 136.4, 134.9, 134.8, 130.69, 
130.67, 128.7, 107.3, 78.3, 72.2, 69.0, 67.1, 41.9, 39.0 (2 C), 34.1, 28.6, 27.8, 
27.4, 27.3, 21.2, 19.8, 13.4. HRMS (ESI+): m/z calcd  for  [C33H48O5NaSi] 
575.3169, found 575.3157, ? = 2.1 ppm. 
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5.3.6 Spiroketal 9 
 
To a solution of pivalate 8 (10.0 mg, 0.014 mmol, 100 mol-%) in CH2Cl2 (1 mL) 
was added chloroacetic acid (0.27 mg, 0.0029 mmol, 20 mol-%) in CH2Cl2 (0.8 
ml) at rt. After 30 min, another portion of chloroacetic acid (0.27 mg, 0.0029 
mmol, 20 mol-%) in CH2Cl2 (0.8  ml)  was  added.  The  resulting  solution  was  
stirred at rt for an additional 4h. The reaction was quenched by addition of sat. aq. 
NaHCO3 (0.5 mL) and H2O (0.5 mL). The layers were separated and the aqueous 
phase was extracted with EtOAc (3 x 5 mL). The combined organic extracts were 
dried  over  Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (3% EtOAc/hexanes) afforded fraction A: spiroketal 10 (1.9 mg, 
24%), fraction B: a mixture of spiroketals 10 and 11 (1.6 mg, 21%), fraction C: 
spiroketal 11 (0.5 mg, 6%), fraction D: spiroketal 9 (containing ca 5% of 117) (3.8 
mg, 49%). 
 
Fraction D: Rf (10  % EtOAc/hexanes)  =  0.20;  [?]D = +5.4 (c 0.28, CH2Cl2); IR 
(film, cm–1): 2929, 2857, 1732, 1463, 1277, 1263, 1156, 1113, 1009, 896, 824, 
748, 703; 1H NMR (400 MHz, CDCl3): ? 7.68-7.65 (m, 4H), 7.48-7.39 (m, 6H), 
4.17 (dt, J = 7.3, 4.6 Hz), 4.02 (dd, 1H, J = 11.1, 4.6 Hz), 3.92 (dd, 1H, J = 11.1, 
7.3 Hz), 3.67 (dd, 1H, J = 9.9, 6.8 Hz), 3.61 (ddd, 1H, J = 11.5, 4.5, 2.3 Hz), 3.52 
(dd, 1H, J = 9.9, 6.0 Hz), 2.42-2.37 (m, 1H), 1.79-1.24 (m, 10H), 1.17 (s, 9H), 
1.04 (s, 9H), 0.89 (d, 3H, J = 6.9 Hz); 13C  NMR  (100  MHz,  CDCl3): ? 178.7, 
136.4, 134.8, 130.7, 128.7, 109.4, 78.1, 75.0, 69.2, 67.0, 41.4, 39.3, 34.8, 32.2, 
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28.9, 27.6, 27.4, 27.2, 22.9, 19.8, 12.3; HRMS (ESI+): m/z calcd for 
[C33H48O5NaSi] 575.3169, found 575.3159, ? = 1.7 ppm. 
 
Spiroketalization with PPTS (Table 1, entry 1) afforded 9 accompanied by ca. 
10% of the inseparable C10 epimer 117. For spiroketal 117, the following 
additional resonances could be observed: ? 4.29-4.22 (m), 4.05 (dd, J = 3.8 Hz), 
3.95 (dd, J = 5.1 Hz), 3.69-3.65 (m), 1.18 (s), 0.89 (d, J = 6.8 Hz). 
5.4 Synthesis of C Ring Fragment 
5.4.1  (E)-Methyl 3-methylhexa-2,5-dienoate 128102 
 
A mixture of CuI (0.29 g, 1.5 mmol, 150 mol-%) and LiCl (64 mg, 1.5 mmol, 150 
mol-%) in THF (2.0 mL) was stirred at rt for 5 min to give a yellow suspension 
and was then cooled to –78 ºC and stirred for 20 min before cooling to –100 ºC. 
Allyllithium solution was prepared at the same time by adding methyllithium 
(1.6M in Et2O, 1.88 mL, 3.0 mmol, 300 mol-%) to a solution of allyltributyltin 
189 (0.93 mL, 1.0 g, 3.0 mmol, 300 mol-%) in THF (3.0 mL) at –78 ºC. The 
resulting yellow solution was stirred at –78 ºC for 15 min before cooling to  
–100 ºC. The allyllithium solution was slowly transferred to the CuI/LiCl 
suspension via dry ice-cooled cannula. The resulting yellow mixture was warmed 
to –78 ºC and a solution of methyl-2-butynoate 127 (98 mg, 1.0 mmol, 100 mol-
%) in THF (2.0 mL) was added. The resulting brownish mixture was stirred at  
–78  ºC  for  30  min  before  sat.  aq.  NH4Cl (10 mL) was added. The mixture was 
allowed to warm to rt and was then diluted with H2O (10 mL) and Et2O (10 mL). 
The layers were separated and the aqueous phase was extracted with Et2O (3 x 20 
mL). The combined organic extracts was washed with sat. aq. NH4Cl (3 x 20 mL) 
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and brine (20 mL), dried over Na2SO4 and concentrated. Purification of the 
residue by flash chromatography (initially 100% hexanes, finally 5% 
EtOAc/hexanes, 2 columns) afforded diene 128 (95 mg, 67%) as light yellow 
liquid. 
 
Rf (30% EtOAc/hexanes) = 0.5; 1H NMR (400 MHz, CDCl3): ??5.79 (ddt, 1H, J = 
17.0, 10.2, 6.8 Hz), 5.70 (q, 1H, J = 1.3 Hz), 5.14-5.08 (m, 2H), 3.69 (s, 3H), 2.87 
(dd, 2H, J = 6.8, 1.1 Hz), 2.16 (d, 3H, J = 1.3 Hz).  
 
When butyllithium was used instead of methyllithium substantial amounts of the 
side product 131 was formed. 
 
To a solution of allyltributyltin (0.96 mL, 3.1 mmol, 155 mol-%) in THF (10 mL) 
was slowly added nBuLi (1.68 M, 1.90 mL, 3.1 mmol, 158 mol-%) at –78 °C. The 
solution was stirred at –78 °C for 30 min and was then cannulated to a suspension 
of CuI (0.57 g, 3.0 mmol, 150 mol-%) in THF (4 mL) at –78 °C. During the 
addition the reaction mixture turned grey and then to black. The reaction mixture 
was allowed to warm to –45 °C during stirring for 45 min. The reaction mixture 
was cooled back to –78 °C and a solution of methyl-2-butynoate 127 (0.20  mL,  
2.0 mmol, 100 mol-%) in THF (4 mL) was added via cannula. The resulting 
mixture was stirred for further 20 min at –78 °C. The reaction was quenched by 
addition  of  sat.  aq.  NH4Cl (10 mL) at –78 °C and the mixture was allowed to 
warm to rt. H2O (20 mL) and Et2O (20 mL) were added, and the layers were 
separated. The aqueous phase was extracted with Et2O  (3  ×  25  mL).  The  
combined organic extracts were washed with sat. aq. NH4Cl (2 × 25 mL) and 
brine (25 mL), dried over MgSO4 and concentrated. Purification of the residue by 
flash chromatography (initially 100% hexanes, finally 5% EtOAc/hexanes) 
afforded a 1:1 mixture of esters 128 and 131 as light yellow oil (0.18 g, 65 %).  
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For 131: Rf (30% EtOAc/hexanes) = 0.58; 1H NMR (400 MHz,  CDCl3): ? 5.67 
(dt, 1H, J = 2.5, 1.2 Hz), 3.68 (s, 3H), 2.15 (d, 3H, J = 1.3 Hz), 2.13 (dd, 2H, J = 
7.8, 0.8 Hz), 1.49-1.42 (m, 2H), 1.36-1.27 (m, 2H), 0.91 (t, 3H, J = 7.3 Hz). The 
data is in agreement with the data presented in literature.134 
5.4.2  (E)-Ethyl 3-methylhexa-2,5-dienoate 130102 
 
A suspension of LiCl (0.14 g, 3.4 mmol, 150 mol-%) and CuI (0.64 g, 3.4 mmol, 
150 mol-%) in THF (5 mL) was stirred at rt for 5 min to get a clear yellow 
solution. The solution was cooled to –78 °C and stirred for 20 min. 
Simultaneously, MeLi (1.6 M in Et2O, 4.19 mL, 6.7 mmol, 300 mol-%) was 
added to a –78 °C solution of allyltributyltin (2.08 mL, 6.7 mmol, 300 mol-%) in 
THF (7 mL). This solution was stirred at –78 °C for 15 min, before it was 
cannulated to the LiCl/CuI solution via dry ice-cooled cannula over a period of 25 
min. A solution of ethyl-2-butynoate 129 (0.26 mL, 2.23 mmol, 100 mol-%) in 
THF (5 mL) was added and the resulting red brownish reaction mixture was 
stirred for further 35 min at –78 °C. The reaction was quenched by addition of sat. 
aq. NH4Cl  (20  mL)  at  –78  °C and  the  mixture  was  allowed to  warm to  rt.  H2O  
(20  mL)  and  Et2O (20 mL) were added, and the layers were separated. The 
aqueous phase was extracted with Et2O (2 × 10 mL). The combined organic 
extracts were washed with sat. aq. NH4Cl (2 × 25 mL) and brine (25 mL), dried 
over MgSO4 and concentrated. Purification of the residue by flash 
chromatography (initially 100% hexanes, then 30% EtOAc/hexanes, and finally 
50% EtOAc/hexanes) afforded ester 130 as light yellow oil (0.32 g, 92 %).  
 
The reaction was also done in bigger scale (51.6 mmol of ethyl-2-butynoate 129). 
The product was purified by distillation under reduced pressure (8 mmHg,  
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80-88 °C) to afford ester 130 that contained some tin impurities. This material was 
used in the following reaction after which the impurities were easily separated. 
 
Rf (50% EtOAc/hexanes) = 0.71; IR (film, cm–1): 3081, 2981, 2930, 1718, 1652, 
1221, 1147; 1H NMR (400 MHz, CDCl3): ? 5.78 (ddt, 1H, J = 17.0, 10.1, 6.8 Hz), 
5.69 (q, 1H, J = 1.3 Hz), 5.14-5.08 (m, 2H), 4.15 (q, 2H, J = 7.1 Hz), 2.87 (dd, 
2H, J = 6.9, 1.1 Hz), 2.16 (d, 3H, J = 1.3 Hz), 1.28 (t, 3H, J = 7.1 Hz); 13C NMR 
(100 MHz, CDCl3): ??167.0, 157.9, 134.4, 118.0, 116.5, 59.7, 45.1, 19.0, 14.5; 
HRMS (ESI+): m/z calcd for [C9H14O2Na] 177.0891, found 177.0879, ? = 6.8 
ppm. 
5.4.3  (E)-3-Methyl-2,5-hexadien-1-ol 126 
 
To  a  solution  of  ester  130 (1.65 g, 10.7 mmol, 100 mol-%) in THF (50 mL) at  
–78 °C was added DIBAL-H (1 M in toluene, 21.4 mL, 21.4 mmol, 200 mol-%). 
The cooling bath was removed and the reaction mixture was stirred at rt for 2 h 40 
min.  Sat.  aq.  Rochelle  salt  (50  mL)  was  added  and  the  reaction  mixture  was  
stirred at rt for further 1 h. The layers were separated and the aqueous phase was 
extracted with Et2O (20 mL). The combined organic extracts were washed with 
H2O (30 mL), sat. aq. NaHCO3 (30 mL) and brine (30 mL), dried over MgSO4 
and concentrated. Purification of the residue by flash chromatography (initially 
20% EtOAc/hexanes, finally 30% EtOAc/hexanes) afforded alcohol 126 as 
colorless oil (1.09 g, 91%). 
 
On a larger scale, the reaction was performed using unpurified ester 130 and 
LiAlH4 as  the  reductant  as  follows:  To  a  suspension  of  LiAlH4 (2.63 g, 69.3 
mmol, 120 mol-%) in Et2O (100 mL) at –78 °C was added a solution of crude 
ester 130 (8.9 g, 57.7 mmol, 100 mol-%) in Et2O (40 mL). The cooling bath was 
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removed and the reaction mixture was stirred at rt for 25 min. The reaction was 
quenched by addition of H2O (2.63 mL) at –78 °C, followed by 15% NaOH  
(2.63 mL) and H2O (7.9 mL). The reaction mixture was allowed to warm to rt and 
stirred for 30 min. The white precipitate was filtered and solvent was evaporated. 
Purification of the residue by distillation under reduced pressure (7 mmHg, 71 °C) 
afforded alcohol 126 as colorless oil (5.1 g, 78 % over 2 steps). It should be noted 
that DIBAL-H in toluene should not be used in this procedure, because toluene 
cannot be separated from the product by distillation. 
 
Rf (50% EtOAc/hexanes) = 0.44; IR (film, cm–1): 3326, 3078, 2978, 2918, 1671, 
1637, 995, 913; 1H NMR (400 MHz, CDCl3): ? 5.79 (ddt, 1H, J = 16.9, 10.2, 6.8 
Hz), 5.44 (tq, 1H, J = 6.9, 1.3 Hz), 5.09-5.03 (m, 2H), 4.17 (d, 2H, J = 6.8 Hz), 
2.76 (d, 2H, J = 6.8 Hz), 1.68 (s, 3H); 13C NMR (100 MHz, CDCl3): ??138.4, 
136.2, 124.4, 116.5, 59.6, 44.1, 16.4; The data is in agreement with the data 
presented in literature.135  
5.4.4 3-Methyl-2(S),3(S)-epoxy-5-hexen-1-ol 13385c  
 
To a suspension of crushed 4Å molecular sieves (1.1 g) in CH2Cl2 (20  mL)  at   
0 °C was added L-(+)-diethyltartrate (0.5 mL, 2.94 mmol, 30 mol-%) and 
titanium(IV) isopropoxide (0.58 mL, 1.96 mmol, 20 mol-%). After 5 min, the 
mixture was cooled to –20 °C and tert-butylhydroperoxide (~5M in iso-octane, 
3.92 mL, 19.61 mmol, 200 mol-%) was added dropwise. The reaction mixture 
was stirred at –20 °C for 20 min and a solution of alcohol 126 (1.1 g, 9.81 mmol, 
100 mol-%) in CH2Cl2 (10 mL) was added. Stirring was continued at –20 °C for 
further 2 h before the reaction was quenching by addition of H2O (8 mL) at  
0 °C. The mixture was vigorously stirred for 1 h and 30% aq. solution of NaOH 
saturated with NaCl (2.5 mL) was added. The mixture was allowed to warm to rt, 
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stirred for further 1 h, and filtered through a sintered funnel. The layers were 
separated and the aqueous phase was extracted with CH2Cl2 (2  ×  10  mL).  The  
combined organic extracts were dried over Na2SO4 and concentrated. Purification 
of the residue by flash chromatography (initially 30% EtOAc/hexanes, finally 
50% EtOAc/hexanes) afforded epoxide 133 as light yellow oil (1.13 g, 90%, 93% 
ee).  
 
Rf (50% EtOAc/hexanes) = 0.29; [?]D = –4.3 (c 1.00, CH2Cl2);  IR (film,  cm–1): 
3401, 3079, 2979, 2930, 1642, 1029; 1H  NMR  (400  MHz,  CDCl3): ? 5.82-5.72 
(m, 1H), 5.15-5.12 (m, 1H), 5.11-5.09 (m, 1H), 3.84 (dd, 1H, J = 12.1,  4.2 Hz),  
3.70 (dd, 1H, J = 12.1, 6.6 Hz), 3.01 (dd, 1H, J = 6.6, 4.3 Hz), 2.37 (ddt, 1H,  
J = 14.4, 7.3, 1.0 Hz), 2.26 (ddt, 1H, J = 14.3, 6.8, 1.2 Hz), 1.81 (br s, 1H), 1.30 
(s, 3H); 13C NMR (100 MHz, CDCl3): ??133.0, 118.5, 62.3, 61.5, 60.8, 42.9, 17.0; 
HRMS (ESI+): m/z calcd for [C7H12O2Na] 151.0735, found 151.0736, ? = 0.7 
ppm. The enantiomeric purity was determined after the next reaction. 
5.4.5 Ester 134 
 
To a solution of epoxide 133 (0.66 g, 5.15 mmol, 100 mol-%) in CH2Cl2 (32 mL) 
was added methyl acrylate (11.6 mL, 128.8 mmol, 2500 mol-%) and a solution of 
Hoveyda-Grubbs 2nd generation catalyst (0.16 g, 0.26 mmol, 5 mol-%) in CH2Cl2 
(32 mL) at rt. Stirring was continued at rt for 3.5 h. The mixture was concentrated, 
and the residue was purified by flash chromatography (initially 100% hexanes, 
then 25% and 40%, and finally 50% EtOAc/hexanes) to afford ester 134 as black 
oil. This product was used as such in the following reaction. However, to remove 
the ruthenium impurities another column (40% EtOAc/hexanes) was needed to 
afford ester 134 as colorless oil (0.82 g, 86%).  
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Rf (50% EtOAc/hexanes) = 0.18; [?]D = –8.0 (c  1.00, CH2Cl2, 93% ee); IR (film, 
cm–1): 3438, 2997, 2954, 2850, 1723, 1658; 1H NMR (400 MHz, CDCl3): ? 6.89 
(dt, 1H, J = 15.6, 7.4 Hz), 5.91 (dt, 1H, J = 15.7, 1.5 Hz), 3.84 (dd, 1H, J = 12.1, 
4.3 Hz), 3.73 (s, 3H), 3.70 (dd, 1H, J = 12.3, 6.6 Hz), 3.00 (dd, 1H, J = 6.4, 4.4 
Hz),  2.51 (ddd, 1H, J = 14.9, 7.5, 1.4 Hz), 2.41 (ddd, 1H, J = 14.9, 7.1, 1.5 Hz), 
1.90 (br s, 1H), 1.32 (s, 3H); 13C NMR (100 MHz, CDCl3): ??166.6, 143.2, 124.3, 
62.2, 61.3, 60.0, 51.7, 41.1, 17.3; HRMS (ESI+): m/z calcd for [C9H14O4Na] 
209.0790, found 209.0778, ? = 5.7 ppm. The enantiomeric purity was determined 
by HPLC (Daicel Chiralcel AD column, 5 % iPrOH/hexanes + 0.01% TFA, flow 
rate 0.8 mL/min): ?major = 30.80 min; ?minor = 36.89 min. 
5.4.6 Ester 135 
 
To a solution of ester 134 (11.2 g, 60.2 mmol, 100 mol-%) in CH2Cl2 (200 mL) 
was added 2,6-lutidine (14.0 mL, 120.4 mmol, 200 mol-%) and TBSOTf (14.5 
mL 63,2 mmol, 105 mol-%) at –78 °C. The reaction mixture was stirred at –78 °C 
for 1h and then quenched by addition of 2M NaOH (80 mL). The solution was 
allowed to warm to rt. The layers were separated, and the organic phase was 
washed with 2 M HCl (80 mL) and brine (80 mL), dried over MgSO4 and 
concentrated. Purification of the residue by flash chromatography (10% 
EtOAc/hexanes) afforded the desired product 135 as light yellow viscous oil (15.5 
g, 86% over 2 steps). 
 
Rf (50% EtOAc/hexanes) = 0.64; [?]D = –3.5 (c 1.00, CH2Cl2);  IR (film,  cm–1): 
2954, 2930, 2886, 2858, 1728, 1660, 838; 1H NMR (400 MHz,  CDCl3): ? 6.92 
(dt, 1H, J = 15.7, 7.2 Hz), 5.92 (dt, 1H, J = 15.7, 1.5 Hz), 3.74 (dd, 2H, J = 5.4, 
1.7 Hz), 3.73 (s, 3H), 2.93 (t, 1H, J = 5.4 Hz), 2.50 (ddd, 1H, J = 15.0, 7.5, 1.4 
Hz), 2.38 (ddd, 1H, J = 15.0, 7.0, 1.5 Hz), 1.29 (s, 3H), 0.90 (s, 9H), 0.08 (2 × s, 
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6H); 13C NMR (100 MHz, CDCl3): ??166.7, 143.5, 124.1, 62.5, 62.1, 59.4, 51.7, 
41.2, 26.0, 18.4, 17.1, –5.1, –5.2; HRMS (ESI+): m/z calcd  for  [C15H28O4NaSi] 
323.1655, found 323.1653, ? = 0.6 ppm. 
5.4.7 Diol 136 
 
A suspension of potassium hexacyanoferrate(III) (50.8 g, 154.3 mmol, 300 mol-
%), K2CO3 (21.3 g, 154,3 mmol, 300 mol-%), methanesulfonamide (4.9 g, 51.4 
mmol, 100 mol-%), potassium osmate(VI) dihydrate (0.95 g, 2.57 mmol, 5 mol-
%) and (DHQD)2PYR (2.72 g, 3.09 mmol, 6 mol-%) in tert-butanol (180 mL) and 
H2O (320 mL) was stirred at  rt  for 45 min until  both phases became clear.  Ester 
135 (15.45 g, 51.4 mmol, 100 mol-%) was added and the reaction mixture was 
stirred  at  rt  for  3  h.  Na2SO3 (3.7 g) was added and stirring was continued for 
further 1 h. The mixture was diluted with Et2O (100 mL) and the layers were 
separated. The separated aqueous phase was extracted with Et2O (2  ×  100  mL).  
The combined organic extracts were washed with H2O (100 mL) and brine (100 
mL), dried over MgSO4 and concentrated. Purification of the residue by flash 
chromatography (initially 20% EtOAc/hexanes, finally 40% EtOAc/hexanes) 
afforded diol 136 as light yellow oil (16.4 g, 95%, contains both diastereomers 
9:1).  
 
Rf (50% EtOAc/hexanes) = 0.27; [?]D =  –5.1  (c 1.00, CH2Cl2),  [?]D =  +6.7   
(c 1.00, MeOH); IR (film, cm–1): 3449, 2955, 2930, 2886, 2858, 1744, 1257; 1H 
NMR  (400  MHz,  CDCl3): ? 4.28-4.22 (m, 1H), 4.11 (dd, 1H, J =  6.5,  1.8  Hz),  
3.84 (s, 3H), 3.78 (dd, 1H, J = 11.4, 5.5 Hz), 3.71 (dd, 1H, J = 11.5, 5.6 Hz), 3.04-
3.00 (m, 2H), 2.66 (d, 1H, J = 6.4 Hz), 1.93-1.83 (m, 2H), 1.37 (s, 3H), 0.89 (s, 
9H), 0.08 (s, 3H), 0.07 (s, 3H); 13C NMR (100 MHz, CDCl3): ??173.6, 73.3, 70.0, 
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62.8, 61.9, 59.3, 53.0, 41.2, 26.0, 18.4, 17.1, –5.1, –5.3; HRMS (ESI+): m/z calcd 
for [C15H30O6NaSi] 357.1709, found 357.1705, ? = 1.1 ppm. It should be noted 
that the concentration of the 1H NMR sample  affects  the  positions  of  the  peaks,  
presumably due to hydrogen bonding–related aggregation effects. 
5.4.8 C Ring Diol 137 
 
To a solution of diol 136 (16.3 g, 48.7 mmol, 100 mol-%) in CH2Cl2 (250 mL) 
was added PPTS (1.22 g, 4.9 mmol, 10 mol-%) at rt. The reaction mixture was 
stirred  for  30  min  and  then  quenched  by  addition  of  sat.  aq.  NaHCO3 (80  mL).  
The layers were separated, and the organic phase was washed with brine (100 
mL), dried over MgSO4 and concentrated. Purification of the residue by flash 
chromatography (initially 20% EtOAc/hexanes, finally 35% EtOAc/hexanes) 
afforded the C ring diol 137 as colorless oil (14.66 g, 90%, only desired 
diastereomer). For X-ray characterization, the product was further crystallized 
using Et2O/pentane to afford white crystalline solid. 
 
Rf (50% EtOAc/hexanes) = 0.51; mp 50-52 ºC; [?]D = –32.2 (c 1.00, CH2Cl2); IR 
(film, cm–1): 3429, 2955, 2930, 2885, 2857, 1740, 1097; 1H NMR (400 MHz, 
CDCl3): ? 4.55 (d, 1H, J = 4.2 Hz), 4.51-4.49 (m, 1H), 3.83 (dd, 1H, J = 7.2, 3.9 
Hz), 3.80 (s, 3H), 3.71 (dd, 1H, J = 10.6, 4.0 Hz), 3.53 (dd, 1H, J = 10.7, 7.2 Hz),  
2.33 (d, 1H, J = 14.3 Hz), 1.92 (dd, 1H, J = 14.3, 5.8 Hz), 1.27 (s, 3H), 0.90 (s, 
9H), 0.08 (s, 6H); 13C NMR (100 MHz, CDCl3): ??170.8, 86.6, 82.4, 76.5, 74.5, 
64.0, 52.4, 41.7, 26.0, 25.3, 18.4, –5.25, –5.27; HRMS (ESI+): m/z calcd for 
[C15H30O6NaSi] 357.1709, found 357.1712, ? = 0.8 ppm; Anal. calcd for 
[C15H30O6Si] C: 53.86, H: 9.04, found C: 54.17, H: 9.31. 
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5.4.9 C Ring Ester 138 
 
To a solution of diol 137 (3.05 g, 9.1 mmol, 100 mol-%) in CH2Cl2 (50 mL) was 
added 2,6-lutidine (4.2 mL, 36.5 mmol, 400 mol-%) and TBSOTf (4.4 mL,  
19.1 mmol, 210 mol-%) at –78 °C. The reaction mixture was stirred at –78 °C for 
1h and then quenched by addition of 2M NaOH (20 mL). The solution was 
allowed to warm to rt. The layers were separated, and the organic phase was 
washed with 2M HCl (20 mL) and brine (20 mL), dried over MgSO4 and 
concentrated. Purification of the residue by flash chromatography (10% 
MTBE/hexanes) afforded the desired product 138 as light yellow very viscous oil 
(4.67 g, 91%). 
 
Rf (15% EtOAc/hexanes) = 0.58; [?]D = –20.5 (c  1.00, CH2Cl2); IR (film, cm–1): 
2955, 2930, 2886, 2857, 1774, 1740, 1473, 1255, 836, 778; 1H NMR (400 MHz, 
CDCl3): ? 4.61 (ddd, 1H, J = 5.8, 5.0, 3.6 Hz), 4.51 (d, 1H, J = 4.9 Hz), 4.08 (dd, 
1H, J = 10.5, 1.5 Hz), 3.96 (dd, 1H, J = 7.6, 1.4 Hz),  3.70 (s, 3H), 3.53 (dd, 1H, J 
= 10.5, 7.7 Hz), 2.21 (dd, 1H, J = 13.4, 3.6 Hz),  1.86 (dd, 1H, J = 13.3, 5.9 Hz), 
1.12 (s, 3H), 0.91 (s, 9H), 0.87 (s, 9H), 0.85 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 
0.09 (s, 3H), 0.08 (s, 3H), 0.06 (s, 3H), 0.03 (s, 3H); 13C  NMR  (100  MHz,  
CDCl3): ??170.2, 85.9, 82.3, 80.2, 74.4, 65.3, 51.7, 46.2, 26.3, 26.2, 25.8, 21.6, 
18.7, 18.5, 18.0, –3.4, –4.5, –4.8, –5.0, –5.2, –5.3; HRMS (ESI+): m/z calcd for 
[C27H58O6NaSi3] 585.3439, found 585.3432, ? = 1.2 ppm. 
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5.4.10 C Ring Aldehyde 139 
 
To a solution of compound 138 (4.57 g, 8.1 mmol, 100 mol-%) in CH2Cl2  
(80 mL) was added dropwise DIBAL-H (1 M in toluene, 8.9 mL, 8.9 mmol, 110 
mol-%) at –90 °C. The reaction mixture was stirred at –90 °C for 20 min and then 
quenched by addition of MeOH (100 mL) at –90 °C. Saturated aq. Rochelle salt 
(60 mL) was added and the mixture was allowed to warm to rt and stirred for 1 h. 
H2O (60 mL) was added to dissolve the precipitate. The layers were separated, 
and the aqueous phase was extracted with CH2Cl2 (50 mL). The combined organic 
extracts were washed with sat. aq. NaHCO3 (40 mL), dried over Na2SO4 and 
concentrated. The crude 1H  NMR  showed  that  the  product  was  a  hemiacetal  
instead of the desired aldehyde. The following procedure was used for the 
hydrolysis of the hemiacetal: To a solution of the crude product in THF (100 mL) 
was added acetic acid (0.8 mL). After 30 min another portion of acetic acid (0.6 
mL) was added. Stirring was continued for further 1h before sat. aq. NaHCO3 (40 
mL) was added. The layers were separated, and the organic phase was washed 
with  brine  (40  mL),  dried  over  Na2SO4 and concentrated. Purification of the 
residue by flash chromatography (15% EtOAc/hexanes) afforded aldehyde 139 as 
light yellow viscous oil (4.02 g, 93%). 
 
Rf (30% EtOAc/hexanes) = 0.52; [?]D = –70.6 (c 1.00, CH2Cl2); IR (film, cm–1): 
2956, 2930, 2886, 2858, 1739, 1255, 836, 778; 1H NMR (400 MHz, CDCl3): ? 
9.59 (d, 1H, J = 2.5 Hz), 4.69 (ddd, 1H, J = 6.0, 5.0, 2.9 Hz), 4.16 (dd, 1H, J = 
4.9, 2.5 Hz), 4.07 (dd, 1H, J = 10.7, 1.7 Hz), 3.92 (dd, 1H, J = 7.0, 1.7 Hz), 3.57 
(dd, 1H, J = 10.6, 7.0 Hz),  2.28 (dd, 1H, J = 13.6, 2.9 Hz), 1.88 (dd, 1H, J = 13.6, 
6.0 Hz), 1.14 (s, 3H), 0.91 (s, 9H), 0.88 (s, 9H), 0.84 (s, 9H), 0.14 (s, 3H), 0.10 (s, 
3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.04 (s, 3H), 0.01 (s, 3H); 13C NMR (100 MHz, 
CDCl3): ??202.6, 87.0, 86.3, 80.0, 76.3, 65.5, 46.5, 26.2, 26.1, 25.9, 21.7, 18.6, 
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18.4, 18.1, –3.4, –4.5, –4.8, –5.08, –5.12, –5.3; HRMS (ESI+): m/z calcd for 
[C26H56O5NaSi3] 555.3333, found 555.3341, ? = 1.4 ppm. 
5.5 Synthesis of CDE Ring Fragment 
5.5.1 Nucleophilic Addition Strategy 
5.5.1.1 ?-Hydroxyketone 141 
 
To a solution of aldehyde 139 (2.90 g, 5.44 mmol, 100 mol-%) in CH2Cl2 (55 mL) 
was added BF3·OEt2 (0.75 mL, 0.85 g, 5.98 mmol, 110 mol-%) and 
(isopropenyloxy)trimethylsilane 145 (1.17 mL, 0.92 g, 7.07 mmol, 130 mol-%) at  
–78 °C. The reaction mixture was stirred at –78 °C for 20 min and was then 
quenched by addition of sat. aq. NaHCO3 (20 mL). The reaction mixture was 
allowed to warm to rt. The layers were separated, and the aqueous phase was 
extracted with CH2Cl2 (10 mL). The combined organic extracts were washed with 
brine (30 mL), dried over MgSO4 and concentrated. No purification is needed and 
the ketone 141 is afforded as yellow viscose oil (3.21 g, 100%). Purification by 
flash chromatography decreases the yield by ~ 20%. 
 
Rf (15% EtOAc/hexanes) = 0.23; [?]D = –30.2 (c 1.00, CH2Cl2); IR (film, cm–1): 
3514, 2956, 2930, 2886, 2857, 1713, 1472, 1463, 1254, 1134, 1104, 1073; 1H 
NMR (400 MHz, CDCl3): ? 4.50 (dt, 1H, J = 6.1, 4.3 Hz), 4.29-4.23 (m, 1H), 3.90 
(dd, 1H, J = 10.5, 1.4 Hz), 3.65 (dd, 1H, J = 8.2, 6.0 Hz), 3.65 (dd, 1H, J = 7.5, 
1.4 Hz), 3.47 (dd, 1H, J = 10.5, 7.3 Hz),  3.21 (d, 1H, J = 3.5 Hz), 2.85 (dd, 1H, J 
= 17.1, 2.4 Hz), 2.59 (dd, 1H, J = 17.1, 9.4 Hz),  2.98 (s, 3H), 2.08 (dd, 1H, J = 
117 
 
 
  
13.4, 4.0 Hz), 1.88 (dd, 1H, J = 13.4, 6.1 Hz), 1.06 (s, 3H), 0.90 (s, 9H), 0.89 (s, 
9H), 0.87 (s, 9H), 0.11 (s, 3H), 0.094 (s, 3H), 0.091 (s, 3H), 0.088 (s, 3H), 0.05 (s, 
3H), 0.03 (s, 3H); 13C NMR (100 MHz, CDCl3): ??209.6, 83.8, 82.6, 80.9, 73.6, 
66.8, 65.5, 47.4, 46.5, 30.9, 26.2, 26.1, 26.0, 21.3, 18.7, 18.4, 18.1, –3.4, –4.3,  
–4.9, –5.1, –5.2 (2H); HRMS (ESI+): m/z calcd for [C29H62O6NaSi3] 613.3752, 
found 613.3781, ? = 4.7 ppm. 
5.5.1.2 TES Protected Ketone 190 
 
To a solution of ketone 141 (0.63 g, 1.06 mmol, 100 mol-%) in CH2Cl2 (10 mL) 
was added 2,6-lutidine (0.25 mL, 0.23 g, 2.12 mmol, 200 mol-%) and TESOTf 
(0.36 mL, 0.42 g, 1.60 mmol, 150 mol-%) at –78 °C. The reaction mixture was 
stirred at –78 °C for 45 min before 2M NaOH (3 mL) was added. The layers were 
separated and the organic phase was washed with 1M HCl (3 mL) and brine (5 
mL), dried over MgSO4 and concentrated. Purification of the residue by flash 
chromatography (3% EtOAc/hexanes) afforded the desired product 190 as light 
yellow viscose oil (0.73g, 98%). 
 
Rf (15% EtOAc/hexanes) = 0.67; [?]D = –17.8 (c 1.00, CH2Cl2); IR (film, cm–1): 
2955, 2931, 2883, 2858, 1722, 1472, 1463, 1255, 1135, 1098, 1072; 1H NMR 
(400 MHz, CDCl3): ? 4.50 (ddd, 1H, J = 8.3, 2.7, 1.7 Hz), 4.29 (ddd, 1H, J = 5.6, 
3.8, 1.7 Hz), 4.05 (dd, 1H, J = 10.5, 1.2 Hz), 3.83 (dd, 1H, J = 3.7, 1.6 Hz), 3.71 
(dd, 1H, J = 7.9, 1.0 Hz), 3.50 (dd, 1H, J = 10.4, 8.0 Hz),  2.84 (dd, 1H, J = 16.8, 
8.4 Hz), 2.77 (dd, 1H, J = 17.1, 3.0 Hz), 2.11 (s, 3H), 2.04 (dd, 1H, J = 13.8, 1.4 
Hz), 1.80 (dd, 1H, J = 13.8, 5.8 Hz), 1.07 (s, 3H), 0.92 (t, 9H, J = 7.9 Hz), 0.92 (s, 
9H), 0.87 (s, 9H), 0.85 (s, 9H), 0.60 (q, 6H, J = 8.0 Hz), 0.12 (s, 3H), 0.01 (s, 3H), 
0.09 (s, 3H), 0.051 (s, 3H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3): ??207.3, 
118 
 
 
  
86.4, 83.4, 80.9, 74.1, 68.1, 65.6, 47.9, 47.6, 31.3, 26.3, 26.1, 26.0, 20.8, 18.7, 
18.5, 18.0, 7.0, 5.3, –3.2, –4.6, –4.9, –5.0, –5.04 (2H); HRMS (ESI+): m/z calcd 
for [C35H76O6NaSi4] 727.4617, found 727.4606, ? = 1.5 ppm. 
5.5.1.3 tert-Butyl(2-methylallyloxy)diphenylsilane 148 
 
To a solution ?-methallyl alcohol 147 (4.2 mL, 3.61 g, 50 mmol, 100 mol-%) in 
DMF (50 mL) was added imidazole (6.81 g, 100 mmol, 200 mol-%) and 
TBDPSCl (14.3 mL, 15.1 g, 55 mmol, 110 mol-%) at rt. The reaction mixture was 
stirred  at  rt  for  3.5  h.  Another  portion  of  TBDPSCl  (2.6  mL,  2.75  g,  10  mmol,   
20 mol-%) was added. After stirring for an additional 2 h, the reaction mixture 
was poured into 1M HCl (20 mL). The layers were separated and the aqueous 
phase was extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts 
were washed with brine (10 mL), dried over MgSO4 and concentrated. 
Purification of the residue by distillation under reduced pressure (14-12 mmHg, 
bp. 195-197 °C) afforded 148 as colorless viscose oil (14.2 g, 92%). 
 
Rf (15 % EtOAc/hexane) = 0.58; 1H NMR (400 MHz, CDCl3): ? 7.74-7.68 (m, 
4H), 7.45-7.36 (m, 6H), 5.14-5.13 (m, 1H), 4.86 (dt, 1H, J = 3.7, 1.4 Hz), 4.08-
4.07 (m, 2H), 1.69 (d, 3H, J = 1.3 Hz), 1.08 (s, 9H); 13C NMR (100 MHz, CDCl3): 
? 144.6, 135.9, 134.1, 130.0, 128.0, 109.5, 67.7, 27.2, 19.7, 19.4. 1H and 13C-
NMR-data match those reported in literature.136 
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5.5.1.4 3-((tert-Butyldiphenylsilyloxy)methyl)but-3-en-1-ol  149137 
 
To a solution of 148 (1.0 g, 3.2 mmol, 100 mol-%) in CH2Cl2 (8 mL) was added 
paraformaldehyde (96 mg, 3.2 mmol, 100 mol-%) and crushed 4Å molecular 
sieves (0.1 g) at rt. The mixture was cooled to –78 °C and dimethylaluminum 
chloride (1M in hexanes, 3.2 mL, 3.2 mmol, 100 mol-%) was added. The reaction 
mixture was allowed to warm to rt and stirred for 5h. After filtration, the mixture 
was washed with sat. aq. NaHCO3 (5 mL) and brine (5 mL), dried over MgSO4 
and concentrated. Purification of the residue by flash chromatography (15% 
EtOAc/hexanes) afforded alcohol 149 as yellow oil (0.27 g, 24%). 
 
Rf (15 % EtOAc/hexane) = 0.10; IR (film, cm–1): 3368, 3071, 3050, 2958, 2931, 
2892, 2858, 1428, 1113; 1H NMR (400 MHz, CDCl3): ? 7.71-7.66 (m, 4H), 7.47-
7.38 (m, 6H), 5.22 (dd, 1H, J = 3.7, 1.5 Hz), 5.00 (dd, 1H, J = 2.0, 1.0 Hz), 4.13 
(s, 2H), 3.68 (t, 2H, J = 6.2 Hz), 2.32 (t, 2H, J = 5.9 Hz), 1.08 (s, 9H); 13C NMR 
(100 MHz, CDCl3): ? 145.0, 135.7, 133.4, 129.9, 127.9, 112.7, 66.8, 61.2, 36.8, 
26.9, 19.4; HRMS (ESI+): m/z calcd for [C21H28O2NaSi] 363.1756, found 
363.1765, ? = 2.5 ppm. 
5.5.1.5 tert-Butyl(4-iodo-2-methylenebutoxy)diphenylsilane 150 
 
To a solution of alcohol 149 (0.23 g, 0.68 mmol, 100 mol-%) in THF (7 mL) was 
added imidazole (0.10 g, 1.5 mmol, 220 mol-%) and triphenylphosphine (0.20 g, 
0.75 mmol, 110 mol-%) at rt. After 5 min, the reaction mixture was cooled to 0 °C 
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and iodine (0.19 g, 0.75 mmol, 110 mol-%) was added. The reaction mixture was 
allowed to warm to rt and stirred for 30 min. Hexanes (15 mL) was added. A 
white insoluble precipitate (triphenylphosphine oxide) and yellow oil separated 
from  the  solution.  These  were  separated  from  the  solution  by  filtration  and  the  
filtrate was concentrated. If white precipitate still formed, the residue was 
triturated again with hexanes, filtrated and concentrated. Purification of the 
residue by flash chromatography (5% EtOAc/hexanes) afforded iodide 150 as 
colorless oil (0.28 g, 92%). 
 
Rf (15 % EtOAc/hexane) = 0.59; IR (film, cm–1): 3070, 3049, 2958, 2930, 2856, 
1427, 1112; 1H NMR (400 MHz, CDCl3): ? 7.70-7.66 (m, 4H), 7.46-7.37 (m, 6H), 
5.23 (d, 1H, J = 1.5 Hz), 4.94 (q, 1H, J = 1.3 Hz), 4.12 (s, 2H), 3.21 (t, 2H, J = 7.7 
Hz), 2.62 (t, 2H, J = 7.6 Hz), 1.07 (s, 9H); 13C NMR (100 MHz, CDCl3): ? 146.8, 
135.7, 133.5, 129.9, 127.9, 111.6, 66.1, 37.5, 27.0, 19.5, 3.6. 
5.5.1.6 4-Bromo-2-methylenebutoxy-tert-butyldiphenylsilane 146 
 
To a solution of alcohol 149 (1.08 g, 3.17 mmol, 100 mol-%) in CH2Cl2 (16 mL) 
was added tetrabromomethane (1.47 g, 4.4 mmol, 140 mol-%) and 
triphenylphosphine (1.16 g, 4.4 mmol, 140 mol-%) at rt. The reaction mixture was 
stirred at rt for 50 min. Hexanes (10 mL) was added. A white insoluble precipitate 
(triphenylphosphine oxide) and yellow oil separated from the solution. These 
were separated from the solution by filtration and the filtrate was concentrated. If 
white precipitate still formed, the residue was triturated again with hexanes, 
filtrated and concentrated. Purification of the residue by flash chromatography 
(5% EtOAc/hexanes) afforded bromide 146 as colorless oil (1.22 g, 95%).  
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Rf (15 % EtOAc/hexane) = 0.59; IR (film, cm–1): 3050, 3071, 2959, 2931, 2893, 
2857, 1429, 1113; 1H NMR (400 MHz, CDCl3): ? 7.70-7.67 (m, 4H), 7.47-7.38 
(m, 6H), 5.24 (d, 1H, J = 1.5 Hz), 5.00 (q, 1H, J = 1.3 Hz), 4.12 (s, 2H), 3.43 (t, 
2H, J = 7.5 Hz), 2.60 (t, 2H, J = 7.5 Hz), 1.09 (s, 9H); 13C  NMR  (100  MHz,  
CDCl3): ? 145.2, 135.7, 133.5, 129.9, 127.9, 112.0, 66.3, 36.5, 31.1, 27.0, 19.5; 
HRMS (ESI+): m/z calcd for [C21H27ONaSiBr] 425.0912, found 425.0896, ? = 3.8 
ppm. 
5.5.1.7 Ethyl-4-benzyloxy-3-oxobutanoate 152138 
 
Sodium hydride (60% dispersion in mineral oil, 0.59 g, 25 mmol, 250 mol-%) was 
washed tree times with pentane and then suspended in THF (10 mL). Benzyl 
alcohol (1.14 mL, 1.2 g, 11 mmol, 110 mol-%) and ethyl 4-chloroacetoacetate 151 
(1,36 mL, 1.65 g, 10 mmol, 100 mol-%) were added to the suspension at rt. 
(CAUTION, heat and gas formation during the addition!) The orange reaction 
mixture was stirred at rt for 21h. The mixture was poured into ice-cold 1M HCl (5 
mL). The layers were separated, and the aqueous phase was extracted with Et2O 
(5 mL). The combined organic extracts were washed with sat. aq. NaHCO3 (2 x 
10 mL) and brine (10 mL), dried over MgSO4 and concentrated. Purification of 
the residue by flash chromatography (20% EtOAc/hexanes) afforded ethyl-4-
benzyloxy-3-oxobutanoate 152 as yellow oil (2.13 g, 90%). 
 
Rf (50 % EtOAc/hexane) = 0.48; 1H NMR (400 MHz, CDCl3): ? 7.37-7.30 (m, 
5H), 4.59 (s, 2H), 4.17 (q, 2H, J = 7.1 Hz), 4.14 (s, 2H), 3.54 (s, 2H), 1.25 (t, 3H, 
J =  7.1  Hz); 13C NMR (100 MHz, CDCl3): ? 201.9, 167.1, 137.1, 128.7, 128.3, 
128.0, 75.0, 73.7, 61.6, 46.2, 14.2; 1H and 13C-NMR-data match those reported in 
literature.139 
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5.5.1.8 Ethyl 2-(2-(benzyloxymethyl)-1,3-dioxolan-2-yl)acetate 153140 
 
To a solution of ethyl-4-benzyloxy-3-oxobutanoate 152 (2.12 g, 9.0 mmol, 100 
 mol-%) in benzene (60 mL) was added ethylene glycol (1.51 mL, 1.67 g, 26.9 
mmol, 300 mol-%) and PPTS (0.56 g, 2.2 mmol, 25 mol-%) at rt. The reaction 
mixture was heated to reflux and stirred for 19h. The water formed in the reaction 
was removed using a Dean-Stark trap. Another portion of ethylene glycol (1.0 
mL, 1.1 g, 17.9 mmol, 200 mol-%) and PPTS (0.56 g, 2.2 mmol, 25 mol-%) were 
added. Refluxing was continued for a further 24h. Solvent was evaporated and the 
residue was diluted with Et2O  (10  mL).  The  solution  was  washed  with  sat.  aq.  
NaHCO3 (5 mL) and brine (5 mL), dried over over MgSO4 and concentrated. 
Purification of the residue by flash chromatography (initially 10% 
EtOAc/hexanes, then 30% and 50% EtOAc/hexanes, and finally 100% EtOAc) 
afforded the desired product 153 as yellow oil (0.43 g, 17%). The product can also 
be used without purification in the following reactions. The unreacted ethyl-4-
benzyloxy-3-oxobutanoate and the side products are more easily separated from 
the product after the reduction/benzyl deprotection step. 
 
Rf (50  %  EtOAc/hexane)  =  0.55;  IR  (film,  cm–1): 2981, 2897, 1736, 1106; 1H 
NMR (400 MHz, CDCl3): ? 7.34-7.27 (m, 5H), 4.61 (s, 2H), 4.13 (q, 2H, J = 7.1 
Hz), 4.03-3.99 (m, 4H), 3.58 (s, 2H), 2.80 (s, 2H), 1.25 (t, 3H, J = 7.1 Hz); 13C 
NMR (100 MHz, CDCl3): ? 169.6, 138.3, 128.5, 127.83, 127.76, 108.2, 73.8, 
72.2, 65.5 (2H), 60.7, 40.6, 14.3; HRMS (ESI+): m/z calcd for [C15H20O5Na] 
303.1208 found 303.1205, ? = 1.0 ppm.  
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5.5.1.9 2-(2-(Benzyloxymethyl)-1,3-dioxolan-2-yl)ethanol 154140 
 
To a suspension of LiAlH4 (67 mg, 1.8 mmol, 120 mol-%) in Et2O (2 mL) at 0 °C 
was added dropwise a solution of ester 153 (0.41 g, 1.5 mmol, 100 mol-%) in 
Et2O (2 mL). After stirring at 0 °C for 1h, the reaction was quenched by addition 
of H2O (70 ?L) at 0 °C, followed by 15% NaOH (70 ?L) and H2O (0.2 mL). The 
reaction mixture was allowed to warm to rt and stirred for 10 min or until white 
precipitate appeared. MgSO4 was added. The precipitate and the drying agent 
were filtrated and the filtrate was concentrated. Purification of the residue by flash 
chromatography (20% EtOAc/hexanes) afforded the desired product 154 as 
colorless oil (0.34g, 100%). 
 
Rf (50 % EtOAc/hexane) = 0.29; IR (film, cm–1): 3437, 2960, 2890, 1454, 1100; 
1H NMR (400 MHz, CDCl3): ? 7.37-7.27 (m, 5H), 4.60 (s, 2H), 4.02 (s, 4H), 3.76 
(t, 2H, J = 5.4 Hz), 3.44 (s, 2H), 2.60 (br s, 1H), 2.04 (t, 2H, J =  5.4  Hz); 13C 
NMR (100 MHz, CDCl3): ? 137.9, 128.6, 127.9, 127.8, 110.4, 73.7, 72.1, 65.4 
(2H), 58.6, 37.2; HRMS (ESI+): m/z calcd for [C13H18O4Na] 261.1103, found 
261.1104, ? = 0.4 ppm. 
5.5.1.10 2-(Benzyloxymethyl)-2-(2-bromoethyl)-1,3-dioxolane 155 
 
To a solution of alcohol 154 (0.34 g, 1.4 mmol, 100 mol-%) in CH2Cl2 (7 mL) 
was added tetrabromomethane (0.66 g, 2.0 mmol, 140 mol-%) and 
triphenylphosphine (0.52 g, 2.0 mmol, 140 mol-%) at rt. The reaction mixture was 
stirred at rt for 30 min and then quenched by addition of sat. aq. NH4Cl (5 mL). 
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The layers were separated, and the organic layer was washed with brine (5 mL), 
dried over MgSO4 and concentrated. Purification of the residue by flash 
chromatography (10% EtOAc/hexanes) afforded bromide 155 as  colorless  oil  
(0.37 g, 87%). 
 
Rf (50  %  EtOAc/hexane)  =  0.54;  IR  (film,  cm–1): 3030, 2889, 1453, 1102; 1H 
NMR (400 MHz, CDCl3): ? 7.39-7.27 (m, 5H), 4.59 (s, 2H), 4.01-3.94 (m, 4H), 
3.43-3.39 (m, 2H), 3.38 (s, 2H), 2.38-2.34 (m, 2H); 13C NMR (100 MHz, CDCl3): 
? 138.0, 128.6, 127.9, 127.8, 109.2, 73.7, 72.0, 65.6 (2H), 39.2, 26.6; HRMS 
(ESI+): m/z calcd for [C13H17O3NaBr] 323.0259, found 323.0266, ? = 2.2 ppm. 
5.5.1.11 Ethyl 2-(2-(hydroxymethyl)-1,3-dioxolan-2-yl)acetate 156 
 
To a solution of ester 153 (1.64 g, 5.9 mmol, 100 mol-%) in MeOH (120 mL) was 
added Pd on charcoal (1.26 g of 5% Pd catalyst, 0.6 mmol, 10 mol-%) under 
argon flow. The reaction flask was repeatedly evacuated and flushed with H2. The 
suspension was vigorously stirred under H2 atmosphere for 18 h and then filtered 
through Celite. The filter pad was washed with EtOAc (3 x 20 mL) and the 
combined filtrates were concentrated. Further filtration through a short pad of 
silica with EtOAc afforded the desired product 156 as colorless oil (1.1 g, 98%). 
 
Rf (50 % EtOAc/hexane) = 0.21; IR (film, cm-1): 3480, 2982, 2898, 1733, 1132; 
1H NMR (400 MHz, CDCl3): ? 4.16 (q, 2H, J = 7.1 Hz), 4.08-4.00 (m, 4H), 3.69 
(d, 2H, J = 7.0 Hz), 2.76 (s, 2H), 2.09 (t, 1H, J = 7.0 Hz), 1.27 (t, 3H, J = 7.1); 13C 
NMR  (100  MHz,  CDCl3): ? 169.6, 108.3, 65.7 (2H), 65.4, 60.9, 40.5, 14.2; 
HRMS (ESI+): m/z calcd for [C8H14O5Na] 213.0739, found 213.0754, ? = 7.0 
ppm. 
 
125 
 
 
  
5.5.1.12 Ester 157 
 
To  a  solution  of  ester  156 (0.48 g, 2.5 mmol, 100 mol-%) in DMF (3 mL) was 
added imidazole (0.34 g, 5.0 mmol, 200 mol-%), TBDPSCl (0.79 mL, 0.83 g,  
3.0 mmol, 120 mol-%) and DMAP (60 mg, 0.5 mmol, 20 mol-%). The reaction 
mixture was stirred at rt for 2h. After dilution with CH2Cl2 (10 mL), the mixture 
was washed with 1M HCl (2 x 5 mL). The combined aqueous layers were 
extracted with CH2Cl2 (10 mL). The combined organic extracts were washed with 
brine (15 mL), dried over over MgSO4 and concentrated. Purification of the 
residue by flash chromatography (30% EtOAc/hexanes) afforded the desired 
product 157 as light yellow viscose oil (0.98 g, 91%). 
 
Rf (50 % EtOAc/hexane) = 0.61; IR (film, cm–1): 3072, 3050, 2958, 2931, 2892, 
2858, 1738, 1113; 1H NMR (400 MHz, CDCl3): ? 7.73-7.70 (m, 4H), 7.44-7.36 
(m, 6H), 4.14 (q, 2H, J = 7.1 Hz), 4.02-3.89 (m, 4H), 3.68 (s, 2H), 2.85 (s, 2H), 
1.24 (t, 3H, J = 7.1 Hz), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3): ? 169.6, 
135.8, 135.5, 134.9, 133.4, 129.8, 127.9, 127.8, 108.7, 66.3, 65.6 (2H), 60.6, 40.4, 
26.9, 26.7, 19.4, 14.3; HRMS (ESI+): m/z calcd for [C24H32O5NaSi] 451.1917, 
found 451.1926, ? = 2.0 ppm. 
5.5.1.13 Alcohol 158 
 
To a suspension of LiAlH4 (29 mg, 0.8 mmol, 120 mol-%) in Et2O (1 mL) at 0 °C 
was added dropwise a solution of ester 157 (0.27 g, 0.6 mmol, 100 mol-%) in 
Et2O (1 mL). After stirring at 0 °C for 1h, the reaction was quenched by addition 
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of H2O (30 ?L) at 0 °C, followed by 15% NaOH (30 ?L) and H2O (90 ?L). The 
reaction mixture was allowed to warm to rt and stirred for 30 min or until white 
precipitate appeared. MgSO4 was added. The precipitate and the drying agent 
were filtrated and the filtrate was concentrated. Purification of the residue by flash 
chromatography (initially 20% EtOAc/hexanes, finally 40% EtOAc/hexanes) 
afforded the desired product 158 as yellow viscose oil (0.23g, 93%).  
 
Rf (50 % EtOAc/hexane) = 0.29; IR (film, cm–1): 3451, 3071, 3049, 2959, 2931, 
2890, 2858, 1428, 1113; 1H NMR (400 MHz, CDCl3): ? 7.72-7.68 (m, 4H), 7.46-
7.37 (m, 6H), 4.01-3.87 (m, 4H), 3.79 (t, 2H, J = 5.4 Hz), 3.56 (s, 2H), 2.80 (br s, 
1H), 2.06 (t, 2H, J = 5.4 Hz), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3): ? 135.8, 
133.2, 129.9, 127.9, 111.1, 66.3, 65.4 (2H), 58.7, 36.7, 26.9, 19.3; HRMS (ESI+): 
m/z calcd for [C22H30O4NaSi] 409.1811, found 409.1818, ? = 1.7 ppm. 
5.5.1.14 Iodide 160 
 
To a solution of alcohol 158 (0.33 g, 0.85 mmol, 100 mol-%) in THF (9 mL) was 
added imidazole (0.15 g, 2.1 mmol, 220 mol-%) and triphenylphosphine (0.25 g, 
0.94 mmol, 110 mol-%) at rt. After 5 min, the reaction mixture was cooled to 0 °C 
and iodine (0.24 g, 0.94 mmol, 110 mol-%) was added. The reaction mixture was 
allowed to warm to rt and stirred for 30 min. Hexanes (5 mL) was added. A white 
insoluble precipitate (triphenylphosphine oxide) and yellow oil separated from the 
solution. These were separated from the solution by filtration and the filtrate was 
concentrated. If white precipitate still formed, the residue was triturated again 
with hexanes, filtrated and concentrated. Purification of the residue by flash 
chromatography (10% EtOAc/hexanes) afforded iodide 160 as white powdery 
solid (0.41 g, 97%). 
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Rf (50 % EtOAc/hexane) = 0.68; mp 83-84 ºC; IR (film, cm–1): 2967, 2929, 2899, 
2856, 1427, 1228, 1112; 1H NMR (400 MHz, CDCl3): ? 7.70-7.68 (m, 4H), 7.46-
7.37 (m, 6H), 3.96-3.87 (m, 4H), 3.49 (s, 2H), 3.19-3.15 (m, 2H), 2.43-2.39 (m, 
2H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3): ? 135.8, 133.2, 129.9, 127.9, 
110.6, 66.2, 65.6 (2H), 40.4, 26.9, 19.3, –2.5; HRMS (ESI+): m/z calcd for 
[C22H29O3NaSiI] 519.0828, found 519.0839, ? = 2.1 ppm. 
5.5.1.15 Bromide 159 
 
To a solution of alcohol 158 (0.43 g, 1.10 mmol, 100 mol-%) in CH2Cl2 (5 mL) 
was added tetrabromomethane (0.51 g, 1.54 mmol, 140 mol-%) and 
triphenylphosphine (0.40 g, 1.54 mmol, 140 mol-%) at rt. The reaction mixture 
was stirred at rt for 1 h 15 min and then quenched by addition of sat. aq. NH4Cl  
(5 mL). The layers were separated, and the organic layer was washed with brine 
(5 mL), dried over MgSO4 and concentrated. Purification of the residue by flash 
chromatography (10% EtOAc/hexanes) afforded bromide 159 as white powdery 
solid (0.48 g, 98%). 
 
Rf (50 % EtOAc/hexane) = 0.60; mp 85-86 ºC;  IR (film, cm–1): 2962, 2930, 2900, 
2856, 1427, 1231, 1112; 1H NMR (400 MHz, CDCl3): ? 7.71-7.68 (m, 4H), 7.46-
7.37 (m, 6H), 3.95-3.86 (m, 4H), 3.50 (s, 2H), 3.45-3.41 (m, 2H), 2.40-2.36 (m, 
2H), 1.06 (s, 9H); 13C NMR (100 MHz, CDCl3): ? 135.8, 133.3, 129.9, 127.9, 
109.9, 66.4, 65.6 (2H), 39.0, 26.9, 26.8, 19.3; HRMS (ESI+): m/z calcd for 
[C22H29O3NaSiBr] 471.0967, found 471.0982, ? = 3.2 ppm. 
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5.5.2 Methylation Strategy 
5.5.2.1 3-Benzyloxy-2-chloromethyl-1-propene 192141  
 
Sodium hydride (60% suspension in mineral oil, 1.92 g, 48 mmol, 120 mol-%) 
was washed with hexanes (2 × 60 mL). After evaporation of the residual hexanes, 
THF (60 mL) was added. To this suspension was added benzyl alcohol (4.97 mL, 
5.2 g, 48 mmol, 120 mol-%) at rt and after stirring for 30 min DMF (13 mL) was 
added. The reaction mixture was warmed to reflux and stirred for 1 h. The color 
changed from yellow to orange during warming. The mixture was allowed to cool 
to rt and then transferred via cannula into a dropping funnel. This solution was 
added dropwise over 30 min to a solution of 3-chloro-2-chloromethyl-1-propene 
191 (4.63 mL, 5.0 g, 40 mmol, 100 mol-%) in THF (40 mL) at rt. The reaction 
mixture was stirred at rt for 18 h, during which time a white precipitate had 
formed. The mixture was quenched by addition of H2O (50 mL). The layers were 
separated and the aqueous phase was extracted with Et2O/hexanes/pentane 
(2:1:1.3, 50 mL). The combined organic extracts were washed with brine (100 
mL),  dried  over  Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (5% Et2O/hexanes) afforded the desired product 192 as colorless 
oil (4.9 g, 62%). 
 
Rf (50 % EtOAc/Hex) = 0.71; 1H NMR (400 MHz, CDCl3): ? 7.38-7.28 (m, 5H), 
5.33 (d, 1H, J = 1.0 Hz), 5.27 (q, 1H, J = 1.0 Hz), 4.53 (s, 2H), 4.14 (d, 2H, J = 
1.0 Hz), 4.13 (s, 2H); 13C NMR (100 MHz, CDCl3): ? 142.0, 138.0, 128.4 (2C), 
127.6 (2C), 116.8 (2C), 72.3, 70.2, 45.2. The data is in agreement with the data 
presented in literature.142 
 
129 
 
 
  
5.5.2.2 3-Benzyloxy-2-bromomethyl-1-propene 193143  
 
Lithium bromide (4.42 g, 50.9 mmol, 200 mol-%) was flame dried under vacuum 
before it was added to a mixture of 3-benzyloxy-2-chloromethyl-1-propene 192 
(5.0 g, 25.5 mmol, 100 mol-%) and tetrabutylammoniumbromide (0.41 g,  
1.3 mmol, 5.0 mol-%). The reaction mixture was stirred at 60 °C for 1.5 h and 
was then allowed to cool to rt. The mixture was filtered through florisil. 
Concentration afforded the desired product 193 as light yellow oil (5.9 g, 97%). 
 
Rf (50 % EtOAc/Hex) = 0.72; 1H NMR (400 MHz, CDCl3): ? 7.39-7.28 (m, 5H), 
5.36 (d, 1H, J = 0.8 Hz), 5.27 (q, 1H, J = 1.3 Hz), 4.54 (s, 2H), 4.15 (s, 2H), 4.05 
(d, 2H, J = 0.8); 13C NMR (100 MHz, CDCl3): ? 142.3, 137.9, 128.3 (2C), 127.5 
(2C), 117.2 (2C), 72.1, 70.8, 33.0. The data is in agreement with the data 
presented in literature.143 
5.5.2.3 2-Acetyl-4-benzyloxymethyl-pent-4-enoic acid ethyl ester 194 
 
Sodium hydride (60% suspension in mineral oil, 1.96 g, 48.9 mmol, 200 mol-%) 
was washed with hexanes (2 × 10 mL). After evaporation of the residual hexanes, 
THF (10 mL) was added. To this suspension at rt was added dropwise ethyl 
acetoacetate (distilled prior to use, 6.2 mL, 48.9 mmol, 200 mol-%). The reaction 
mixture was stirred at rt for 30 min and then a solution of 3-benzyloxy-2-
bromomethyl-1-propene 193 (5.9 g, 24.5 mmol, 100 mol-%) in THF (5 mL) was 
added. Stirring was continued at  rt  for 1.5 h.  The mixture was diluted with Et2O 
(20 mL) and washed with H2O (2 x 50 mL). The separated aqueous phases were 
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back-extracted with Et2O (30 mL). The combined organic extracts were washed 
with  brine  (50  mL),  dried  over  Na2SO4 and concentrated. Purification of the 
residue by flash chromatography (15% MTBE/hexanes) afforded the desired 
product 194, containing small amounts of ethyl acetoacetate (5.0 g).  
 
Rf (10 % EtOAc/toluene) = 0.41; IR (film, cm–1): 2983, 2858, 1742, 1716, 1651, 
1454, 1359, 1247, 1148, 1074, 911, 739, 699; 1H NMR (400 MHz, CDCl3): ? 
7.37-7.27 (m, 5H), 5.10 (s, 1H), 4.96 (s, 1H), 4.48 (s, 2H), 4.18 (dq, 2H, J = 7.1, 
0.6 Hz), 3.98-3.96 (m, 2H), 3.74 (t, 1H, J = 7.6 Hz), 2.66 (d, 2H, J = 7.6 Hz), 2.22 
(s, 3H), 1.25 (t, 3H, J =  7.1  Hz); 13C NMR (100 MHz, CDCl3): ? 202.4, 169.3, 
142.4, 138.1, 128.4 (2C), 127.7 (2C), 127.6, 114.3, 72.9, 72.0, 61.4, 58.0, 31.5, 
28.9, 14.0; HRMS (ESI+): m/z calcd for [C17H22O4Na] 313.1416, found 313.1406, 
? = 3.2 ppm. 
5.5.2.4 5-Benzyloxymethyl-hex-5-en-2-one 98 
 
This reaction was not carried out under argon atmosphere. To neat ester 194  
(5.0 g, ~17 mmol, 100 mol-%) was added 5 M NaOH in H2O (15.0 mL, 2.94 g 
NaOH,  73.5  mmol,  ~432  mol-%).  After  stirring  at  rt  for  21  h,  the  mixture  was  
poured into a separation funnel charged with 2 M HCl (20 mL) and H2O (60 mL). 
The mixture was extracted with Et2O  (3  ×  50  mL).  After  concentration,  the  
residue was dissolved to methanol (40 mL) and 5 M HCl in methanol (15.0 mL, 
73.5 mmol, ~432 mol-%) was added. The reaction mixture was stirred at rt for  
25 h. The reaction mixture was poured into a separating funnel containing H2O 
(50  mL),  Et2O (50 mL) and pentane (50 mL). The layers were separated. The 
aqueous phase was extracted with hexane/pentane (1:1, 100 ml) and with Et2O  
(3 x 100 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated. Purification of the residue by flash chromatography (30% 
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MTBE/hexanes) afforded the desired product 98 as yellow oil (3.2 g, 60% over 2 
steps). 
 
Rf (30  %  MTBE/Hex)  =  0.28;  IR  (film,  cm–1): 2955, 2855, 1717, 1652, 1453, 
1358, 1160, 1095, 1073, 1028, 905, 738, 698; 1H NMR (400 MHz, CDCl3): ? 
7.37-7.27 (m, 5H), 5.07 (d, 1H, J = 1.2 Hz), 4.91 (s, 1H), 4.49 (s, 2H), 3.97 (d, 
2H, J = 0.4 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.37 (t, 2H, J = 7.6 Hz), 2.14 (s, 3H); 13C 
NMR (100 MHz, CDCl3): ? 208.1, 144.7, 138.2, 128.4 (2C), 127.7 (2C), 127.6, 
112.3, 73.2, 72.0, 41.7, 29.9, 27.1; HRMS (ESI+): m/z calcd for [C14H18O2Na] 
241.1204, found 241.1211, ? = 2.8 ppm. 
5.5.2.5 TMS Enolate 195 
 
To a solution of diisopropylamine (96 ?L, 0.69 mmol, 150 mol-%) in THF (3 mL) 
was added nBuLi (2.2 M in hexanes, 0.31 mL, 0.69 mmol, 150 mol-%) at –78 °C. 
After stirring for 30 min, a solution of ketone 98 (0.1 g, 0.46 mmol,  
100 mol-%) in THF (3 mL) was added. Stirring was continued at –78 °C for 
further 30 min and TMSCl (88 ?L, 0.69 mmol, 150 mol-%) was added. The 
reaction mixture was stirred for 15 min and then diluted with Et2O (5 mL) and sat. 
aq. NH4Cl (5 mL) was added. The layers were separated, and the organic phase 
was washed with brine (5 mL), dried over MgSO4 and concentrated. Purification 
of the residue by flash chromatography (10% EtOAc/hexanes) afforded the 
desired product 195 as colorless oil (0.11 g, 83%).  
 
Rf (50 % EtOAc/Hex) = 0.60; IR  (film,  cm–1): 2958, 2925, 2854, 1654, 1635, 
1253, 846; 1H NMR (400 MHz, CDCl3): ? 7.36-7.27 (m, 5H), 5.07 (s, 1H), 4.96 
(d, 1H, J = 0.7 Hz), 4.50 (s, 2H), 4.06 (d, 1H, J = 0.7 Hz), 4.05 (d, 1H, J = 0.8 
Hz), 3.98 (s, 2H), 2.29-2.18 (m, 4H), 0.21 (s, 9H); 13C NMR (100 MHz, CDCl3): 
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? 159.1, 145.6, 138.6, 128.5, 127.8, 127.7, 112.0, 90.1, 73.3, 72.1, 34.9, 30.7, 0.3; 
HRMS (ESI+): m/z calcd for [C17H26O2NaSi] 313.1600, found 313.1585, ? = 4.8 
ppm. 
5.5.2.6 ?-Hydroxyketone 165 
 
A stock solution of LDA (0.5 M) was prepared as follows: To a solution of 
diisopropylamine (0.66 mL, 5.0 mmol, 176 mol-%) in THF (8 mL) was added 
nBuLi (2.8 M in hexanes, 1.7 mL, 4.8 mmol, 171 mol-%) at 0 °C. The reaction 
mixture was stirred at 0 °C for 5 min. A portion of the LDA solution (0.5 M, 6.04 
mL, 3.02 mmol, 110 mol-%) was transferred via syringe to solution of ketone 98 
(0.6 g, 2.8 mmol, 100 mol-%) in THF (15 mL) at –78 °C. After 4 min, a –78 °C 
solution of aldehyde 139 (1.68 g, 3.2 mmol, 115 mol-%) in THF (15 mL) was 
cannulated into the reaction mixture. Stirring was continued at –78 °C for 5 min 
before  sat.  aq.  NH4Cl (10 mL) was added. The reaction mixture was allowed to 
warm to rt  and then diluted with Et2O (20 mL) and sat.  aq.  NH4Cl (20 mL) was 
added. The layers were separated, and the organic phase was washed with sat. aq. 
NH4Cl (30 mL) and brine (30 mL), dried over Na2SO4 and concentrated. 
Purification of the residue by flash chromatography (10% EtOAc/hexanes) 
afforded the desired product 165 as yellow viscous oil (1.7 g, 82%). The product 
contains small amounts of impurities that can be easily separated after the 
following step. These impurities are the result of the reaction between aldehyde 
139 and the undesired thermodynamic enolate of ketone 98. 
 
Rf (30% EtOAc/hexanes) = 0.42; [?]D = –20.3 (c 1.00, CH2Cl2); IR (film, cm–1): 
3514, 2955, 2930, 2885, 2856, 1708, 1254, 1071, 835, 778; 1H NMR (400 MHz, 
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CDCl3): ? 7.35-7.26 (m, 5H), 5.07 (d, 1H, J = 1.0 Hz), 4.90 (s, 1H), 4.49 (s, 3H), 
4.30-4.25 (m, 1H), 3.96, (s, 2H), 3.90 (dd, 1H, J = 10.5, 1.4 Hz), 3.67-3.63 (m, 
2H), 3.47 (dd, 1H, J = 10.5, 7.3 Hz), 3.19 (d, 1H, J = 3.8 Hz), 2.79 (dd, 1H, J = 
16.9, 2.4 Hz), 2.66-2.57 (m, 3H), 2.38 (t, 2H, J = 7.5 Hz),  2.09 (dd, 1H, J = 13.5, 
3.7 Hz), 1.87 (dd, 1H, J = 13.4, 6.0 Hz), 1.06 (s, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 
0.87 (s, 9H), 0.11 (s, 3H), 0.092 (s, 3H), 0.091 (s, 3H), 0.087 (s, 3H), 0.04 (s, 3H), 
0.03 (s, 3H); 13C NMR (100 MHz, CDCl3): ??210.9, 144.9, 138.4, 128.5, 127.9, 
127.7, 112.4, 83.9, 82.7, 80.8, 73.6, 73.3, 72.2, 66.7, 65.5, 46.6, 46.5, 41.8, 26.8, 
26.2, 26.1, 26.0, 21.3, 18.7, 18.4, 18.2, –3.4, –4.3, –4.9, –5.09, –5.12, –5.2; 
HRMS (ESI+): m/z calcd for [C40H74O7NaSi3] 773.4640, found 773.4662, ? = 2.8 
ppm. 
5.5.2.7 Aldol Reaction Screen 
The results using different enolate precursors for the aldol reaction are presented 
in Table 13. Compared to lithium enolate, enolsilane (TMS/BF3·OEt2) gave 
similar selectivities but reduced yields, which is mainly due to uncompleted 
reaction. Also, the unreacted ketone was very difficult to separate from the aldol 
product. 
Table 13. Aldol reaction screen 
Enolate precursor Yield [%] 
TMS/BF3·OEt2 61 
Li 82 
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5.5.2.8 Diol 166 
 
Optimized procedure:144 
A stock triisopropoxymethyltitanium solution (0.5 M) was prepared as follows: 
To a gently cooled (~5 °C) titanium(IV) isopropoxide (2.68 mL, 9 mmol, 2250 
mol-%) was added dropwise titanium tetrachloride (0.32 mL, 3 mmol, 750 mol-
%). The mixture was allowed to warm to rt and stirred for 5 min. Et2O (13.5 mL) 
was added and stirring was continued at rt for 30 min. The reaction mixture was 
cooled  to  0  °C and  MeLi  (1.6  M in  Et2O, 7.5 mL, 12 mmol, 3000 mol-%) was 
added. During the addition LiCl precipitates and the color of the suspension 
changes from orange to bright yellow. After 1 h, a portion of the 
triisopropoxymethyltitanium solution (0.5 M, 12.0 mL, 6.0 mmol, 1500 mol-%) 
was transferred to another flask and cooled to –78 °C. A solution of ketone 165 
(0.3 g, 0.4 mmol, 100 mol-%) in Et2O (9 mL) was added. The reaction mixture 
was stirred at –78 °C for 10 min and then the dry ice bath was changed into an ice 
bath. Stirring was continued at 0 °C for further 10 min. The reaction mixture was 
diluted  with  Et2O  (5  mL)  and  2  M  HCl  (5.0  mL)  was  added  dropwise.  The  
mixture was allowed to warm to rt and stirred vigorously until both phases were 
clear. The layers were separated, and the organic phase was washed with brine  
(10 mL), dried over Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (15% EtOAc/hexanes) afforded the desired product 166 as light 
yellow viscous oil (0.28 g, 91%). 
 
Rf (30% EtOAc/hexanes) = 0.31; [?]D = –28.2 (c 1.00, CH2Cl2); IR (film, cm–1): 
3429, 2955, 2929, 2885, 2856, 1254, 836, 777; 1H NMR (400 MHz, CDCl3): ? 
7.35-7.27 (m, 5H), 5.07 (s, 1H), 4.96 (s, 1H), 4.61 (q, 1H, J =  6.0  Hz),  4.51  (s,  
2H), 4.21 (dd, 1H, J = 10.2, 8.3 Hz), 3.98, (s, 2H), 3.88 (dd, 1H, J = 10.3, 1.3 Hz), 
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3.70 (br s, 1H), 3.64 (dd, 1H, J = 8.2, 5.4 Hz), 3,61 (br s, 1H), 3.58 (dd, 1H, J = 
7.3, 1.3 Hz), 3.48 (dd, 1H, J = 10.4, 7.3 Hz), 2.28-2.08 (m, 2H), 1.98 (dd, 2H, J = 
6.1, 2.4 Hz), 1.89-1.82 (m, 2H), 1.69 (dd, 1H, J = 14.7, 10.9 Hz), 1.67-1.61 (m, 
1H), 1.20 (s, 3H), 1.06 (s, 3H), 0.91 (s, 9H), 0.89 (s, 9H), 0.87 (s, 9H), 0.13 (s, 
3H), 0.12 (s, 3H), 0.11 (s, 3H), 0.09 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR 
(100 MHz, CDCl3): ??146.6, 138.6, 128.5, 127.8, 127.7, 111.1, 83.6, 82.3, 81.3, 
74.3, 73.3, 72.7, 72.2, 68.8, 65.5, 46.2, 44.3, 38.8, 28.1, 27.9, 26.3, 26.1, 25.9, 
21.2, 18.6, 18.4, 18.0, –3.4, –4.1, –4.9, –5.07, –5.13 (2C); HRMS (ESI+): m/z 
calcd for [C41H78O7NaSi3] 789.4953, found 789.4968, ? = 1.9 ppm. 
General procedure for the methylation reactions:115 
Generally, a stock solution of the methylation reagent (~0.5 M) was prepared in 
situ. A portion of the reagent was transferred to another flask and ketone 165 in 
Et2O or THF (~0.04 M) was added. However, there was no effect whether the 
methylation reagent was added to the ketone or the other way around. For entry 8 
(Table 14), MeTi(OiPr)3 was prepared according to the optimized procedure and 
then Kugelrohr distilled after removal of solvent directly from the precipitated 
lithium chloride (0.4 mmHg, 85-90 °C) before used for the methylation as 
described above. For reaction temperatures and times see Table 14. The work-up 
was always done according to the optimized procedure. Conversions and 
diastereoselectivities were determined by 1H NMR from the crude reaction 
mixture.  
Synthesis of MeTi(OiPr)3 using MeMgBr instead of MeLi (Table 14, entry 5):  
To a gently cooled (~5 °C) titanium(IV) isopropoxide (0.89 mL, 3 mmol, 300 
mol-%) was added dropwise titanium tetrachloride (0.11 mL, 1 mmol, 100  
mol-%). The mixture was allowed to warm to rt and stirred for 5 min. THF (4 mL) 
was added and stirring was continued at rt for 30 min. The solution was cooled to 
0 °C and MeMgBr (3.0 M in Et2O, 1.33 mL, 4 mmol, 400 mol-%) was added. The 
reaction mixture was stirred at 0 °C for 1 h before used for methylation of ketone 
165. 
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Methylation with MeTi(OiPr)3 using excess Ti(OiPr)4 (Table 14, entry 9):   
To a gently cooled (~5 °C) titanium(IV) isopropoxide (0.89 mL, 3 mmol, 300 
mol-%) was added dropwise titanium tetrachloride (0.11 mL, 1 mmol, 100  
mol-%).  The  mixture  was  allowed  to  warm  to  rt  and  stirred  for  5  min.  Et2O (4 
mL) was added and stirring was continued at rt for 30 min. The reaction mixture 
was cooled to 0 °C and MeLi (1.6 M in Et2O, 2.5 mL, 4 mmol, 400 mol-%) was 
added.  Stirring  was  continued  at  0  °C  for  1  h.  A  portion  of  the  
triisopropoxymethyltitanium solution (0.5 M, 0.39 mL, 0.2 mmol, 1500 mol-%) 
was transferred to another flask and cooled to –78 °C. Ti(OiPr)4 (58 ?L, 0.2 
mmol, 1500 mol-%) and a solution of ketone 165 (10 mg, 0.013 mmol, 100 mol-
%) in Et2O (0.3 mL) were added consecutively. Work-up according to the 
optimized procedure. 
Synthesis of MeTi(OMe)3 (Table 14, entry 10):  
Synthesized according to the optimized procedure using Ti(OMe)4 instead of 
Ti(OiPr)4. 
Synthesis of MeTi(OiPr)2Cl (Table 14, entries 11-13):  
To a gently cooled (~5 °C) titanium(IV) isopropoxide (0.3 mL, 1 mmol, 100  
mol-%) was added dropwise titanium tetrachloride (0.11 mL, 1 mmol, 100  
mol-%).  The  mixture  was  allowed  to  warm  to  rt  and  stirred  for  5  min.  THF  or  
Et2O (2.3 mL) was added and stirring was continued at rt for 30 min. The solution 
was  cooled  to  0  °C  and  MeLi  (1.6  M  in  Et2O, 1.24 mL, 2 mmol, 200  
mol-%) was added. The reaction mixture was stirred at 0 °C for 1 h before used 
for methylation of ketone 165. 
Synthesis of Me2Ti(OiPr)2 and Me2Ti(OMe)2 (Table 14, entries 14-17):  
To a gently cooled (~5 °C) titanium(IV) isopropoxide (0.3 mL, 1 mmol, 100  
mol-%) was added dropwise titanium tetrachloride (0.11 mL, 1 mmol, 100  
mol-%).  The  mixture  was  allowed  to  warm  to  rt  and  stirred  for  5  min.  THF  or  
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Et2O (5.0 mL) was added and stirring was continued at rt for 30 min. The solution 
was cooled to 0 °C and MeLi (1.6 M in Et2O, 2.5 mL, 4 mmol, 400  
mol-%) was added. The reaction mixture was stirred at 0 °C for 1 h before used 
for methylation of ketone 165. Me2Ti(OMe)2 was prepared in similar manner 
using Ti(OMe)4 instead of Ti(OiPr)4. 
Synthesis of MeTiCl3 (Table 14, entry 18):  
Et2O (1.3 mL) was cooled to –78 °C. Titanium tetrachloride (0.11 mL,  
1 mmol, 100 mol-%) and MeLi (1.6 M in Et2O, 0.63 mL, 1 mmol, 100 mol-%) 
were added consecutively. The reaction mixture was allowed to warm to 0 °C and 
stirred for 20 min before used for methylation of ketone 165. 
Methylation using MeLi/ZnBr2 (Table 14, entry 19):  
To a solution of ketone 165 (10 mg, 0.013 mmol, 100 mol-%) in CH2Cl2 (0.8 mL) 
was added ZnBr2 (6.1 mg, 0.027 mmol, 200 mol-%). The suspension was stirred 
at rt for 1 h and was then cooled to –78 °C and MeLi (1.6 M in Et2O, 33 ?L, 0.053 
mmol, 400 mol-%) was added. After stirring at –78 °C for 2 h another portion of 
MeLi (1.6 M in Et2O, 33 ?L, 0.053 mmol, 400 mol-%) was added. Stirring was 
continued at –78 °C for further 2 h. Work-up according to the optimized 
procedure. 
Methylation using MeMgBr (Table 14, entry 20):  
To a solution of ketone 165 (10 mg, 0.013 mmol, 100 mol-%) in Et2O (0.3 mL) 
was added MeMgBr (3.0 M in Et2O, 43 ?L, 0.13 mmol, 100 mol-%) at –78 °C. 
The reaction mixture was stirred at –78 °C for 15 min and then diluted with Et2O 
(2.0  mL)  and  H2O  (0.3  mL)  was  added.  The  layers  were  separated,  and  the  
organic phase was washed with brine (2.0 mL), dried over MgSO4 and 
concentrated. 
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Table 14. Methylation screens. 
Entry Methylation reagenta Equiv Solvent Temperature [ºC]
Time                              
[min at –78/0 ºC] dr
b Conversionb  [%] 
1 MeTi(Oi Pr)3 5 THF  0 10 3:1 100
2 MeTi(Oi Pr)3 5 THF  –78 2h no reaction
3 MeTi(Oi Pr)3 5 THF  –30 10 3:1 20
4 MeTi(Oi Pr)3c 5 THF  –30 10 no reaction
5 MeTi(Oi Pr)3
d 5 THF  –78 to 0 30/10 2:1 100
6 MeTi(Oi Pr)3 5 Et2O  –78 to 0 10/10 8:1 - 2:3 100
7 MeTi(Oi Pr)3 15 Et2O  –78 to 0 10/10 9:1 100
8 MeTi(Oi Pr)3 15 Et2O  –78 to 0 10/10 4:1 80
9 MeTi(Oi Pr)3e 15 Et2O  –78 to 0 10/10 4:1 80
10 MeTi(OMe)3 15 Et2O  –78 to 0 10/10 4:1 100
11 MeTi(Oi Pr)2Cl
f 5 THF  –10 30 2:1 100
12 MeTi(Oi Pr)2Cl 5 THF  –78 to 0 10/15 3:1 100
13 MeTi(Oi Pr)2Cl 15 Et2O  –78 to 0 10/10 3:1 100
14 Me2Ti(Oi Pr)2 2 THF  0 15 4:1 100
15 Me2Ti(Oi Pr)2 15 Et2O  –78 to 0 10/10 6:1 100
16 Me2Ti(OMe)2 2 THF  0 12 6:1 100
17 Me2Ti(OMe)2 15 Et2O  –78 to 0 10/10 2:1 100
18 MeTiCl3 15 Et2O  –78 to 0 10/10 1:1 20
19 MeLi/ZnBr2 4 CH2Cl2  –78 240 3:2 100
20 MeMgBr 1 Et2O  –78 15 2:1 100  
a Reagents were prepared in situ, except in entry 8 where MeTi(OiPr)3 was distilled prior to use. 
b Determined by 1H NMR from the crude reaction mixture. c LiI as additive. d Prepared using 
MeMgBr. e Excess Ti(OiPr)4 (15 equiv) was used.  
f The methylation reagent was added over a 
period of 30 min to a solution of ketone using a syringe pump. 
5.5.2.9 CDE Ring Fragment 167 
 
A three-necked flask was charged with diol 166 (0.23 g, 0.3 mmol, 100 mol-%) in 
CH2Cl2 (8 mL) and cooled to –78 °C. Ozone was bubbled through the reaction 
mixture for 30 sec or until blue color emerged. Oxygen was then allowed to pass 
through the mixture for 5 min. Dimethylsulfide (0.44 mL, 6.0 mmol, 2000 mol-%) 
was added and the reaction mixture was allowed to warm to rt. After 1h, another 
portion of dimethylsulfide (0.88 mL, 12 mmol, 4000 mol-%) was added. Stirring 
was continued at rt for further 2h. Concentration and purification of the residue by 
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flash chromatography (initially 5% EtOAc/hexanes, finally 9% EtOAc/hexanes) 
afforded the desired product 167 as colorless viscose oil (0.28 g, 91%). 
 
Rf (30% EtOAc/hexanes) = 0.60; [?]D = –13.6 (c 1.00, CH2Cl2); IR (film, cm–1): 
2955, 2929, 2856, 1471, 1254, 835, 777; 1H  NMR  (400  MHz,  CDCl3): ? 7.35-
7.25 (m, 5H), 4.62 (ddAB, 2H,?JAB?= 12.4 Hz, ?v = 33.0 Hz), 4.26 (dd, 1H, J = 
4.6, 3.1 Hz), 4.13 (ddd, 1H, J = 11.4, 7.9, 3.8 Hz), 3.99 (dd, 1H, J = 10.7, 1.0 Hz), 
3.75 (dd, 1H, J = 7.5, 0.9 Hz), 3.57 (dd, 1H, J = 8.0, 3.0 Hz), 3.52 (ddAB, 
2H,?JAB?= 10.7 Hz, ?v = 22.9 Hz), 3.44 (dd, 1H, J = 10.7, 7.6 Hz), 2.18 (dt, 1H, 
J = 13.1, 4.4 Hz), 2.15 (d, 1H, J = 13.7 Hz), 2.00 (ddd, 1H, J = 13.6, 9.4, 5.2 Hz), 
1.85-1.79 (m, 1H), 1.74-1.64 (m, 3H), 1.57 (dd, 1H, J = 13.2, 4.0 Hz), 1.39 (s, 
3H), 1.04 (s, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.86 (s, 9H), 0.11 (s, 3H), 0.08 (s, 
3H), 0.06 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), –0.03 (s, 3H); 13C NMR (100 MHz, 
CDCl3): ??138.5 (-Bn, Cq), 128.4 (-Bn, 2 x CH=), 127.9 (-Bn, 2 x CH=), 127.6  
(-Bn, CH=), 106.4 (21-Cq), 85.0 (15-CH), 83.6 (12-Cq), 81.1 (18-Cq or 11-CH), 
80.9 (18-Cq or 11-CH), 73.8 (Ph, CH2), 72.4 (14-CH), 71.9 (22-CH2), 66.6 (16-
CH), 65.6 (10-CH2), 47.0 (13-CH2), 40.8 (17-CH2), 34.4 (19-CH2), 31.8 (20-
CH2), 26.35 (43-CH3), 26.30 (-TBS, 3 x CH3), 26.2 (-TBS, 3 x CH3), 26.1 (-TBS, 
3 x CH3), 21.2 (12a-CH3), 18.8 (-TBS, Cq), 18.4 (-TBS, Cq), 18.1 (-TBS, Cq), –3.4  
(-TBS, -CH3), –4.4 (-TBS, -CH3),  –4.8  (-TBS,  -CH3),  –5.0  (-TBS,  -CH3), –5.07  
(-TBS, -CH3), –5.09 (-TBS, -CH3); HRMS (ESI+): m/z calcd for [C40H74O7NaSi3] 
773.4640, found 773.4638, ? = 0.3 ppm. 
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5.6 Synthesis of ABCDE Ring Fragment 
5.6.1 CDE Ring Alcohol 170 
 
To a solution of compound 167 (2.0 g, 2.66 mmol, 100 mol-%) in THF (8.0 mL) 
was added HF·pyridine (70% HF, 2.08 mL, 1.6 g, 80.0 mmol, 3000 mol-%) at rt. 
The reaction mixture was stirred at rt for 1.5 h before sat. aq. NaHCO3 (50 mL) 
was added dropwise. The mixture was allowed to stir for 10 min, and then the 
layers were separated. The organic layer was washed with sat. aq. NaHCO3 (2 x 
50 mL). The combined aqueous layers were extracted with Et2O (2 x 50 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. Purification 
of the residue by flash chromatography (initially 10% EtOAc/hexanes, finally 
MeOH) afforded the desired product 170 as light yellow viscous oil (0.76 g, 
45%). Other collected fractions contained the starting material 167 (0.64 g) and a 
mixture of diol 196 and triol 197 (0.26 g). After another reaction with the recycled 
starting material, the desired product 170 was obtained in 58% combined yield 
(0.98g). 
 
Rf (30% EtOAc/hexanes) = 0.49; [?]D = –12.2 (c 1.00, CH2Cl2); IR (film, cm–1): 
3514, 2955, 2930, 2885, 2857, 1472, 1463, 1254, 1120, 1110, 1067; 1H NMR 
(400 MHz, CDCl3): ? 7.33-7.25 (m, 5H), 4.61 (ddAB, 2H,?JAB?= 12.3 Hz, ?v = 
29.5 Hz), 4.29 (dd, 1H, J = 4.4, 3.0 Hz), 4.15 (ddd, 1H, J = 11.5, 8.0, 3.7 Hz), 
3.82 (dd, 1H, J = 8.0, 3.9 Hz), 3.77 (dd, 1H, J = 10.6, 8.0 Hz), 3.60 (dd, 1H, J = 
8.2, 2.9 Hz), 3.51 (ddAB, 2H,?JAB?= 10.7 Hz, ?v = 22.0 Hz), 3.56-3.50 (m, 1H), 
2.94 (s, 1H), 2.19 (dt, 1H, J = 13.2, 4.2 Hz), 2.08-1.95 (m, 2H), 1.92-1.83 (m, 
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2H), 1.74-1.64 (m, 2H), 1.51 (dd, 1H, J = 13.1, 3.9 Hz), 1.37 (s, 3H), 1.17 (s, 3H), 
0.90 (s, 9H), 0.87 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H), –0.02 (s, 3H); 
13C NMR (100 MHz, CDCl3): ?????????????????????????????????????????????????
81.0, 76.2, 73.8, 71.92, 71.87, 66.1, 64.7, 48.0, 40.7, 34.2, 31.8, 26.3, 26.1, 25.9, 
20.5, 18.1 (2H), –3.8, –4.4, –4.5, –5.0; HRMS (ESI+): m/z calcd for 
[C34H60O7NaSi2] 659.3775, found 659.3775, ? = 0.2 ppm. 
5.6.2 CDE Ring Aldehyde 171 
 
To a solution of oxalyl chloride (21 ?L, 30 mg, 0.24 mmol, 120 mol-%) in 
CH2Cl2 (1.5 mL) was added DMSO (36 ?L, 40 mg, 0.5 mmol, 250 mol-%) at  
–50 ºC. After stirring for 8 min, a solution of alcohol 170 (0.13 g, 0.2 mmol, 100  
mol-%) in CH2Cl2 (2.5 mL) was added. The resulting mixture was stirred for 45 
min keeping the temperature below –30 ºC. Triethylamine (0.13 mL, 91 mg, 0.90 
mmol, 450 mol-%) was then added dropwise. Stirring was continued at –30 ºC for 
an additional 10 min and then the mixture was allowed to warm to rt. H2O (5 mL) 
was added and the separated aqueous phase was extracted with CH2Cl2 (5 mL). 
The combined organic extracts were washed with brine (10 mL), dried over 
Na2SO4 and concentrated. Purification of the residue by flash chromatography 
(10% EtOAc/hexanes) afforded the desired product 171 as light yellow oil (0.12 
g, 93%). 
 
Rf (30% EtOAc/hexanes) = 0.70; [?]D = –64.9 (c 1.00, CH2Cl2); IR (film, cm–1): 
2954, 2930, 2857, 1736, 1255, 1105; 1H NMR (400 MHz, CDCl3): ? 9.80 (s, 1H), 
7.34-7.27 (m, 5H), 4.62 (ddAB, 2H,?JAB?= 12.3 Hz, ?v = 30.9 Hz), 4.33 (dd, 1H, 
J = 4.6, 2.9 Hz), 4.25 (s, 1H), 4.18 (ddd, 1H, J = 11.0, 8.2, 4.1 Hz), 3.65 (dd, 1H, 
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J = 8.2, 2.8 Hz), 3.52 (ddAB, 2H,?JAB?= 10.6 Hz, ?v = 21.3 Hz), 2.19 (dt, 1H, J = 
13.1, 4.7 Hz), 2.17 (d, 1H, J = 14.0 Hz), 2.01 (ddd, 1H, J = 13.6, 9.2, 4.8 Hz), 
1.93-1.89 (m, 1H), 1.85 (dd, 1H, J = 14.0, 5.0 Hz), 1.76-1.57 (m, 4H), 1.39 (s, 
3H), 1.13 (s, 3H), 0.901 (s, 9H), 0.900 (s, 9H), 0.11 (s, 3H), 0.05 (s, 3H), 0.01 (s, 
3H), –0.0002 (s, 3H); 13C NMR (100 MHz, CDCl3): ??????????????????????????????
????????????????????????? 82.9, 81.1, 73.8, 72.1, 72.0, 66.4, 47.0, 40.7, 34.3, 31.9, 
26.3, 26.1, 26.0, 22.8, 18.5, 18.1, –3.8, –4.4, –4.9, –5.0; HRMS (ESI+): m/z calcd 
for [C34H58O7NaSi2] 657.3619, found 657.3605, ? = 2.1 ppm. 
5.6.3 CDE Ring Allylic Alcohols 198 and 173 
 
To a solution of aldehyde 171 (0.10 g, 0.16 mmol, 100 mol-%) in THF (3.5 mL) 
was added vinylmagnesium chloride (1M in THF, 0.64 mL, 0.64 mmol, 400  
mol-%) at –78 ºC. The reaction mixture was stirred at –78 ºC for 25 min and then 
quenched with sat. aq. NH4Cl (4 mL). The reaction mixture was allowed to warm 
to rt and H2O (4 mL) was added to dissolve the precipitate. The separated organic 
layer was dried over Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (initially 5% EtOAc/hexanes, then 7%, and finally 10% 
EtOAc/hexanes) afforded the major product 198 as light yellow oil (71 mg, 67%). 
Also a mixture containing the major and the minor diastereomers in 1:2 ratio (30 
mg) was isolated. 
 
Rf (30% EtOAc/hexanes) = 0.55; [?]D = –1.9 (c 1.00, CH2Cl2);  IR (film,  cm–1): 
3497, 2954, 2929, 2857, 1254, 1100; 1H  NMR  (400  MHz,  CDCl3): ? 7.33-7.27 
(m, 5H), 5.95 (ddd, 1H, J = 17.3, 10.6, 4.3 Hz), 5.31 (dd, 1H, J = 17.2, 1.9 Hz), 
5.13 (dd, 1H, J = 10.6, 1.9 Hz), 4.62 (ddAB, 2H,?JAB?= 12.4 Hz, ?v = 30.7 Hz), 
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4.38 (ddd, 1H, J = 9.1, 4.3, 2.2 Hz), 4.29 (dd, 1H, J = 4.1, 3.1 Hz), 4.14 (ddd, 1H, 
J = 11.4, 8.0, 3.7 Hz), 3.82 (d, 1H, J = 2.4 Hz), 3.56 (dd, 1H, J = 8.2, 2.9 Hz), 
3.52 (ddAB, 2H,?JAB?= 10.5 Hz, ?v = 22.5 Hz), 2.91 (d, 1H, J = 9.1 Hz), 2.20 
(dt, 1H, J = 13.0, 4.1 Hz), 2.02-1.95 (m, 2H), 1.90-1.85 (m, 1H), 1.84 (dd, 1H, J = 
13.7, 5.3 Hz), 1.75-1.65 (m, 2H), 1.59-1.56 (m, 1H), 1.39 (s, 3H), 1.23 (s, 3H), 
0.902 (s, 9H), 0.896 (s, 9H), 0.10 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H), –0.02 (s, 3H);  
13C NMR (100 MHz, CDCl3): ????????????????????????????????????????????????????
??????????, 81.1, 79.2, 3.8, 72.3, 72.1, 72.0, 66.2, 48.9, 40.8, 34.3, 31.8, 26.3, 
26.12, 26.06, 22.3, 18.4, 18.1, –3.4, –4.0, –4.3, –5.0; HRMS (ESI+): m/z calcd for 
[C36H62O7NaSi2] 685.3932, found 685.328, ? = 0.6 ppm. 
 
When the reaction was done in a similar manner using vinyllithium, an undesired 
side product 199 was formed. This product was isolated and characterized as a 
mixture with the desired product. Only one diastereomer of 199 was observed and 
the stereochemistry of the C10 was not determined.  
 
For 199: Rf (15% EtOAc/hexanes) = 0.55; 1H NMR (400 MHz, CDCl3): ? 7.33-
7.32 (m, 5H), 6.00 (ddd, 1H, J = 17.3, 10.4, 7.0 Hz), 5.16 (dt, 1H, J = 17.3, 1.5 
Hz), 5.09 (ddd, 1H, J = 10.3, 1.7, 1.0 Hz), 4.62 (ddAB, 2H,?JAB?= 12.4 Hz, ?v = 
28.1 Hz), 4.08 (ddd, 1H, J = 9.8, 7.9, 5.3 Hz), 3.58 (t, 1H, J = 3.1 Hz), 3.52 (ddAB, 
2H,?JAB?= 10.6 Hz, ?v = 21.7 Hz), 3.51-3.47 (m, 1H), 3.40 (d, 1H, J = 3.3 Hz), 
2.43 (d, 1H, J = 14.2 Hz), 2.25-2.15 (m, 2H), 2.04-1.95 (m, 1H), 1.90-1.83 (m 
1H), 1.74-1.61 (m, 3H), 1.38 (s, 3H), 1.21 (s, 3H), 0.89 (s, 18H), 0.063 (s, 3H), 
0.058 (s, 3H), 0.03 (s, 3H), 0.00 (s, 3H). HRMS (ESI+): m/z calcd for 
[C36H62O7NaSi2] 685.3932, found 685.3925, ? = 1.0 ppm. 
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5.6.4 A Ring Triflate 98 
 
To a solution of lactone 111 (100 mg, 0.25 mmol, 100 mol-%) in THF (5.0 mL) 
was added Comins` reagent (0.2 g, 0.50 mmol, 200 mol-%) and KHMDS (0.5M 
in toluene, 1.5 mL, 0.75 mmol, 300 mol-%) at –78 ºC. The reaction mixture was 
stirred at –78 ºC for 10 min and then quenched with sat. aq. NaHCO3 (5 mL). The 
layers were separated and the aqueous layer was extracted with Et2O (4 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. Purification 
of the residue by flash chromatography (25% EtOAc/hexanes) afforded the 
desired product 98 as colorless oil (128 mg, 96%). 
 
Rf (50% EtOAc/hexanes) = 0.68; [?]D =  8.8  (c 1.00, CH2Cl2); IR (film, cm–1): 
2931, 2858, 1701, 1426, 1219, 1113; 1H  NMR  (400  MHz,  CDCl3): ? 7.70-7.65 
(m, 4H), 7.48-7.39 (m, 6H), 4.80 (ddd, 1H, J = 5.1, 2.5, 0.6 Hz), 4.32 (ddd, 1H, J 
= 11.0, 4.4, 2.0 Hz), 3.68 (dd, 1H, J = 10.1, 6.9 Hz), 3.59 (dd, 1H, J = 10.1, 5.8 
Hz), 2.27-2.10 (m, 2H), 2.03-1.96 (m, 1H), 1.82 (dtdd, 1H, J = 14.0, 2.1, 6.2, 0.9 
Hz), 1.70 (dd, 1H, J = 10.7, 6.1 Hz), 1.03 (s, 9H), 0.95 (d, 3H, J = 7.0 Hz);  13C 
NMR (100 MHz, CDCl3): ??150.9, 150.4, 141.3, 136.4, 134.52, 134.48, 130.8, 
128.77, 128.75, 89.0, 82.2, 66.1, 40.3, 27.2, 25.0, 20.6, 19.8, 11.4; HRMS (ESI+): 
m/z calcd for [C25H31O5F3NaSSi3] 551.1511, found 551.1517, ? = 1.2 ppm. 
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5.6.5 Ketone 175 
 
To a solution of lactone 111 (0.11 g, 0.27 mmol, 100 mol-%) in THF (3.0 mL) 
was added vinylmagnesium chloride (1M in THF, 0.33 mL, 0.33 mmol, 120 mol-
%) at –78 ºC. The reaction mixture was stirred at –78 ºC for 30 min and then 
quenched with sat. aq. NH4Cl (3 mL). The reaction mixture was allowed to warm 
to rt and H2O (3 mL) was added to dissolve the precipitate. The separated organic 
layer  was  washed  with  brine  (3  mL),  dried  over  Na2SO4 and concentrated. 
Purification of the residue by flash chromatography (20% EtOAc/hexanes) 
afforded the desired product 175 as light yellow oil (0.11 g, 94%). 
 
Rf (30 % EtOAc/Hex) = 0.29; [?]D = 0.6 (c 1.00, CH2Cl2); IR (film, cm–1): 3503, 
2959, 2931, 2858, 1681, 1428, 1112; 1H  NMR  (400  MHz,  CDCl3): ? 7.68-7.65 
(m, 4H), 7.46-7.37 (m, 6H), 6.36 (dd, 1H, J = 17.7, 10.5 Hz), 6.23 (dd, 1H, J = 
17.7, 1.2 Hz), 5,82 (dd, 1H, J = 10.5, 1.2 Hz), 3.86 (m, 1H), 3.75 (dd, 1H, J = 
10.1, 4.2 Hz), 3.66 (dd, 1H, J = 10.1, 6.0 Hz), 2.84 (d, 1H, J = 4.0 Hz),  2.63 (dt, 
2H, J = 7.3, 2.3 Hz), 1.85-1.65 (m, 3H), 1.57-1.37 (m, 2H), 1.06 (s, 9H), 0.90 (d, 
3H, J =  7.1  Hz);  13C  NMR  (100  MHz,  CDCl3): ? 135.7, 133.2, 133.1, 130.0, 
129.95, 128.2, 127.92, 127.86, 74.0, 68.7, 39.6, 39.3, 33.7, 27.0, 20.8, 19.3, 10.4; 
HRMS (ESI+): m/z calcd for [C26H36O3NaSi] 447.2331, found 447.2333, ? = 0.3 
ppm. 
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5.6.6 Ketodiol 200 
 
To a solution of ketone 175 (0.15 g, 0.34 mmol, 150 mol-%) and alcohol 198 
(0.15 g, 0.23 mmol, 100 mol-%) in CH2Cl2 (7  mL)  was  added  Grubbs  2nd  
generation catalyst (9.8 mg, 0.012 mmol, 5 mol-%). The reaction mixture was 
warmed to reflux and stirred for 17h. Solvent was evaporated and the residue was 
purified by flash chromatography (30% MTBE/hexanes, 50 ?L Et3N in 500 mL 
eluent) to give ketodiol 200 as tanned oil (0.12 g, 52%). 
 
Rf (30% EtOAc/hexanes) = 0.27; [?]D = –7.9 (c 1.00, CH2Cl2);  IR (film,  cm–1): 
3480, 2955, 2931, 2858, 1694, 1472, 1255, 1111; 1H NMR (400 MHz, CDCl3): ? 
7.68-7.65 (m, 4H), 7.46-7.37 (m, 6H), 7.33-7.32 (m, 5H), 6.96 (dd, 1H, J = 15.9, 
3.5 Hz), 6.41 (dd, 1H, J = 15.8,  2.2 Hz),  4.61 (ddAB, 2H,?JAB?= 12.3 Hz, ?v = 
28.4 Hz), 4.55-4.51 (m, 1H), 4.29 (dd, 1H, J = 4.4, 2.9 Hz), 4.13 (ddd, 1H, J = 
11.4, 8.0, 3.7 Hz), 3.93 (d, 1H, J = 3.2 Hz), 3.87-3.84 (m, 1H), 3.74 (dd, 1H, J = 
10.4, 4.2 Hz), 3.66 (dd, 1H, J = 10.1, 5.9 Hz), 3.56 (dd, 1H, J = 8.2, 2.8 Hz), 3.51 
(ddAB, 2H,?JAB?= 10.7 Hz, ?v = 21.6 Hz), 3.25 (d, 1H, J = 8.5 Hz), 2.84 (d, 1H, 
J = 3.9 Hz), 2.58 (dt, 2H, J = 7.5, 1.6 Hz), 2.18 (dt, 1H, J = 13.0, 4.2 Hz), 2.02-
1.64 (m, 8H), 1.86 (dd, 1H, J = 13.9, 5.2 Hz), 1.55 (dd, 1H, J = 13.1, 3.9 Hz), 
1.52-1.44 (m, 2H), 1.39 (s, 3H), 1.05 (s, 9H), 1.05 (s, 3H), 0.91 (obscured d, 3H), 
0.906 (s, 9H), 0.895 (s, 9H), 0.11 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H), –0.01 (s, 3H); 
13C NMR (100 MHz, CDCl3): 200.1, 148.4, 138.5, 135.7, 133.2, 133.1, 130.1, 
130.0, 129.9, 128.5, 128.4, 128.2, 127.92, 127.89, 126.6, 106.4, 85.0, 84.9, 81.1, 
78.5, 74.7, 73.8, 72.0, 71.97, 71.94, 68.8, 66.0, 48.9, 41.0, 40.8, 39.3, 34.2, 33.9, 
31.9, 27.0, 26.3, 26.05, 26.01, 22.3, 20.8, 19.3, 18.3, 18.1, 10.3, –3.6, –4.0, –4.3, –
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5.1; HRMS (ESI+): m/z calcd for [C60H94O10NaSi3] 1081.6053, found 1081.6072, 
? = 6.3 ppm. 
5.6.7 Diene 201 
 
To a solution of ketone 175 (58 mg, 0.14 mmol, 150 mol-%) and alcohol 198  
(60 mg, 0.09 mmol, 100 mol-%) in CH2Cl2 (3 mL) was added Hoveyda-Grubbs 
2nd generation catalyst (2.8 mg, 0.005 mmol, 5 mol-%). The reaction mixture was 
warmed to reflux and stirred for 20 h. Solvent was evaporated and the residue was 
purified by flash chromatography (10% EtOAc/hexanes, 50 ?L Et3N in 500 mL 
eluent) to give diene 201 (49 mg, 52%) as a mixture with the starting alcohol 198.  
 
For 201: Rf (30% EtOAc/hexanes) = 0.51; 1H NMR (400 MHz, CDCl3): ? 7.67-
7.65 (m, 4H), 7.44-7.28 (m, 11H), 5.98 (s, 2H), 4.73 (dd, 1H, J = 4.6, 2.5 Hz), 
4.63 (ddAB, 2H,?JAB?= 12.4 Hz, ?v = 31.7 Hz), 4.51 (d, 1H, J = 9.3 Hz), 4.30 
(dd, 1H, J = 4.1, 3.0 Hz), 4.15 (ddd, 1H, J = 11.4, 8.1, 3.8 Hz), 3.83 (ddd, 1H, J = 
16.4, 5.8, 1.4 Hz), 3.82 (dd, 1H, J = 10.5, 2.1 Hz), 3.74 (dd, 1H, J = 10.1, 5.6 Hz), 
3.64 (dd, 1H, J = 10.1, 5.7 Hz), 3.57 (dd, 1H, J = 8.2, 2.9 Hz), 3.54 (ddAB, 
2H,?JAB?= 10.7 Hz, ?v = 23.1 Hz), 2.77 (d, 1H, J = 9.4 Hz), 2.20 (dt, 1H, J = 
13.0, 4.0 Hz), 2.14-1.56 (m, 12H), 1.37 (s, 3H), 1.23 (s, 3H), 1.06 (s, 9H), 0.91 
(obscured d, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H), 0.02 (s, 
3H), –0.01 (s, 3H); 13C  NMR  (100  MHz,  CDCl3): 151.2, 138.6, 135.8, 134.1, 
130.4, 129.8, 128.5, 128.0, 127.9, 127.8, 127.7, 125.5, 106.4, 101.7, 84.67, 84.66, 
81.21, 81.19, 79.7, 79.3, 76.5, 73.9, 72.2, 72.0, 71.5, 66.3, 66.2, 48.8, 40.9, 40.8, 
34.4, 31.9, 27.1, 26.4, 26.22, 26.18, 26.1, 25.8, 22.3, 21.8, 19.6, 18.5, 18.2, 12.8,  
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–3.5, –3.9, –4.2, –5.0; HRMS (ESI+):  m/z calcd for [C60H92O9NaSi3] 1063.5947, 
found 1063.5996, ? = 4.6 ppm. 
5.6.8 Ketodiol 184 
 
To a solution of ketone 200 (56 mg, 0.053 mmol, 100 mol-%) and pyridine  
(6.3 ?L, 6.3 mg, 0.078 mmol, 150 mol-%) in EtOAc (5 mL) was added Pd on 
charcoal (11.2 mg of 5% Pd catalyst, 0.005 mmol, 10 mol-%) under argon flow. 
The reaction flask was repeatedly evacuated and flushed with H2. The suspension 
was vigorously stirred under H2 atmosphere for 4 h and then filtered through 
Celite. The filter pad was washed with EtOAc (2 x 5 mL) and the combined 
filtrates were concentrated. Purification of the residue by flash chromatography 
(30% EtOAc/hexanes, 50 ?L Et3N in 500 mL eluent) afforded the desired product 
184 as colorless oil (53 mg, 94%). 
 
Rf (30% EtOAc/hexanes) = 0.25; [?]D = –5.9 (c 1.00, CH2Cl2);  IR (film,  cm–1): 
3502, 2954, 2930, 2857, 1713, 1472, 1254, 1111; 1H NMR (400 MHz, CDCl3): ? 
7.68-7.65 (m, 4H), 7.46-7.28 (m, 11H), 4.62 (ddAB, 2H,?JAB?=  12.4  Hz,  ?v  =  
31.1 Hz), 4.29 (dd, 1H, J = 4.2, 3.1 Hz), 4.14 (ddd, 1H, J = 12.0, 7.4, 4.0 Hz), 
3.85-3.82 (m, 1H), 3.76-3.62 (m, 4H), 3.59-3.55 (m, 1H), 3.52 (ddAB, 2H,?JAB?= 
10.6 Hz, ?v = 22.7 Hz), 2.84 (d, 1H, J = 3.8 Hz), 2.65 (ddd, 1H, J = 15.9, 8.3, 6.5 
Hz), 2.57 (d, 1H, J = 8.4 Hz), 2.51-2.42 (m, 3H), 2.19 (dt, 1H, J = 13.0, 4.0 Hz), 
2.02-1.42 (m, 14H), 1.39 (s, 3H), 1.06 (s, 9H), 1.05 (s, 3H), 0.91 (s, 9H), 0.90 (s, 
9H), 0.89 (obscured d, 3H), 0.131 (s, 3H), 0.129 (s, 3H), 0.04 (s, 3H), –0.02 (s, 
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3H); 13C NMR (100 MHz, CDCl3): 211.9, 138.5, 135.8, 135.7, 133.2, 133.1, 
130.0, 129.9, 128.4, 127.9, 127.89, 127.85, 127.6, 106.4, 84.4, 84.3, 81.1, 79.2, 
74.0, 73.8, 72.1, 71.9, 70.8, 68.8, 66.2, 48.5, 43.0, 40.8, 39.8, 39.3, 34.2, 33.9, 
31.8, 30.1, 27.0, 26.3, 26.2, 26.1, 22.0, 20.6, 19.3, 18.5, 18.1, 10.4, –3.69, –3.73, –
4.4, –5.0; HRMS (ESI+):  m/z  calcd  for  [C60H96O10NaSi3] 1083.6209, found 
1083.6238, ? = 9.6 ppm. 
5.6.9 Spiroketals 185 and 186 
 
To a solution of ketone 184 (53 mg, 0.049 mmol, 100 mol-%) in CH2Cl2 (3.5 mL) 
was added chloroacetic acid (2.3 mg, 0.024 mol-%, 50 mol-%) at rt. The reaction 
mixture  was  stirred  at  rt  for  1  h  and  then  diluted  with  CH2Cl2 (5  mL)  and  
quenched with sat. aq. NaHCO3 (5 mL). The separated organic layer was dried 
over Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (10% EtOAc/hexanes, 50 ?L Et3N in 250 mL eluent) afforded 
the nonanomeric isomer 185 as colorless oil (15 mg, 29%) and a mixture of the 
nonanomeric and anomeric isomers in (35 mg, combined total yield 98%). 
 
For 185: Rf (15% EtOAc/hexanes) = 0.38; [?]D = –13.2 (c 0.50, CH2Cl2); IR (film, 
cm–1): 2953, 2929, 2856, 1472, 1106; 1H NMR (400 MHz, C6D6): ? 7.82-7.78 (m, 
4H), 7.36-7.19 (m, 10H), 7.11-7.07 (m, 1H), 4.54 (ddAB, 2H,?JAB?= 12.3 Hz, ?v 
= 23.9 Hz), 4.40-4.34 (m, 2H), 4.22 (dd, 1H, J = 4.7, 2.8 Hz), 3.88 (d, 1H, J = 8.2 
Hz), 3.58 (dd, 1H, J = 9.7, 7.3 Hz),  3.80 (s, 2H), 3.62 (dd, 1H, J = 11.1, 2.9 Hz), 
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3.60 (dd, 1H, J = 9.7, 6.0 Hz), 3.58-3.56 (m, 1H), 2.41 (dt, 1H, J = 13.2, 4.5 Hz), 
2.32 (d, 1H, J = 13.9 Hz), 2.23-1.96 (m, 5H), 1.90-1.49 (m, 12H), 1.29 (s, 3H), 
1.24 (s, 3H), 1.19 (s, 9H), 1.10 (s, 9H), 1.04 (s, 9H), 1.00 (d, 3H, J = 6.8 Hz), 0.48 
(s, 3H), 0.37 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H);  13C NMR (100 MHz, CD3CN): 
139.6, 136.4, 136.3, 134.80, 134.76, 130.6, 130.7, 129.2, 128.8, 128.75, 128.72, 
128.4, 108.0, 107.0, 85.9, 84.6, 81.8, 81.4, 80.2, 74.0, 73.5, 72.94, 72.88, 67.2, 
66.6, 49.2, 41.6, 41.3, 35.6, 34.7, 33.7, 32.5, 29.3, 28.9, 27.2, 26.7, 26.41, 26.37, 
23.0, 21.8, 19.8, 19.3, 18.6, 11.6, –2.7, –4.1, –4.2, –4.9; HRMS (ESI+): m/z calcd 
for [C60H94O9NaSi3] 1065.6103, found 1065.6095, ? = 0.8 ppm. 
5.6.10 Spiroketals 185 and 186 (aqueous conditions) 
 
To a solution of ketone 184 (6 mg, 0.006 mmol, 100 mol-%) in THF:H2O (0.4:0.1 
mL) was added Cl3CCOOH (0.6 mg in 10 ?L THF, 0.0034 mol-%, 60 mol-%) at 
rt. The reaction mixture was stirred at rt for 4 h and then diluted with Et2O (5 mL) 
and quenched with sat. aq. NaHCO3 (3 mL). The separated organic layer was 
dried over Na2SO4 and concentrated. The crude 1H NMR showed a 1:1 mixture of 
the spiroketals 185 and 186. 
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5.6.11 Thermodynamic Equilibration of Spiroketals 185 and 186  
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To a solution of 1:1 mixture of spiroketals 185 and 186 (40 mg, 0.038 mmol, 100 
mol-%) in CH2Cl2 (2.0 mL) was added PPTS (1.9 mg, 0.0075 mmol, 20 mol-%) 
at rt. After 4h, another portion of PPTS (9.5 mg, 0.038 mmol, 100 mol-%) was 
added. Stirring was continued at rt for 2h. The reaction mixture was diluted with 
CH2Cl2 (5 mL) and then quenched by addition of sat. aq. NaHCO3 (4 mL). The 
layers were separated and the organic layer was dried over Na2SO4 and 
concentrated. Purification of the residue by flash chromatography (10% 
EtOAc/hexanes, 25 ?L Et3N in 125 mL eluent) afforded the anomeric isomer 186 
as colorless oil (26.5 mg, 67%). 
 
For 186: Rf (15% EtOAc/hexanes) = 0.34; [?]D = 0.6 (c 0.50, CH2Cl2); IR (film, 
cm–1): 2953, 2929, 2856, 1472, 1110; 1H NMR (400 MHz, C6D6): ? 7.85-7.79 (m, 
4H), 7.36-7.18 (m, 10H), 7.10-7.06 (m, 1H), 4.54 (ddAB, 2H,?JAB?= 12.3 Hz, ?v 
= 26.4 Hz), 4.35 (ddd, 1H, J = 11.2, 4.7, 2.8 Hz), 4.20 (dd, 1H, J = 5.0, 3.2 Hz), 
3.96-3.86 (m, 3H), 3.81 (d, 1H, J = 7.8 Hz),  3.79 (s, 2H), 3.69 (dd, 1H, J = 9.9, 
7.0 Hz), 3.64 (dd, 1H, J = 8.2, 3.1 Hz), 2.37 (dt, 1H, J = 13.1, 4.3 Hz), 2.37-2.28 
(m, 1H), 2.28 (d, 1H, J = 14.1 Hz), 2.17 (ddd, 1H, J = 13.7, 9.2, 4.8 Hz), 1.99-
1.83 (m, 5H), 1.74-1.38 (m, 10H), 1.35 (d, 3H, J = 6.8 Hz), 1.30 (s, 3H), 1.22 (s, 
9H), 1.15 (s, 3H), 1.09 (s, 9H), 1.07 (s, 9H), 0.43 (s, 3H), 0.36 (s, 3H), 0.14 (s, 
6H);  13C NMR (100 MHz, CD3CN): 139.5, 136.42, 136.37, 136.36, 134.8, 130.7, 
130.6, 129.2, 128.74, 128.66, 128.62, 128.4, 107.0, 105.8, 85.7, 84.7, 84.6, 83.0, 
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81.5, 74.0, 73.4, 72.9, 72.7, 67.5, 66.6, 49.7, 42.1, 41.4, 40.4, 34.8, 34.7, 32.5, 
28.5, 28.0, 27.3, 26.52, 26.47, 26.41, 21.1, 21.0, 19.8, 19.2, 18.6, 15.1, –2.7, –3.9, 
–4.4, –4.7; HRMS (ESI+): m/z calcd for [C60H94O9NaSi3] 1065.6103, found 
1065.6104, ? = 0.1 ppm. 
5.6.12 [6,6]-Spiroketal 202 
 
 
To  a  solution  of  spiroketal  186 (6.0 mg, 0.006 mmol, 100 mol-%) in THF (0.5 
mL) was added TBAF (1M in THF, 56 ?L, 0.06 mmol, 1000 mol-%) at rt. The 
reaction mixture was stirred at rt for 24 h and was then diluted with Et2O (4 mL). 
Orange oil separated from the solution. The oil was separated from the solution by 
filtration, and solvent was evaporated. The crude product was dissolved in CH2Cl2 
(1 mL) and p-TsOH (0.5 mg, 0.003 mmol, 50 mol-%) was added. The reaction 
mixture was stirred at rt for 19h. The reaction mixture was diluted with CH2Cl2 (4 
mL) and sat.  aq.  NaHCO3 (2 mL) was added. The layers were separated and the 
organic layer was dried over Na2SO4 and concentrated. Purification of the residue 
by flash chromatography (90% EtOAc/hexanes) afforded the [6,6]-spiroketal 
product 202 as colorless oil (2.8 mg, 86%). 
 
Rf (90% EtOAc/hexanes) = 0.26; [?]D =  1.7  (c 0.23, CH2Cl2);  IR  (film,  cm–1) 
3401, 2918, 2850, 1454, 1099; 1H  NMR  (400  MHz,  CD3CN): ? 7.36-7.28 (m, 
4H), 4.56 (s, 2H), 4.19 (d, 1H, J = 10.7 Hz), 4.19-4.14 (m, 1H), 4.03-3.99 (m, 
1H), 3.81-3.78 (m, 1H), 3.74 (ddd, 1H, J = 11.6, 5.1, 2.2 Hz), 3.56-3.53 (m, 1H), 
3.51 (d, 1H, J = 1.1 Hz), 3.47 (s, 2H), 3.42 (dd, 1H, J = 7.9, 2.4 Hz), 3.39-3.33 
(m, 1H), 2.77 (d, 1H, J = 6.4 Hz), 2.66 (dd, 1H, J = 6.5, 4.9 Hz), 2.49 (d, 1H, J = 
153 
 
 
  
14.5 Hz), 2.12-1.96 (m, 2H), 1.87-1.36 (m, 16H), 1.29 (s, 3H), 1.20 (s, 3H), 0.91 
(d, 3H, J = 6.9 Hz); HRMS (ESI+): m/z calcd for [C32H48O9Na] 599.3196, found 
599.3219, ? = 3.8 ppm. 
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